FADS gene variants, diet and atopic phenotypes and lipids in children by Standl, Marie
From
Dr. von Hauner Children's Hospital
Ludwig-Maximilians-University, Munich, Germany
Director: Prof. Dr. Dr. Christoph Klein
Division of Metabolic Diseases and Nutritional Medicine
Prof. Dr. med. Berthold Koletzko
and
The Institute of Epidemiology I, Acting director: Dr. Joachim Heinrich
Helmholtz Zentrum München 
German Research Center for Environmental Health (GmbH)
FADS gene variants, diet and
atopic phenotypes and lipids in children.
Thesis
submitted for a Doctoral degree in Human Biology at the Faculty of Medicine,
Ludwig-Maximilians-University, Munich, Germany
by
Marie Standl
from
Munich, Germany
2013
With approval of the Medical Faculty of the
Ludwig-Maximilians-University of Munich
Supervisor / Examiner: Prof. Dr. med. Berthold Koletzko
Co-Examiners: Priv. Doz. Dr. Bärbel Otto
Prof. Dr. Markus Braun-Falco
Co-Supervisor: Dr. Joachim Heinrich
Dean: Prof. Dr. med. Dr. h.c. M. Reiser, FACR, FRCR
Date of oral examination: 08. 07. 2013
Contents
Contents I
Abbreviations III
Summary IV
Zusammenfassung VII
1 Introduction 1
1.1 Allergy, Allergic Sensitization and Atopy . . . . . . . . . . . . . . . . . 1
1.2 Polyunsaturated Fatty Acid Metabolism and the FADS Gene Cluster . . 2
1.2.1 The Polyunsaturated Fatty Acid Metabolism . . . . . . . . . . 2
1.2.2 The FADS Gene Cluster . . . . . . . . . . . . . . . . . . . . . 2
2 Speciﬁc Aims and Results 5
2.1 Speciﬁc Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.2 Study Population and Methods . . . . . . . . . . . . . . . . . . . . . 5
2.2.1 Study Population . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.2.2 The Food Frequency Questionnaire . . . . . . . . . . . . . . . 6
2.2.3 Tested Variants of the FADS Gene Cluster . . . . . . . . . . . 6
2.2.4 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.4 Strengths and Limitations . . . . . . . . . . . . . . . . . . . . . . . . 8
3 Conclusion and Outlook 11
References 12
4 Paper 1: FADS Variants, Dietary Fatty Acid Intake and Atopic Dis-
eases in Children
(Standl et al. Clinical & Experimental Allergy, 2011) 19
5 Paper 2: FADS Variants, Exclusive Breastfeeding and Asthma in
Children
(Standl et al. Allergy, 2012) 39
6 Paper 3: Meta-analysis of Genome-wide Association Studies on Atopic
Dermatitis
(Paternoster* & Standl* et al. Nature Genetics, 2012) 55
7 Paper 4: Regional and Socioeconomic Diﬀerences in Dietary Intake
in Children
(Sausenthaler* & Standl* et al. Public Health Nutrition, 2011) 147
I
8 Paper 5: FADS Variants, Dietary Fatty Acid Intake and Lipids in
Children
(Standl et al. PLoS ONE, 2012) 161
Acknowledgments 179
Curriculum Vitae 180
Publications 182
Erklärung 184
* These authors contributed equally to this work.
II
Abbreviations
AA arachidonic acid
ALA α-linolenic acid
DHA docosahexaenoic acid
EPA eisosapentaenoic acid
FADS fatty acid desaturase
FFQ food frequency questionnaire
GWAS genome-wide association study
HDL high-density lipoprotein
IgE Immunoglobulin E
LA linoleic acid
LDL low-density lipoprotein
PUFA polyunsaturated fatty acid
SNP single-nucleotide polymorphism
III

Summary
The prevalence of allergic diseases has increased over the past decades. Dietary
changes, especially the altered fatty acid consumption, is suggested to be partly respon-
sible. There is a growing body of evidence that polyunsaturated fatty acids (PUFAs)
play a major role in the development of atopic diseases in children, although the re-
sults have been inconsistent. Also the development of cardiovascular diseases seems to
be dependent on PUFA composition as PUFA levels are believed to lower high blood
lipid concentrations. Elevated cholesterol levels during childhood may be an important
predictor for later disease in life.
The conversion of essential fatty acids to longer chain, biological active metabolites
is regulated by the enzymes ∆5 and ∆6 desaturase, which are encoded by the genes
fatty acid desaturase 1 and 2 (FADS1 and FADS2). Therefore, it is hypothesized that
inter-individual genetic diﬀerences may modify the association of dietary fatty acid
intake and allergic diseases or lipids.
This thesis comprises ﬁve publications, which are based on data from the GINIplus and
LISAplus studies.
The ﬁrst publication investigated the inﬂuence of variants in the FADS1 FADS2 gene
cluster on the association of dietary fatty acid and margarine intake and atopic diseases,
as well as allergic sensitization. In the stratiﬁed analysis, a higher margarine intake was
positively associated with a higher risk for asthma in homozygous major allele carriers.
In the second publication, the modulating eﬀect of variants in the FADS gene cluster
on the association of breastfeeding and asthma up to 10 years of age was evaluated.
A strong interaction eﬀect between the duration of exclusive breastfeeding and the
six tested SNPs was observed. Individuals carrying at least one minor allele who were
exclusively breastfed for more than three months, showed a reduced risk for asthma,
whereas there was no genetic eﬀect in homozygous major allele carriers.
The third publication included data from the GINIplus and LISAplus studies to a world-
wide meta-analysis of genome-wide association studies on atopic dermatitis. Three new
risk loci were identiﬁed. Two of these loci are near genes, which are related to epidermal
proliferation and diﬀerentiation. The third locus is located near immune-related genes.
These results underline the hypothesis, that atopic dermatitis is caused by epidermal
barrier abnormalities and immunological features. However, further research is needed
to identify causal variants at these loci and to understand the mechanisms through
which they aﬀect atopic dermatitis.
Regional and socio-economic diﬀerences in dietary intake of school-aged children were
investigated in the fourth publication. A higher level of parental education was asso-
ciated with a higher intake of more healthy food, such as bread, butter, eggs, pasta,
vegetables/salad and fruit, whereas intakes of margarine, meat products, pizza, desserts
and soft drinks were inversely associated with parental education. Additionally, sub-
stantial diﬀerences in food intake between eastern and western Germany were observed.
In the ﬁfth publication, the association between blood lipid concentrations and variants
of the FADS gene cluster was assessed. Individuals carrying the homozygous minor
V
allele were found to have lower levels of total cholesterol and low-density lipoprotein
(LDL) compared to homozygous major allele carriers. Carriers of the heterozygous
allele had lower levels of high-density lipoprotein (HDL) and higher levels of triglycerides
compared to homozygous major allele carriers. Additionally, the inﬂuence of dietary
n-3 PUFA intake was tested. A higher intake of n-3 fatty acids was related to higher
levels of total cholesterol, LDL, HDL and lower triglyceride levels.
In summary, these results support the hypothesis, that there is a causal association
between dietary fatty acid intake and atopic diseases or lipids in children and may
help to better understand the complex association between allergic inﬂammation and
PUFAs.
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Zusammenfassung
Die Prävalenz allergischer Erkrankungen stieg in den vergangenen Jahrzehnten stark
an. Es wird vermutet, dass unter anderem veränderte Ernährungsgewohnheiten, ins-
besondere die Zusammensetzung der Fettsäuren in der Nahrung, teilweise dafür ver-
antwortlich sein könnten. Obwohl nicht alle Untersuchungsergebnisse konsistent sind,
gibt es doch deutliche Hinweise darauf, dass mehrfach ungesättigte Fettsäuren (po-
lyunsaturated fatty acids, PUFAs) eine große Rolle bei der Entstehung allergischer
Erkrankungen bei Kindern spielen.
Ferner ist bekannt, dass die Aufnahme mehrfach ungesättigter Fettsäuren, neben an-
deren Faktoren, erhöhten Blutfettwerten entgegenwirkt. Erhöhte Cholesterinwerte in
der Kindheit und Jugend können ein Risikofaktor für die Entstehung kardiovaskulärer
Erkrankungen im Erwachsenenalter sein.
Die Umwandlung von essentiellen Fettsäuren zu längerkettigen, biologisch aktiven Me-
taboliten wird durch die Enzyme ∆5 und ∆6 Desaturase gesteuert, die durch die Gene
FADS1 und FADS2 (fatty acid desaturase 1 und 2) kodiert werden. Daraus lässt sich
die Hypothese ableiten, dass inter-individuelle genetische Unterschiede den Zusammen-
hang zwischen Fettsäurenaufnahme aus der Ernährung und allergischen Erkrankungen
und Lipidwerten beeinﬂussen können.
Diese Dissertation umfasst fünf Publikationen, basierend auf den Daten der GINIplus
und LISAplus Studien.
In der ersten Publikation wird der Einﬂuss von Varianten aus dem FADS1 FADS2
Gencluster auf den Zusammenhang zwischen Fettsäurenaufnahme und Margarinekon-
sum und atopischen Erkrankungen bzw. allergischer Sensibilisierung untersucht. Dabei
war eine höhere Margarineaufnahme mit einem höheren Asthmarisiko bei Kindern, die
homozygot die häuﬁge Variante tragen, assoziiert.
Die zweite Publikation befasst sich mit dem Zusammenhang zwischen Varianten aus
dem FADS Gencluster, Stillen und Asthma bis zum Alter von 10 Jahren. Hier wurde ein
starker Interaktioneﬀekt zwischen der Dauer, die ausschließlich gestillt wurde und den
sechs getesteten SNPs beobachtet. Kinder, die mindestens ein seltenes Allel tragen
und für mindestens drei Monate ausschließlich gestillt wurden, hatten ein deutlich
niedrigeres Risiko an Asthma zu erkranken. Für Kinder, die homozygot die häuﬁge
Variante tragen, wurde kein genetischer Eﬀekt beobachtet.
Die dritte Publikation ist eine Meta-Analyse von genomweiten Assoziationsstudien, in
die auch Daten der GINIplus und LISAplus Studien miteingegangen sind. Es konnten
drei neue Risikovarianten für atopischer Dermatitis identiﬁziert werden. Zwei dieser
Loci liegen in der Nähe von Genen, die mit epidermaler Zellproliferation und Zelldiﬀe-
rentierung in Verbindung gebracht werden, während der dritte Locus in der Nähe von
Genen liegt, die die Immunantwort regulieren. Diese Ergebnisse stützen die Hypothe-
se, dass atopische Dermatitis durch Defekte in der natürlichen Hautbarriere und der
Immunregulation verursacht wird. Allerdings sind weitere Untersuchungen erforderlich
um die ursächlichen Varianten an diesen Loci zu identiﬁzieren und den Mechanismus
zu verstehen, durch den atopische Dermatitis hervorgerufen wird.
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Regionale und sozio-ökonomische Unterschiede in der Ernährung von Kindern im Schulal-
ter wurden in der vierten Publikation untersucht. Ein höherer Grad elterlicher Bildung
war mit einem höheren Konsum gesunder Nahrungsmittel, wie Brot, Butter, Eier, Nu-
deln, Gemüse/Salat und Obst und einer niedrigeren Aufnahme von Margarine, Fleisch-
produkten, Pizza, Nachspeise und Limonaden assoziiert. Außerdem wurden grundsätz-
liche Unterschiede in der Ernährung zwischen Ost- und Westdeutschland beobachtet.
In der fünften Publikation wird der Zusammenhang zwischen Lipiden und Varianten des
FADS Genclusters untersucht. Kinder, die homozygot das seltene Allel tragen, hatten
im Vergleich zu Kindern, die das häuﬁge Allel homozygot tragen, niedriger Choleste-
rinwerte und LDL-Konzentration. Träger des homozygoten Allels zeigten, im Vergleich
zu Kindern, die das häuﬁge Allel homozygot tragen, niedrigere HDL-Werte und höhere
Triglyzeridwerte. Zusätzlich wurde der Einﬂuss der n-3 Fettsäurenaufnahme geprüft.
Eine höhere n-3 Fettsäurenaufnahme war assoziiert mit einer höheren Cholesterin-,
LDL- und HDL-Konzentration und niedrigeren Triglyzeridwerten. Es wurde allerdings
keine Interaktion mit dem FADS Genotyp beobachtet.
Diese Ergebnisse lassen auf einen Zusammenhang zwischen FADS Gencluster, Fett-
säurenaufnahme und allergischen Erkrankungen oder Lipiden bei Kindern schließen.
Dadurch wird die Hypothese gestützt, dass ein kausaler Zusammenhang zwischen Fett-
säurenaufnahme aus der Nahrung und atopischen Erkrankungen bei Kindern besteht.
Dies könnte helfen, den komplexen Zusammenhang zwischen allergischer Inﬂammation
und Fettsäuren zu verstehen.
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1 Introduction
1 Introduction
The prevalence of allergic diseases was increasing over the past decades with about 30-
40% of the world population now being aﬀected1. Changes in dietary intake, especially
the altered fatty acid consumption, were suggested to be partly responsible for the
increasing prevalence of allergies2, although the results are inconsistent3.
Polyunsaturated fatty acids (PUFAs) have a major impact on health and development
and have been associated with cardiovascular diseases4,5, mental health6,7 and cog-
nitive development8,9, immunologial and inﬂammatory responses as well as related
diseases such as allergic diseases10,11.
The development and programming of the immune system is related to PUFA intake
during pregnancy, lactation, infancy and early childhood and the development and
manifestation of atopic diseases and allergies can be prevented thereby12,13.
Among other factors, dietary PUFA intake can attenuate high blood lipid concen-
trations1416. Elevated cholesterol levels during childhood and adolescence increase
the risk for cardiovascular diseases later in life. Treatments which eﬀectively lower
cholesterol levels early in life have been shown to prevent disease manifestation in
adulthood1719.
1.1 Allergy, Allergic Sensitization and Atopy
Allergy is deﬁned as a hypersensitivity reaction initiated by speciﬁc immunologic
mechanisms, based on the nomenclature developed by the European Academy of
Allergology and Clinical Immunology (EAACI) and updated by the World Allergy Or-
ganization (WAO), and can be antibody- or cell-mediated20. The presence of speciﬁc
immunoglobulin E (IgE) antibodies is called sensitization. In most patients allergy is
initiated by increased levels of IgE antibodies to speciﬁc antigens. Allergic symptoms
may be referred to as atopic, if IgE sensitization has been documented by IgE an-
tibodies in serum or by a positive skin prick test20. Therefore, atopy is deﬁned as
a personal and/or familial tendency, usually in childhood or adolescence, to become
sensitized and produce IgE antibodies in response to ordinary exposures to allergens,
usually proteins. As a consequence, these persons can develop typical symptoms of
asthma, rhinoconjunctivitis, or eczema. 20.
Asthma and allergies are complex diseases with high hereditary. The susceptibility
to asthma and allergies is inﬂuenced by environmental factors, but with a strong ge-
netic background21. Recently, a large genome-wide association study on asthma was
published22. The results show that asthma is genetically heterogeneous with diﬀerent
characteristics in children and adults. Several genes could be identiﬁed, initiating as
well as down-regulating airway inﬂammation processes. Additionally, little overlap be-
tween asthma and total serum IgE levels was reported. Therefore, the authors suggest
that elevated total serum IgE concentration do not play a major role in the development
of asthma, but rather, are a secondary eﬀect of asthma22.
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1.2 Polyunsaturated Fatty Acid Metabolism and the FADS
Gene Cluster
1.2.1 The Polyunsaturated Fatty Acid Metabolism
There is strong evidence that fatty acids play a major role in programming of the
immune system and the development of atopic diseases in children12,13, although the
underlying biological mechanism is still not entirely clear and the results have been
inconsistent3,23.
In general, fatty acids containing more than one double bond in the chain are called
polyunsaturated fatty acids. The main n-6 PUFA is linoleic acid (LA, 18:2n-6) and
the main essential n-3 PUFA is α-linolenic acid (ALA, 18:3n-3)24. The essential fatty
acids LA and ALA cannot be synthesized by mammalian cells, but they can be me-
tabolized by desaturation (introduction of double bonds) and elongation (lengthening
the hydrocarbon chain). The fatty acid metabolism is presented in ﬁgure 1. The n-6
PUFA LA is converted into γ-linolenic acid (18:3n-6), dihomo-γ-linolenic acid (20:3n-
6) and arachidonic acid (AA, 20:4n-6). ALA can be converted to the long-chain fatty
acids eisosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3),
using the same enzymatic pathway as n-6 PUFAs24.
The key link between PUFAs and inﬂammation is the synthesis of eicosanoids, which
are generated from PUFAs25. AA is the major substrate for eicosanoid synthesis,
which are mediators and regulators of inﬂammation. In contrast, n-3 PUFAs are sug-
gested to have anti-inﬂammatory eﬀects by decreasing the production of inﬂammatory
eicosanoids and cytokines25. Since n-3 and n-6 PUFAs use the same enzymatic path-
way, a higher proportion of n-3 PUFAs leads to less substrate which is available for
eicosanoid synthesis from AA. Additionally, there is evidence that n-3 PUFAs alter
the expression of inﬂammatory genes and increase the production of anti-inﬂammatory
mediators24,25.
This led to the hypothesis that n-6 PUFA intake may enhance the development of
allergic diseases in susceptible individuals. In contrast, n-3 PUFA are suggested to
have protective eﬀects with regard to allergic diseases3.
1.2.2 The FADS Gene Cluster
The conversion of the essential fatty acids LA and ALA to longer chain, biological active
metabolites is regulated by the enzymes ∆5 and ∆6 desaturase, which are encoded by
the genes fatty acid desaturase 1 and 2 (FADS1 and FADS2)26.
The FADS gene cluster is located at chromosome 11q12-13.127 and comprises the
genes FADS1, FADS2 and FADS3. Whereas the function of FADS1 and FADS2 is
well studied, the function of FADS3 is not entirely clear28.
Several genetic association studies showed that carriers of the minor alleles of single-
nucleotide polymorphisms (SNPs) in the FADS gene cluster exhibit increased levels of
desaturase substrates and decreased levels of desaturase products. This might arise
from lowered transcriptional levels or diminished conversion rates of the enzymes in
individuals carrying the minor alleles29.
Variants of the FADS gene cluster can explain up to almost 30% of the variations
in the fatty acid levels29. Several studies have shown strong associations between
2
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Figure 1: Metabolism of n-6 and n-3 PUFAs (adapted from Calder (2005)24)
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the FADS gene cluster and fatty acid levels in serum phospholipids29,30, plasma and
adipose tissue samples31, erythrocyte cell membranes30,32, breast milk30,33,34 and red
blood cells35.
Additionally, recent genome-wide association studies on blood lipid levels in adults
have identiﬁed several genetic loci including the FADS gene cluster3640. Lower total
cholesterol36, low-density lipoprotein (LDL)3638, high-density lipoprotein (HDL)38,39
and higher triglyceride levels39,40 are all associated with the minor alleles of the tested
FADS polymorphisms.
Therefore, it is hypothesized that inter-individual genetic diﬀerences may inﬂuence the
association of dietary fatty acid intake and fatty acid related phenotypes26,4143. As
the conversion rate of essential fatty acids to longer chain metabolites is hypothesized
to be lower in individuals carrying the minor allele, it would be expected that the pro-
inﬂammatory eﬀects of n-6 fatty acids and the protective eﬀects of n-3 fatty acids
would be stronger in major allele carriers, because a higher percentage of the essential
fatty acids is converted to longer chain, biological active metabolites.
Beside diet and nutrition, the FADS gene cluster plays an important role in the reg-
ulation of the PUFAs. A modulating eﬀect of variants in the FADS gene cluster on
intelligence development, risk of myocardial infarction and metabolic syndrome was re-
ported26. Further, there is some evidence, that variants in the FADS gene cluster may
also inﬂuence the association of PUFAs on allergies26,41,43. In summary, these results
make these genes good candidates and underline the importance of further research on
the modifying eﬀect of variants in the FADS gene cluster on the association of PUFAs
and fatty acid related phenotypes.
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2 Speciﬁc Aims and Results
2.1 Speciﬁc Aims
The aim of this thesis was to investigate the association between dietary intake, FADS
variants and atopic phenotypes or lipids in children. The main objectives were
• to assess the inﬂuence of FADS1 FADS2 gene cluster polymorphisms on the
association between dietary fatty acid intake and atopic diseases and allergic
sensitization.
• to evaluate the impact of FADS1 FADS2 gene cluster polymorphisms on the
association between breastfeeding and asthma.
• to identify new risk loci for atopic dermatitis in a meta-analysis of genome-wide
association studies.
• to describe regional diﬀerences between eastern and western Germany with regard
to food, nutrient and supplement intake in children, and analyze the association
with parental education and equivalent income.
• to investigate whether lipid levels are inﬂuenced by the FADS genotype already
in children and whether this association interacts with dietary intake of n-3 fatty
acids.
This thesis is based on ﬁve manuscripts, which are published in Clinical & Experimental
Allergy, Allergy  the European Journal of Allergy and Clinical Immunology, Nature
Genetics, Public Health Nutrition and PLoS ONE.
For all publications, I am the ﬁrst, or shared ﬁrst author. I was signiﬁcantly involved
in developing the research question, study design, performed the statistical analyses
and interpreted the results. All comments and suggestions from the co-authors were
included in the ﬁnalized version.
2.2 Study Population and Methods
2.2.1 Study Population
All manuscripts are based on data from the GINIplus44 and LISAplus45 studies. Brieﬂy,
a total of 5991 mothers and their newborns were recruited into the German Infant study
on the inﬂuence of Nutrition Intervention PLUS environmental and genetic inﬂuences
on allergy development (GINIplus) between September 1995 and June 1998 in Munich
and Wesel. Infants with at least one allergic parent and/or sibling were allocated to
the interventional study arm investigating the eﬀect of diﬀerent hydrolysed formulas
for allergy prevention in the ﬁrst year of life44. All children without a family history of
allergic diseases and children whose parents did not give consent for the intervention
were allocated to the non-interventional arm. The inﬂuence of Life-style factors on the
development of the Immune System and Allergies in East and West Germany PLUS
the inﬂuence of traﬃc emissions and genetics (LISAplus) Study is a population based
birth cohort study. A total of 3097 healthy, fullterm neonates were recruited between
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1997 and 1999 in Munich, Leipzig, Wesel and Bad Honnef. The participants were not
pre-selected based on family history of allergic diseases45.
Detailed descriptions of the LISAplus and GINIplus studies have been published else-
where (44 and45, respectively).
2.2.2 The Food Frequency Questionnaire
A food frequency questionnaire (FFQ) was developed to measure children's usual food
and nutrient intake over the past 12 months, and more speciﬁcally to estimate energy,
fatty acid and antioxidant intake at 10 years of age. The FFQ comprised a list of
82 food items accompanied by several questions about the preferred fat and energy
content of products, preparation methods, diets and food preferences, buying habits
and dietary supplement use. The consumption frequencies and portion size estimates
were converted to average consumption in grams per day and linked to the German
Nutrient Data Base (BLS) version II.3.146. The design of the FFQ, including the
selection of the food item list, validation, and the calculation of food and nutrient
intake is described further by Stiegler et al.47. Information obtained by FFQ was used
for the ﬁrst, second, fourth and ﬁfth manuscript.
2.2.3 Tested Variants of the FADS Gene Cluster
Six SNPs of the FADS1 FADS2 gene cluster (rs174545, rs174546, rs174556, rs174561,
rs174575 and rs3834458) were typed. Five of these variants (rs174545, rs174546,
rs174556, rs174561 and rs3834458) were selected based on the previous publications
in adult populations29,48. Moreover, the SNP rs174575 was included in order to obtain
a better coverage of the FADS gene cluster. This SNP was selected based on a previous
publication in children49.
2.2.4 Methods
Up to now, the association between dietary fatty acid intake and the development of
atopic diseases has been inconsistent3. The ﬁrst publication (chapter 4) investigated
whether the association between dietary fatty acid intake and atopic diseases and
allergic sensitization is modiﬁed by variants of the FADS gene cluster.
Margarine and fatty acid intake was assessed by FFQ. Information on atopic diseases
for each year of life up to 10 years of age was collected using a self-administered
questionnaire completed by the parents and speciﬁc IgE antibodies against common
food and inhalant allergens were measured. Six variants of the FADS1 FADS2 gene
cluster were tested. In total, complete information was available for 2000 children.
In this analysis, the impact of inter-individual genetic diﬀerences on the association
between dietary fatty acid intake and atopy was investigated.
The second manuscript (chapter 5) evaluated the eﬀect of variants of the FADS gene
cluster on the association between exclusive breastfeeding and the development of
asthma. The analysis was based on 2245 children. Information on ever having a
doctor's diagnosis of asthma up to 10 years of age and breastfeeding during the ﬁrst
6 months was collected using parental questionnaires. Six SNPs of the FADS1 FADS2
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gene cluster were tested. Within this study, the inconsistencies in the association
between breastfeeding and asthma may be partly explained by inter-individual genetic
diﬀerences.
The scope of the third publication (chapter 6) was to identify new genetic risk variants
for atopic dermatitis in a meta-analysis of genome-wide association studies. Within the
EArly Genetics & Lifecourse Epidemiology (EAGLE) Consortium a well-powered, two-
stage genome-wide association meta-analysis was performed. The discovery analysis
included 5606 aﬀected individuals and 20565 controls from 16 population-based cohorts
and the ten most strongly associated new susceptibility loci were examined in additional
5419 aﬀected individuals and 19833 controls from 14 studies.
The aim of the fourth publication (chapter 7) was to analyze the eﬀect of socio-
economic factors and regional diﬀerences in food consumption and supplement intake.
Information on food, nutrient and supplement intake of 3435 children derived by FFQ
was analyzed in respect to regional diﬀerences between eastern and western Germany
and the association with parental education and equivalent income was assessed.
In adults, it had been shown that the blood lipid concentrations are strongly inﬂuenced
by variants of the FADS gene cluster. Therefore, the ﬁfth publication (chapter 8)
investigated whether blood lipid levels are inﬂuenced by polymorphisms in the FADS
gene cluster already in children and whether this association interacts with dietary
fatty acid intake. During the 10 year follow-up of the GINIplus and LISAplus studies
total cholesterol, HDL, LDL and triglycerides were measured. Six SNPs of the FADS
gene cluster were genotyped and dietary fatty acid intake was assessed by FFQ. In
this analysis, the inﬂuence of FADS variants on lipid concentrations in children was
evaluated.
2.3 Results
In the ﬁrst publication (chapter 4) the inﬂuence of polymorphisms in the FADS1 FADS2
gene cluster on the association between dietary fatty acid intake and atopic diseases and
allergic sensitization was evaluated. Margarine intake was associated with an increased
risk for asthma in individuals carrying the homozygous major allele. The ratio of n-3
to n-6 fatty acids was related to higher hay fever risk, although this association was
not signiﬁcant after adjustment for multiple testing. These results suggest that the
eﬀect of dietary fatty acid intake on atopic diseases might be modulated by the FADS1
FADS2 genes in children.
In the second publication (chapter 5) the impact of variants of the FADS gene cluster
on the association of breastfeeding and asthma was assessed. A strong, highly signif-
icant interaction eﬀect was identiﬁed. Exclusive breastfeeding for at least 3 months
showed a protective eﬀect in heterozygous and homozygous carriers of the minor allele,
whereas no eﬀect of exclusive breastfeeding was observed for individuals carrying the
homozygous major allele. These results suggest a modulating eﬀect of the FADS1
FADS2 gene cluster on the association of the duration of exclusive breastfeeding and
the development of asthma in later life.
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A meta-analysis of genome-wide association studies on atopic dermatitis identiﬁed
three new risk loci. Three polymorphisms reached genome-wide signiﬁcance in the
combined analysis of discovery and replication cohorts. Two of these loci are near genes,
which are related to epidermal proliferation and diﬀerentiation (rs479844 upstream of
OVOL1 and rs2164983 near ACTL9). The third locus, rs2897442 in IL4KIF3A lo-
cated at 5q31.1, seems to be composed of two independent signals (IL4KIF3A and
IL13RAD50), which contain cytokine and immune-related genes. Additionally, the
association with the well-studied FLG locus and two signals which were recently iden-
tiﬁed by two GWA studies could be replicated. These results strengthen the hypothesis,
that atopic dermatitis is caused by epidermal barrier abnormalities and immunologi-
cal features. However, further research is needed to identify causal variants at these
loci and to understand the mechanisms through which they aﬀect atopic dermatitis
(chapter 6).
The fourth publication (chapter 7) aimed to describe regional diﬀerences between east-
ern and western Germany and the association between dietary intake and the level of
parental education and equivalent income. A higher level of parental education was
associated with a higher intake of healthy food, like bread, butter, eggs, pasta, vegeta-
bles/salad and fruit, whereas intakes of margarine, meat products, pizza, desserts and
soft drinks were inversely associated with parental education. The association between
dietary intake and equivalent income was weaker. Additionally, substantial diﬀerences
in food intake between eastern and western Germany were observed. Therefore, nu-
tritional education programs and dietary recommendations for school-aged children
should take these regional and socio-economic diﬀerences into account.
The association between blood lipid concentrations and variants of the FADS gene
cluster was investigated in the ﬁfth publication (chapter 8). Individuals carrying the
homozygous minor allele were found to have lower levels of total cholesterol and LDL
compared to homozygous major allele carriers. Carriers of the heterozygous allele had
lower levels of HDL and higher levels of triglycerides compared to homozygous major
allele carriers. Additionally, the inﬂuence of dietary n-3 PUFA intake was tested. A
higher intake of n-3 fatty acids was related to higher levels of total cholesterol, LDL,
HDL and lower triglyceride levels. However, these associations did not interact with
the FADS1 FADS2 genotype. These results show, that total cholesterol, HDL, LDL,
and triglyceride levels are inﬂuenced by the FADS gene cluster already in 10 year
old children. This might diﬀerentially predispose individuals to the development of
cardiovascular diseases later in life.
2.4 Strengths and Limitations
A detailed discussion of strengths and limitations can be found in the ﬁve publications.
Here, a few major aspects will be brieﬂy summarized.
Dietary intake was assessed by a FFQ, which is generally believed to overestimate
dietary intakes50. As an objective measurement, this FFQ was developed and validated
for the speciﬁc aim to assess intake of n-3 and n-6 fatty acids. Thus, this developed
FFQ for children goes beyond common used other FFQs. The FFQ measured dietary
8
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intakes over the past 12 months and was validated for dietary fatty acid intake47. Fatty
acid concentrations in blood at 10 years of age were not available so far.
Further, it should be considered, that ﬁve of the six SNPs from the FADS gene cluster,
which were analyzed, were selected based on previous publications in adult popula-
tions29,48. The SNPs are in high linkage disequilibrium with each other and do not
cover the complete region of the FADS gene cluster.
A longitudinal analysis to identify age dependent diﬀerences is not possible due to a
low prevalence especially of asthma in children up to 10 years of age. The deﬁnition
of asthma and allergies was based on questionnaire information on having a doctor's
diagnosis for each year of live. A clinical ascertainment of these information in each
year of life was beyond the scope of this study. However, the presence of speciﬁc IgE
antibodies was measured at 6 and 10 years of age and blood lipid levels were measured
during the 10 year follow-up.
Further, the results of the meta-analysis of genome-wide association studies on atopic
dermatitis underline the importance of careful phenotyping. In this analysis, several
studies with diﬀerences in case deﬁnition and age of onset were included and some loci
showed evidence for heterogeneity. Additional sensitivity analyses on age of onset and
a more stringent deﬁnition based on reported physician's diagnosis could partly explain
the heterogeneity.
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This thesis aimed to investigate the association between dietary intake, the FADS1
FADS2 gene cluster and atopic phenotypes as well as lipids in children. An association
between dietary fatty acid intake, the FADS1 FADS2 gene cluster and allergies was
identiﬁed. Margarine intake was related with an increased risk for asthma in children
carrying the homozygous major allele. Additionally, a protective eﬀect of breastfeeding
for at least three months on the development of asthma later in life was observed
in children carrying at least one minor allele, whereas there was no association for
individuals carrying the homozygous major allele. Further, it could be shown that total
cholesterol, HDL, LDL and triglyceride concentrations are associated with dietary n-3
PUFA intake and variants in the FADS gene cluster already in 10-year-old children,
although no interaction with dietary fatty acid intake was observed.
So far, the results from several studies, which have investigated the association be-
tween dietary PUFA intake and atopic diseases, were not conclusive3,23. Although the
mechanism seems biological plausible, the evidence remains scarce. One reason for
this might be inter-individual genetic diﬀerences. In fact, the results presented in this
thesis indicate that individual diﬀerences in the fatty acid metabolism, inﬂuenced by
the FADS genes, may be partly responsible for these inconsistencies.
These individual diﬀerences in the fatty acid metabolism, presumably induced by the
FADS genotype, may lead to diﬀerent nutritional requirements to ensure the necessary
fatty acid supply. A further investigation of the individual diﬀerences in the conversion
of dietary fatty acid intake to longer chain, biological active metabolites against the
background of the FADS genotype may enhance the knowledge about the underlying
mechanism. Therefore, it would be interesting to include as a further step the fatty
acid composition in blood in further analyses.
The development and programming of the immune system is related to PUFA intake
during pregnancy and lactation12,13. It is known, that the FADS genotype inﬂuences,
upon PUFA levels in blood, the fatty acid composition of breast milk. Therefore, the
suﬃcient supply with PUFA of the mother during pregnancy and lactation is essential
for the development. Moreover, it would be highly interesting to investigate the inﬂu-
ence of the maternal genotype and thereby account for the variation of PUFA supply
during pregnancy and lactation, which is caused by the maternal FADS genotype.
In summary, these results suggest that there is an association between the FADS gene
cluster, dietary fatty acid intake and atopic diseases or lipids in children. The clinical
relevance of the FADS genotype itself is weak, because the percentage of variance
explained is low and therefore cannot be used for prevention purposes, but these results
may help to identify possible biological pathways. Thereby, the hypothesis, that there
is a causal association between dietary fatty acid intake and atopic diseases or lipids
in children is supported. Therefore, the FADS genotype should be included in further
studies on PUFA and fatty acid related phenotypes and this may help to improve
understanding the complex association between PUFAs and allergic inﬂammation.
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Summary
Background The association between dietary fatty acid intake and the development of atopic
diseases has been inconsistent. This could be due to inter-individual genetic differences in
fatty acid metabolism.
Objective The aim of the current study was to assess the influence of FADS1 FADS2 gene
cluster polymorphisms on the association between dietary fatty acid intake and atopic
diseases and allergic sensitization in 10-year-old children.
Methods The analysis was based on data from two German prospective birth cohort studies.
Data on margarine and fatty acid intake were collected using a food frequency questionnaire.
Information on atopic diseases was collected using a questionnaire completed by the parents.
Specific IgE against common food and inhalant allergens were measured. Six variants of the
FADS1 FADS2 gene cluster (rs174545, rs174546, rs174556, rs174561, rs174575 and
rs3834458) were tested. Logistic regression modelling, adjusted for gender, age, maternal
education level and study centre, was used to analyse the association between fatty acid
intake and atopic diseases stratified by genotype.
Results No significant association was found between the six FADS single nucleotide
polymorphisms (SNPs) and allergic diseases or atopic sensitization. The total n-3/total n-6
ratio was positive associated with an increased risk of hayfever in homozygous major allele
carriers ranging from an adjusted odds ratios of 1.25 (95%-CI: 1.00–1.57) to 1.31 (95%-CI:
1.01–1.69) across the six tested SNPs although this association was not significant anymore
after correcting for multiple testing. Daily margarine intake was significantly associated with
asthma [1.17 (1.03–1.34) to 1.22 (1.06–1.40)] in individuals carrying the homozygous major
allele. This association was also significant after correcting for multiple testing.
Conclusions & Clinical Relevance The association between dietary intake of fatty acids and
allergic diseases might be modulated by FADS gene variants in children.
Keywords atopy, children, epidemiology, FADS, fatty acid intake, FFQ, specific IgE
Submitted 4 January 2011; revised 21 June 2011; accepted 22 June 2011.
Introduction
Dietary factors may be partly responsible for the increas-
ing prevalence of atopic diseases in children. The altered
consumption of polyunsaturated fatty acids (PUFA) has
been suggested to contribute to this increase. This is due to
a reduction in the consumption of animal fat and an
increase in the use of margarine and vegetable oils
containing proinflammatory n-6 PUFA [1]. However, the
results of previous studies are not consistent [2, 3].
Linoleic acid (LA, 18 : 2n-6), the most common dietary n-
6 PUFA, is metabolized to g-linoleic acid (GLA, 18 : 3n-6),
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which is converted to arachidonic acid (AA, 20 : 4n-6). AA
can act as substrate of inflammatory eicosanoids. N-3
PUFAs are reported to have beneficial effects on allergic
inflammation. a-Linolenic acid (ALA, 18 : 3n-3) can be
converted to the long-chain fatty acids eisosapentaenoic
acid (EPA, 20 : 5n-3), docosapentaenoic acid (DPA,
22 : 5n-3) and docosahexaenoic acid (DHA, 22 : 6n-3),
using the same enzymatic pathway as n-6 PUFA. Thereby,
n-3 PUFA can competitively inhibit the production of pro-
inflammatory AA [4, 5]. This led to the hypothesis that n-6
PUFA intake may enhance the development of allergic
diseases in susceptible individuals, mediated at least
partly through an increase in IgE synthesis. In contrast,
n-3 PUFA is suggested to have protective effects against
allergic diseases.
The genes fatty acid desaturase 1 and 2 (FADS1 and
FADS2) encode the enzymes delta-5-desaturase and del-
ta-6-desaturase, respectively, which are involved in the
fatty acid metabolic pathway [6]. Several studies have
shown strong associations between the FADS gene cluster
and fatty acid levels in serum phospholipids [7, 8], plasma
and adipose tissue samples [9], erythrocyte cell mem-
branes [8, 10], breast milk [8] and red blood cell lipids
[11]. Carriers of the minor allele exhibit increased levels of
desaturase substrates and decreased levels of desaturase
products. This might arise from lowered transcriptional
levels or diminished conversion rates of the enzymes in
individuals carrying the minor alleles.
Inter-individual genetic differences in fatty acid meta-
bolism might be one of the reasons for the inconsistent
association between intake of fatty acids and atopic
phenotypes [1, 12]. Therefore, we investigated, whether
the association between fatty acid intake and atopic
diseases could be modified by genetic variants of the
FADS gene cluster.
Methods
Study population
Data from two ongoing German birth cohort studies were
included in this investigation, the German LISAplus (Life-
style Related Factors on the Immune System and the
Development of Allergies in Childhood) and GINIplus
(German Infant Nutritional Intervention) studies. LISA-
plus is a population based birth cohort study. A total of
3097 neonates were recruited between 1997 and 1999 in
Munich, Leipzig, Wesel and Bad Honnef. The participants
were not pre-selected based on family history of allergic
diseases [13]. A total of 5991 mothers and their newborns
were recruited into the GINIplus study between September
1995 and June 1998 in Munich and Wesel. Infants with at
least one allergic parent and/or sibling were allocated to
the interventional study arm investigating the effect of
different hydrolysed formulas for allergy prevention in
the first year of life [14]. All children without a family
history of allergic diseases and children whose parents did
not give consent for the intervention were allocated to
the non-interventional arm. Detailed descriptions of the
LISAplus and GINIplus studies have been published
elsewhere ([13] and [14], respectively).
In both studies only individuals with Caucasian German
descent were included.
For both studies, approval by the local Ethics Commit-
tees (Bavarian General Medical Council, University of
Leipzig, Medical Council of North-Rhine-Westphalia) and
written consent from participant’s families were obtained.
Food frequency questionnaire (FFQ)
The FFQ was developed to measure children’s usual food
and nutrient intake over the past year, and more specifi-
cally to estimate energy, fatty acid and antioxidant intake
at 10 years of age. The FFQ comprised a list of 82 food
items accompanied by several questions about the pre-
ferred fat and energy content of products, preparation
methods, diets and food preferences, buying habits and
dietary supplement use. To estimate how often foods were
eaten by their child on average over the previous year,
parents were asked to choose one of nine frequency
categories. In addition, common portion sizes were given
for each food to enable an estimation of quantities. For
foods which were difficult to describe in common house-
hold measures, coloured photographs from the European
Prospective Investigation into Cancer and Nutrition (EPIC)
study showing three different portion sizes were included
[15]. The consumption frequencies and portion size esti-
mates were converted to average consumption in grams
per day and linked to the German Nutrient Data Base (BLS)
version II.3.1 [16]. The design of the FFQ, including the
selection of the food item list, validation, and the calcula-
tion of food and nutrient intake is described further by
Stiegler et al. [17].
For the present analysis, information on fatty acid
intake and margarine consumption was used.
Genotyping
Six variants of the FADS1 FADS2 gene cluster (rs174545,
rs174546, rs174556, rs174561, rs174575 and rs3834458)
were typed. Five of these single nucleotide polymorphisms
(SNPs) (rs174545, rs174546, rs174556, rs174561 and
rs3834458) have been previously shown to be in strong
linkage disequilibrium (LD) with each other (r240.7,
D’40.9) [7]. These five SNPs were selected based on
previous publications in adult populations [7, 18]. More-
over, we included the SNP rs174575. In addition, applying
the tagger server program (http://www.broadinstitute.org/
mpg/tagger/) in combination with HapMap we found that
with the three SNPs rs174545, rs174546 and rs174556 we
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could tag 27 SNPs between basepair positions 61234329
and 61372379 of FADS1 FADS2. The efficiency was 10.7
fold although the two further SNPs rs174561 and
rs3834458 could not be included as these are not included
in the hapmap database. Genotyping of SNPs was realized
with the iPLEX (Sequenom, San Diego, CA, USA) method
by means of matrix assisted laser desorption ionization-
time of flight mass spectrometry method (MALDI-TOF MS,
Mass Array; Sequenom, San Diego, CA, USA) in one
laboratory according to the manufacturer’s instructions.
Standard genotyping quality control included 10% dupli-
cate and negative samples. Genotyping discordance rate
was below 0.3%.
Definition of outcome variables
Information on allergic diseases was collected using a
self-administered questionnaire at 10 years of age com-
pleted by the parents. The questions for physician-diag-
nosed asthma, eczema or hayfever at age 6, 7, 8 or 9 were
used to define binary outcome variables for ever having a
diagnose.
Allergic sensitization was defined by specific serum IgE
concentrations, which were assayed by the CAP-RAST
FEIA system (Pharmacia Diagnostics, Freiburg, Germany)
according to the manufacturer’s instructions. Screening
tests were used for testing allergic sensitization against
food allergens (fx5: egg, cow milk, wheat, peanut, soy-
bean, and codfish) and inhalant allergens (sx1: Dermato-
phagoides pteronyssinus, cat, dog, rye, timothy grass,
Cladosporium herbarum, birch, mugwort). The limit of
detection for specific IgE was 0.35 kU/L. Children were
assigned as IgE positive, if their IgE values exceeded the
detection limit in at least one of both RAST tests.
Statistical analysis
Variables of interest were the ratio of n-3 (ALA1EPA1D-
PA1DHA) to n-6 (LA1AA) fatty acids and daily margar-
ine intake. Due to implausible values of the total n-3/total
n-6 ratio, eight subjects were excluded from this analysis.
To evaluate the differences between the genotypes a
stratified analysis was used.
Multiple logistic regression analysis was applied to
estimate the adjusted odds ratios (aOR) with 95% con-
fidence intervals (CI) for the association between fatty
acid intake and the binary health outcomes asthma,
hayfever, eczema and IgE positive. Statistical significance
was defined by a two-sided alpha level of 5%.
According to Nyholt [19], the number of effective loci
of the six SNPs in the FADS gene cluster was computed as
2. In order to correct for multiple testing, the alpha level is
divided by the two effective loci multiplied by the four
phenotypes, which leads to a corrected two-sided alpha
level of 0.63%.
The adjusted odds ratios are shown for interquartile
range (IQR) increase. Differences between both studies
were tested using Fisher’s exact test, Wilcoxon rank sum
test or Pearson’s chi-squared test.
Statistical power was calculated for both margarine
consumption and total n-3/total n-6 fatty acid intake.
Owing to the distribution of the variables of interest, the
fatty acid intake was log transformed and power calcula-
tion was approximated with a two sample t-test regarding
the differences of the means in the group with atopic
diseases or allergic sensitization and the control group.
All models are adjusted for gender, age, maternal
education level (low, medium and high) and study centre
(Munich, Leipzig, Wesel and Bad Honnef).
Statistical analysis was performed using the statistical
software R, version 2.9.1 (R Development Core Team,
2009) [20]. For haplotype construction, haplo.em() from
the package Haplo Stats, version 1.4.0 was used.
Results
Complete information on dietary fatty acid and margarine
intake, FADS1 FADS2 genotype and allergic diseases was
available for 2000 children [1301 (65.05%) children from
the GINIplus Study and 699 (34.95%) children from the
LISAplus Study]. IgE data existed for 1703 of these
children [1102 (64.71%) children from the GINIplus Study
and 601 (35.29%) children from the LISAplus Study].
Basic characteristics of the study population are de-
scribed in the tables. Children from the GINIplus Study
were on average older than children in the LISAplus Study
(mean age difference of 6 months) (Table 1). Owing to the
age difference, total nutrient and dietary fatty acid intake
was higher in children from the GINIplus Study. 52.3% of
the cohort had mothers with education beyond 10th grade.
The prevalence for atopic outcome variables ranged from
about 6.5% for asthma to 46.6% for IgE positive. The
margarine intake and total n-3/total n-6 ratio were found
to be significantly different in the GINIplus and LISAplus
Study (P-value 0.0001 and 0.002, respectively). In the
GINIplus Study, the intake of the fatty acids LA and AA
was significantly higher than in the LISAplus Study (P-
value 0.0109 and 0.0192, respectively).
The genotype and allele frequencies of the six SNPs
which were included in the analysis are shown in Table 2.
Five of the six SNPs (rs174545, rs174546, rs174556,
rs174561 and rs3834458) are in high LD with each other
(supporting information, Figure S1). For these five SNPs,
the pairwise squared correlations r2 ranged between 0.82
and 0.99 and Lewontin’s D’ ranged between 0.98 and 1 in
the GINIplus Study. For the LISAplus Study r2 ranged
between 0.85 and 1 and D’ ranged between 0.99 and 1.
For rs174575, the LD is lower. The pairwise correlation
r2 for this SNP ranged between 0.48 and 0.66 in the
GINIplus Study and between 0.49 and 0.62 in the LISAplus
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Study. Lewontin’s D’ ranged between 0.75 and 0.95
(GINIplus) and between 0.78 and 0.94 (LISAplus).
Median dietary fatty acid intake was not significantly
increased in children with and without atopic diseases
(Table 3), although children having asthma or eczema
have a higher dietary margarine intake and the total n-3/
total n-6 ratio is higher in children having hayfever.
The mean margarine intake is higher in homozygous
minor allele carriers than in homozygous or heterozygous
major allele carriers, also this association is only border-
line significant for two SNPs (rs174545 and rs174546).
After correction for multiple testing (acorr = 0.05/
2 = 0.025), this difference is not significant anymore
(supporting information, Table S1).
The prevalence of atopic outcomes stratified by geno-
type for the FADS gene cluster was not significantly
associated with atopic diseases or allergic sensitization
(Table 4). However, when analysing the influence of
dietary fatty acid intake on atopic disease risk stratified
by the FADS genotype, the total n-3/total n-6 ratio was
positive associated with an increased risk of hayfever in
homozygous major allele carriers ranging from an aOR of
1.25 (95%-CI: 1.00–1.57) to 1.31 (95%-CI: 1.01–1.69)
across the six tested SNPs although this association was
not significant anymore after correcting for multiple
testing (supporting information, Table S2).
The impact of margarine consumption on atopic dis-
eases and allergic sensitization is shown in Table 5. The
total n-3/total n-6 ratio was inversely correlated with the
daily margarine intake (Spearman’s rank correlation
r=0.14, Po0.0001).
Higher margarine intake was associated with a signifi-
cantly increased risk for asthma among those who were
homozygous for the major allele of each SNP [aOR
between 1.17 (95%-CI: 1.03–1.34) and 1.23 (95%-CI:
1.06–1.40)]. This association remained significant for
Table 1. Basic characteristics of the 10 year follow-up of the study population
LISAplus (n= 699) GINIplus (n=1301) Total (n= 2000)
P-value% or mean (SD) % or mean (SD) % or mean (SD)
Boys (%) 54.6 49.8 51.5 0.03911
Age (month) 126 (3) 132 (6) 130 (6) o0.00012
High maternal education (%) 57.1 49.6 52.3 0.00083
Asthma (DD) (%) 5.5 7 6.5 ns1
Hay fever (DD) (%) 11.6 12.6 12.3 ns1
Eczema (DD) (%) 6.5 8.9 8.1 ns1
IgE positive (%) 47.1 46.3 46.6 ns1
Margarine intake (g/d) 3 (5) 4 (7) 4 (7) 0.00012
Total n-3/total n-6 ratio 0.153 (0.033) 0.148 (0.032) 0.149 (0.033) 0.00202
ALA (n-3) (mg) 1099 (421) 1139 (470) 1125 (454) ns2
EPA (n-3) (mg) 44.7 (41.5) 46.5 (59.4) 45.9 (53.8) ns2
DHA (n-3) (mg) 90.7 (68) 93.4 (92.3) 92.4 (84.6) ns2
LA (n-6) (mg) 8262 (3304) 8889 (4264) 8670 (3965) 0.01092
AA (n-6) (mg) 182 (95) 196 (116) 191 (109) 0.01922
DPA (n-6) (mg) 12.7 (9.6) 13.6 (12.9) 13.3 (11.8) ns2
1P-value derived from Fisher’s exact test.
2P-value derived from Wilcoxon’s rank sum test.
3P-value derived from Pearson’s chi-squared test.
ns, nonsignificant; DD, doctor diagnosed; ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; AA,
arachidonic acid; DPA, docosapentaenoic acid.
Table 2. Characteristics of the SNPs in the FADS gene cluster
SNP Alleles (major/minor) 1/2 N
Number of subjects with
Genoype (%) Allele (%)
11 12 22 1 2
rs174545 G/C 1817 828 (46%) 790 (43%) 199 (11%) 2446 (67%) 1188 (33%)
rs174546 G/A 1844 845 (46%) 799 (43%) 200 (11%) 2489 (67%) 1199 (33%)
rs174556 G/A 1835 922 (50%) 757 (41%) 156 (9%) 2601 (71%) 1069 (29%)
rs174561 A/G 1855 934 (50%) 765 (41%) 156 (8%) 2633 (71%) 1077 (29%)
rs174575 C/G 1970 1109 (56%) 728 (37%) 133 (7%) 2946 (75%) 994 (25%)
rs3834458 T/del 1967 908 (46%) 852 (43%) 207 (11%) 2668 (68%) 1266 (32%)
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three out of six SNPs after correction for multiple testing
(acorr = 0.0063).
A higher risk for eczema was observed in individuals
carrying the homozygous major allele (G/G) of SNP
rs174556, although this effect did not reach significance
after adjusting for multiple testing.
No association between margarine intake and atopic
diseases or allergic sensitization was observed for homo-
zygous or heterozygous minor allele carriers.
The analyses stratified for the GINIplus and LISAplus
studies did not indicate heterogeneity (data not shown).
Haplotypes for the six FADS SNPs were computed using
the EM algorithm (supporting information, Table S3).
Only four haplotypes had a frequency 41%. The most
common haplotype (66.7%) is carrying only major alleles
and the next frequent haplotype (20.7%) is carrying only
minor alleles at all loci.
There were no differences in the constructed haplotypes
between the GINIplus and LISAplus studies.
Discussion
The present study investigated the influence of the FADS1
FADS2 gene cluster on the association between dietary
fatty acid intake and atopic diseases and allergic sensiti-
zation in 10-year-old children from the GINIplus and
LISAplus birth cohort studies. The crude analysis showed
no significant association between individuals with atopic
characteristics and fatty acid intake. Further, there was no
significant difference in the prevalence of atopic diseases
dependent on the FADS genotype. However, in stratified
analyses the total n-3/total n-6 ratio was positively
associated with an increased risk for hayfever. This effect
was significant for individuals carrying the major allele,
but not after correcting for multiple testing. A higher daily
margarine intake was a significant risk factor for asthma
in major allele carriers.
Comparison with other studies
Sausenthaler et al. [2] reviewed findings from studies
estimating the association of dietary fat intake with
allergic diseases and allergic sensitization. Although the
mechanism seems biological plausible, the evidence that
n-6 PUFA intake is a risk factor and n-3 PUFA intake is a
protective factor for allergic diseases remains scarce and
the results are not conclusive. However, margarine intake
has been positively linked to an increased risk for allergic
sensitization and atopic diseases in children [2]. It was
suggested that the high content of n-6 LA in margarine
may have a negative effect on allergic disease develop-
ment. However, it is not clear why a large proportion of
studies analysing n-6 PUFA intake failed to find any
association with atopic outcomes. One reason might be
inter-individual genetic differences in fatty acid metabo-
lism. In fact, our study indicates that FADS genotypes
modulate the association between fatty acid intake and
atopic diseases.
In our study, margarine consumption was positively
associated with asthma, but only in individuals who are
homozygous for the major allele. This is in line with
Table 3.Median dietary fatty acid intake and atopy
Total n-3/total n-6 ratio Margarine (g/d)
Median 95%-CI Median 95%-CI
Asthma (DD)
No (n = 1815) 0.146 (0.144,0.147) 0.95 (0.79,1.11)
Yes (n = 126) 0.149 (0.144,0.155) 2.00 (1.12,2.88)
Hay fever (DD)
No (n = 1689) 0.146 (0.144,0.147) 1.00 (0.83,1.17)
Yes (n = 236) 0.151 (0.147,0.156) 1.00 (0.56,1.44)
Eczema (DD)
No (n = 1779) 0.146 (0.144,0.147) 0.93 (0.77,1.09)
Yes (n = 156) 0.149 (0.144,0.154) 1.43 (0.62,2.24)
IgE positive
No (n = 910) 0.147 (0.145,0.150) 0.79 (0.58,1.01)
Yes (n = 794) 0.146 (0.144,0.149) 0.71 (0.48,0.95)
DD, doctor diagnosed.
Table 4. Prevalence of atopic characteristics stratified by genotype for
FADS gene cluster
Asthma (DD) Hayfever (DD) Eczema (DD) IgE positive
% (n/N) % (n/N) % (n/N) % (n/N)
rs174545
C/C 4.5 (9/199) 12.1 (24/199) 7.5 (15/199) 38.7 (77/199)
C/G 6.2 (49/790) 11.0 (87/790) 8.0 (63/790) 40.3 (318/790)
G/G 7.4 (61/828) 12.3 (102/828) 7.7 (64/828) 39.5 (327/828)
rs174546
A/A 4.5 (9/200) 12.0 (24/200) 7.5 (15/200) 38.5 (77/200)
A/G 6.1 (49/799) 11.0 (88/799) 8.0 (64/799) 39.9 (319/799)
G/G 7.2 (61/845) 12.4 (105/845) 7.7 (65/845) 39.6 (335/845)
rs174556
A/A 3.8 (6/156) 10.3 (16/156) 9.6 (15/156) 39.7 (62/156)
A/G 5.8 (44/757) 11.0 (83/757) 7.1 (54/757) 39.0 (295/757)
G/G 7.5 (69/922) 12.9 (119/922) 8.0 (74/922) 40.7 (375/922)
rs174561
G/G 5.1 (8/156) 9.6 (15/156) 9.6 (15/156) 39.7 (62/156)
A/G 5.5 (42/765) 10.8 (83/765) 7.3 (56/765) 39.3 (301/765)
A/A 7.3 (68/934) 12.7 (119/934) 8.1 (76/934) 40.0 (374/934)
rs174575
G/G 5.3 (7/133) 12.8 (17/133) 9.0 (12/133) 36.8 (49/133)
C/G 5.4 (39/728) 10.9 (79/728) 8.2 (60/728) 42.3 (308/728)
C/C 6.9 (77/1109) 12.4 (137/1109) 7.4 (82/1109) 38.7 (429/1109)
rs3834458
del/del 3.9 (8/207) 11.6 (24/207) 7.7 (16/207) 39.6 (82/207)
del/T 5.9 (50/852) 11.3 (96/852) 8.3 (71/852) 40.7 (347/852)
T/T 7.3 (66/908) 12.6 (114/908) 7.3 (66/908) 39.3 (357/908)
N: Total number of children stratified by FADS genotype.
n: Number of cases stratified by FADS genotype.
DD, doctor diagnosed.
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previous studies [2]. Although the fatty acid intake was
calculated based on the dietary intake, we could not find
any significant association between the total n-3/total n-6
ratio and asthma. It is likely that the negative effect of
margarine consumption on allergic diseases is not exclu-
sively caused by the high content of n-6 fatty acids.
In contrast to the theory by Black and Sharpe [1], a
higher total n-3/total n-6 ratio did not show protective
effects on atopic diseases and allergic sensitization. Actu-
ally, a higher total n-3/total n-6 ratio was linked to an
increased risk for hayfever in individuals carrying the
homozygous major allele. However, homozygous minor
allele carriers also had an increased risk for hayfever, but
this was nonsignificant, possibly due to loss of power from
the reduced sample size.
Molto´-Puigmartı´ et al. [21] reported that FADS gene
variants modify the association between fish intake and
DHA contents in human milk lipids. The percentage
contribution of DHA to total milk lipids was similar in
women with low fish intake for all genotypes, whereas
DHA increased with higher fish consumption in carriers of
major but not of homozygous minor alleles. Lu et al. [22]
examined the influence of the FADS1 genotype on the
association between dietary intake of n-6 and n-3 PUFAs
and plasma concentrations of total, HDL- and non-HDL-
cholesterol. Significant associations were observed in
major allele carriers, but only in the groups with high
dietary intake of n-6 and n-3 PUFAs and not in the groups
with low intake. Both studies observed effects of a higher
dietary intake only in individuals carrying the major
allele. In the current study we also found significant
effects only in homozygous major allele carriers.
In our study, margarine intake was positively associated
with the development of atopic diseases. It was previously
suggested that the high content of n-6 LA in margarine is
associated with allergic diseases and symptoms. LA is a
precursor of AA, which can act as a substrate of inflam-
matory eicosanoids. Thirty percent of the variance of AA
is explained by genetic predisposition. In individuals
carrying the major allele of the FADS gene cluster, a
higher percentage of LA is metabolized to AA [7]. There-
fore, it is hypothesized that the negative effect of margar-
ine consumption on the development of atopic diseases is
stronger in major allele carriers.
It is hypothesized that n-6 PUFA may increase the IgE
synthesis and thus enhance the development of allergic
diseases [4, 5]. Our data does not support this hypothesis.
There was no association between fatty acid intake and
increased specific IgE against food or inhalant allergens.
While the association between FADS genotype and
fatty acid composition in serum phospholipids or plasma
is well established [6], the association between FADS
variants and atopic diseases is less clear. A study in adults
reported a decreased risk for allergic rhinitis and atopic
eczema in minor allele carriers [7], although thers
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associations did not reach the significance level after
adjusting for multiple testing. Singmann et al. [23] in-
vestigated the association between five SNPs in the
FADS1 FADS2 gene cluster and doctor-diagnosed atopic
diseases in 6-year-old children from the GINIplus and
LISAplus birth cohort studies. None of the atopic out-
comes were associated with any of the SNPs. Rzehak et al.
[24] combined data from the LISAplus study in Munich
and the KOALA study in Dutch children. There were no
significant association between FADS1 FADS2 variants
and parental reported eczema during the first 2 years of
life.
A review by Lattka et al. [25] reported a modulating
effect of FADS genotypes on fatty acid related phenotypes
such as intelligence development, risk of myocardial
infarction and metabolic syndrome. This illustrates that
FADS genotypes have a modulating effect on fatty acid
metabolism and may explain the findings of this study.
The haplotype construction revealed four haplotypes
with frequencies41%. The two most frequent haplotypes
are the same haplotypes Schaeffer et al. [7] computed in
the 5-Locus haplotype analysis. The frequencies of these
two haplotypes were also very similar to the haplotypes
provided by Schaeffer et al. [7] (66.7% vs. 68.8% and
20.7% vs. 25.7%).
Strength and limitations
Blood levels of the fatty acids LA and ALA and their
derivatives are influenced mainly by diet, but also by
genetic variants [26]. Consequently, we assessed both
dietary intake and the genotype. The FFQ used in the
present study measured dietary intake over the past 12
months. We could not measure fatty acid blood levels over
a year due to study constraints, so it was not possible to
compare fatty acid intake to blood levels.
To evaluate the effect of the single FADS genotypes we
stratified the data by alleles for analysis. Owing to this
stratification the sample size was reduced, especially in
the group of homozygous minor allele carriers. Depending
on the different magnitudes of the prevalence of atopic
outcomes, the retrospective assessment of the statistical
power was heterogeneous. Additionally, the analysed
FADS variants do not cover the complete FADS gene
cluster as they were selected for genotyping based on
previous publications [7].
Population stratification is present in Northern Europe
[27] and also in Germany [28]. Although only Caucasians
were included in both studies and the analyses were
adjusted for study centre, population substructure might
still be present. Steffens et al. [28] observed only low
levels of population sub-structuring within the German
population, therefore we do not think that a potential
population substructure would affect our results substan-
tially.
A major strength of our investigation compared with
other studies is the assessment of the physician-diagnosed
atopic diseases such as asthma, hayfever and eczema.
Further, specific IgE against common food and inhalant
allergens from blood samples were measured.
Conclusion and clinical relevance
The association between dietary intake of fatty acids and
allergic diseases might be modulated by FADS gene
variants in children.
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Supplementary Table S1 Margarine intake [g/d] stratified by genotype 
  Homozygous minor allele Heterozygous allele 
Homozygous 
major allele p-value
1 
rs174545 
    Mean (25%Q.,75%Q.) 4.21 (0.08,4.71) 3.99 (0.00,4.57) 3.60 (0.00,4.03) 0.0469 
rs174546 
    Mean (25%Q.,75%Q.) 4.12 (0.08,4.71) 4.04 (0.00,4.62) 3.59 (0.00,4.03) 0.0470 
rs174556 
    Mean (25%Q.,75%Q.) 4.15 (0.08,4.43) 4.05 (0.00,4.86) 3.59 (0.00,4.00) 0.0951 
rs174561 
    Mean (25%Q.,75%Q.) 3.97 (0.07,4.33) 4.11 (0.00,5.00) 3.60 (0.00,4.00) 0.1005 
rs174575 
    Mean (25%Q.,75%Q.) 4.01 (0.14,4.71) 3.99 (0.00,4.41) 3.65 (0.00,4.13) 0.0859 
rs3834458 
    Mean (25%Q.,75%Q.) 4.01 (0.07,4.45) 4.04 (0.00,4.57) 3.54 (0.00,4.00) 0.0838 
 
1  p-value derived from Kruskal-Wallis test 
  
 2 
Supplementary Table S2  Logistic regression analyses of total n-3/total n-6 ratio and atopic outcomes  
rs174545 
total n-3/total n-6 ratio total n-3/total n-6 ratio total n-3/total n-6 ratio 
C/C (n=199) C/G (n=790) G/G (n=828) 
aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ 
Asthma (DD) 1.44  (0.51,4.06) 0.4948 0.97  (0.67,1.41) 0.8777 1.27  (0.91,1.75) 0.1567 
Hay fever (DD) 1.46  (0.78,2.71) 0.2346 1.06  (0.80,1.41) 0.6862 1.29  (1.00,1.68) 0.0526 
Eczema (DD) 1.89  (0.85,4.20) 0.1195 0.93  (0.67,1.30) 0.6795 0.98  (0.70,1.37) 0.9114 
IgE positive 0.88  (0.57,1.35) 0.5610 0.91  (0.75,1.11) 0.3601 0.91  (0.74,1.10) 0.3245 
          
rs174546 
A/A (n=200) A/G (n=799) G/G (n=845) 
aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ 
Asthma (DD) 1.33  (0.47,3.73) 0.5873 0.98  (0.68,1.42) 0.9227 1.28  (0.92,1.77) 0.1375 
Hay fever (DD) 1.46  (0.78,2.71) 0.2359 1.07  (0.81,1.42) 0.6444 1.31  (1.01,1.69) 0.0410 
Eczema (DD) 1.84  (0.83,4.08) 0.1340 0.92  (0.67,1.28) 0.6348 0.97  (0.70,1.36) 0.8748 
IgE positive 0.86  (0.56,1.32) 0.4852 0.93  (0.76,1.12) 0.4379 0.93  (0.76,1.12) 0.4398 
          
rs174556 
A/A (n=156) A/G (n=757) G/G (n=922) 
aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ 
Asthma (DD) 0.84  (0.23,3.12) 0.7995 0.93  (0.62,1.38) 0.7087 1.30  (0.96,1.75) 0.0903 
Hay fever (DD) 1.32  (0.65,2.70) 0.4399 1.04  (0.77,1.40) 0.8118 1.31  (1.03,1.66) 0.0291 
Eczema (DD) 1.88  (0.85,4.14) 0.1168 0.97  (0.68,1.38) 0.8700 0.94  (0.69,1.28) 0.6734 
IgE positive 0.85  (0.53,1.35) 0.4804 0.96  (0.78,1.18) 0.7072 0.88  (0.74,1.06) 0.1876 
          
rs174561 
G/G (n=156) A/G (n=765) A/A (n=934) 
aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ 
Asthma (DD) 1.35  (0.47,3.92) 0.5795 0.85  (0.57,1.29) 0.4523 1.30  (0.96,1.76) 0.0879 
Hay fever (DD) 1.50  (0.71,3.15) 0.2881 1.04  (0.77,1.41) 0.7800 1.30  (1.03,1.65) 0.0296 
Eczema (DD) 1.97  (0.90,4.31) 0.0897 0.96  (0.68,1.36) 0.8260 0.94  (0.69,1.27) 0.6765 
IgE positive 0.88  (0.55,1.40) 0.5908 0.99  (0.81,1.22) 0.9440 0.88  (0.74,1.06) 0.1814 
          
rs174575 
G/G (n=133) C/G (n=728) C/C (n=1109) 
aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ 
Asthma (DD) 1.00  (0.30,3.37) 0.9971 1.08  (0.72,1.62) 0.7172 1.18  (0.89,1.58) 0.2515 
Hay fever (DD) 1.40  (0.68,2.91) 0.3616 1.06  (0.79,1.44) 0.6871 1.25  (1.00,1.57) 0.0518 
Eczema (DD) 1.31  (0.56,3.08) 0.5302 0.95  (0.67,1.35) 0.7805 0.96  (0.72,1.29) 0.8039 
IgE positive 0.87  (0.51,1.46) 0.5889 0.92  (0.75,1.13) 0.4409 0.94  (0.79,1.11) 0.4685 
          
rs3834458 
del/del (n=207) del/T (n=852) T/T (n=908) 
aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ aORIQR$ 95%-CI p-value$$ 
Asthma (DD) 0.67  (0.22,2.07) 0.4853 1.08  (0.76,1.54) 0.6725 1.27  (0.93,1.73) 0.1309 
Hay fever (DD) 1.46  (0.79,2.71) 0.2238 1.05  (0.80,1.38) 0.7171 1.29  (1.01,1.65) 0.0430 
Eczema (DD) 1.74  (0.81,3.72) 0.1560 0.94  (0.69,1.28) 0.6712 0.95  (0.68,1.32) 0.7515 
IgE positive 0.88  (0.58,1.33) 0.5348 0.92  (0.76,1.11) 0.3830 0.95  (0.79,1.14) 0.5780 
 
$ Odds ratios per interquartile range increase adjusted for gender, age, maternal education and study 
centre. IQR(total n-3/total n-6 ratio) = 0.041 
$$ 5% significance level adjusted for multiple testing: αcorr=0.0063 
DD doctor diagnosed
 3 
Supplementary Table S3 Haplotype characteristics for the haplotypes constructed based on the 
six SNPs in the FADS1 FADS2 gene cluster with frequency >1%.  
  
Haplotype 
Alleles 
(1: major/ 
2: minor) 
Frequency  
(%) 
LISAplus 
   Major allele haplotype GGGACT 111111 67.1 
Minor allele haplotype CAAGGdel 222222 20.4 
Haplotype 1 CAAGCdel 222212 8.2 
Haplotype 2 CAGAGdel 221122 2.7 
GINIplus 
   Major allele haplotype GGGACT 111111 66.5 
Minor allele haplotype CAAGGdel 222222 20.9 
Haplotype 1 CAAGCdel 222212 7.9 
Haplotype 2 CAGAGdel 221122 3.4 
Total 
   Major allele haplotype GGGACT 111111 66.7 
Minor allele haplotype CAAGGdel 222222 20.7 
Haplotype 1 CAAGCdel 222212 8.0 
Haplotype 2 CAGAGdel 221122 3.1 
 
 4 
 
Legend to Figure 
 
Supplementary Figure 1 
Pairwise LD pattern between the six SNPs in the FADS gene cluster measured by Lewontin’s D’ 
(a. LISAplus study, c. GINIplus study) and r² (b. LISAplus study, d. GINIplus study). 
 
a                        b
c                        d
rs3834458rs174575rs174561rs174556rs174546rs174545
 
rs3834458rs174575rs174561rs174556rs174546rs174545
 
rs3834458rs174575rs174561rs174556rs174546rs174545
 
rs3834458rs174575rs174561rs174556rs174546rs174545
 

5 Paper 2: FADS Variants, Exclusive
Breastfeeding and Asthma in Children
(Standl et al. Allergy, 2012)
Original title: FADS gene cluster modulates the eﬀect of breastfeeding on asthma.
Results from the GINIplus and LISAplus studies.
Authors: M Standl, S Sausenthaler, E Lattka, S Koletzko, C-P Bauer, H-E
Wichmann, A von Berg, D Berdel, U Krämer, B Schaaf, I Lehmann,
O Herbarth, N Klopp, B Koletzko, J Heinrich
Journal: Allergy
Volume: 67
Pages: 8390
Year: 2012
Reproduced with permission from John Wiley and Sons.
39

ORIGINAL ARTICLE EPIDEMIOLOGY AND GENETICS
FADS gene cluster modulates the effect of breastfeeding
on asthma. Results from the GINIplus and LISAplus studies
M. Standl1, S. Sausenthaler1, E. Lattka2, S. Koletzko3, C.-P. Bauer4, H.-E. Wichmann1,5, A. von
Berg6, D. Berdel6, U. Kra¨mer7, B. Schaaf8, I. Lehmann9, O. Herbarth10, N. Klopp2, B. Koletzko3 &
J. Heinrich1 for the GINIplus* and LISAplus Study Group
1Helmholtz Zentrum Mu¨nchen, German Research Centre for Environmental Health, Institute of Epidemiology I, Neuherberg; 2Research Unit
of Molecular Epidemiology, Helmholtz Zentrum Mu¨nchen, German Research Centre for Environmental Health, Neuherberg; 3Dr. von Hauner
Children’s Hospital, University of Munich Medical Centre, Munich; 4Department of Pediatrics, Technical University of Munich, Munich;
5Institute of Medical Data Management, Biometrics and Epidemiology, Ludwig Maximilians University, Munich; 6Department of Pediatrics,
Marien-Hospital Wesel, Wesel; 7IUF – Leibniz-Institut fu¨r umweltmedizinische Forschung, Du¨sseldorf; 8Medical Practice for Pediatrics, Bad
Honnef; 9UFZ – Helmholtz Centre for Environmental Research, Department for Environmental Immunology, Leipzig; 10Faculty of Medicine,
University of Leipzig, Environmental Medicine and Hygiene, Leipzig, Germany
To cite this article: Standl M, Sausenthaler S, Lattka E, Koletzko S, Bauer C-P, Wichmann H-E, von Berg A, Berdel D, Kra¨mer U, Schaaf B, Lehmann I, Herbarth
O, Klopp N, Koletzko B, Heinrich J For the GINIplus and LISAplus study Group. FADS gene cluster modulates the effect of breastfeeding on asthma. Results from
the GINIplus and LISAplus studies. Allergy 2012; 67: 83–90.
Breastfeeding (BF) is widely recognized to have beneﬁcial
effects on asthma and atopy (1), although not all results are
conclusive (2) and the underlying biological mechanism is not
entirely clear. Among other factors in breast milk, the com-
position of polyunsaturated fatty acids (PUFA) of breast
milk has been proposed to cause the protective effect (3).
Linoleic acid (LA, 18:2n-6), the most common dietary n-6
PUFA, is metabolized to arachidonic acid (AA, 20:4n-6).
Arachidonic acid can act as substrate of inﬂammatory eico-
sanoids. Eicosapentaenoic acid (EPA, 20:5n-3) and docosa-
hexaenoic acid (DHA, 22:6n-3), products of the metabolism
of the essential n-3 fatty acid a-linolenic acid (ALA,
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Abstract
Background: The protective effect of breastfeeding (BF) on the development of
asthma has been widely recognized, even if not all results have been consistent.
Gene variants of the FADS gene cluster have a major impact on fatty acid composi-
tion in blood and in breast milk. Therefore, we evaluated the inﬂuence of the
FADS1 FADS2 gene cluster polymorphisms on the association between BF and
asthma.
Methods: The analysis was based on data (N = 2245) from two German prospective
birth cohort studies. Information on asthma and BF during the ﬁrst 6 months was
collected using questionnaires completed by the parents. Logistic regression model-
ling was used to analyse the association between exclusive BF and ever having
asthma stratiﬁed by genotype.
Results: In the stratiﬁed analyses, BF for 3 or 4 months after birth had a protective
effect for heterozygous and homozygous carriers of the minor allele (adjusted odds
ratio between 0.37 (95% CI: 0.18–0.80) and 0.42 (95% CI: 0.20–0.88). Interaction
terms of BF with genotype were signiﬁcant and ranged from )1.17 (P-value: 0.015)
to )1.33 (0.0066). Moreover, heterozygous and homozygous carriers of the minor
allele who were exclusively breastfed for 5 or 6 months after birth had a reduced
risk of asthma [0.32 (0.18–0.57) to 0.47 (0.27–0.81)] in the stratiﬁed analyses. For
individuals carrying the homozygous major allele, BF showed no signiﬁcant effect
on the development of asthma.
Conclusions: The association between exclusive BF and asthma is modiﬁed by the
genetic variants of FADS genotypes in children.
Allergy
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18:3n-3), have been suggested to have beneﬁcial effects on
allergic inﬂammation. n-6 and n-3 fatty acids use the same
enzymatic pathway (4, 5). This led to the hypothesis that
n-6 PUFA intake may enhance the development of allergic
diseases in susceptible individuals. In contrast, n-3 PUFA
are suggested to have protective effects against allergic dis-
eases (6).
The fatty acid desaturase 1 and 2 genes (FADS1 and
FADS2) encode the enzymes delta-5-desaturase and delta-6-
desaturase, respectively, which regulate the conversion of the
precursor essential fatty acids to long chain metabolites (7).
Several studies have shown strong associations between the
FADS gene cluster and fatty acid levels in serum phospholip-
ids (8, 9), plasma and adipose tissue samples (10), erythrocyte
cell membranes (9, 11), breast milk (9, 12, 13) and red blood
cell lipids (14). Carriers of the minor allele exhibit increased
levels of desaturase substrates and decreased levels of desat-
urase products. This might arise from lowered transcriptional
levels or diminished conversion rates of the enzymes in indi-
viduals carrying the minor alleles.
Inter-individual genetic differences in fatty acid metabo-
lism might be one of the reasons for the controversial associ-
ation between BF and atopic phenotypes (3). Therefore, we
investigated whether the association between exclusive BF
and later development of asthma could be modiﬁed by
genetic variants of the FADS gene cluster.
Methods
Study population
Data from two ongoing German birth cohort studies were
included in this investigation, the German LISAplus (Life-
style Related Factors on the Immune System and the
Development of Allergies in Childhood) and GINIplus
(German Infant Nutritional Intervention) studies. LISAplus
is a population-based birth cohort study. A total of 3097
neonates were recruited between 1997 and 1999 in Munich,
Leipzig, Wesel and Bad Honnef. The participants were not
preselected based on family history of allergic diseases (15).
A total of 5991 mothers and their newborns were recruited
to the GINIplus study between September 1995 and June
1998 in Munich and Wesel. Infants with at least one aller-
gic parent and/or sibling were allocated to the intervention-
al study arm investigating the effect of different hydrolysed
formulas for allergy prevention in the ﬁrst year of life (16).
All children without a family history of allergic diseases
and children whose parents did not give consent for the
intervention were allocated to the noninterventional arm.
Detailed descriptions of the LISAplus and GINIplus stud-
ies have been published elsewhere [(15) and (16), respec-
tively].
In both studies, only individuals with Caucasian German
descent were included.
For both studies, approval by the local ethics committees
(Bavarian Board of Physicians, University of Leipzig, Board
of Physicians of North-Rhine-Westphalia) and written con-
sent from participant’s families were obtained.
Definition of exclusive breastfeeding
Questions on infant feeding during the ﬁrst 6 months of life
were answered by the parents during the 1-year follow-up in
the GINIplus study and during the 6-month follow-up in the
LISAplus study. The parents were asked for each of the ﬁrst
6 months of life whether the newborns were exclusively
breastfed, exclusively bottle-fed or both breastfed and bottle-
fed. Mutually exclusive categories were built based on the
number of months the children were exclusively breastfed
after birth (no exclusive BF, up to 2 months, up to 4 months
or more than 4 months of exclusive BF). Children who were
exclusively bottle-fed or mixed breastfed and bottle-fed were
categorized as the reference group ‘No exclusive BF’ to reach
sufﬁcient numbers for the reference group.
Genotyping
Six single-nucleotide polymorphisms (SNPs) of the FADS1
FADS2 gene cluster (rs174545, rs174546, rs174556, rs174561,
rs174575 and rs3834458) were typed. Five of these variants
(rs174545, rs174546, rs174556, rs174561 and rs3834458) have
been previously shown to be in strong linkage disequilibrium
(LD) with each other (r2 > 0.7, D’ > 0.9) (8). These ﬁve
SNPs were selected based on the previous publications in
adult populations (8, 17). Moreover, we included the SNP
rs174575. In addition, applying the tagger server program
(http://www.broadinstitute.org/mpg/tagger/) in combination
with HapMap, we found that with the three SNPs rs174545,
rs174546 and rs174556 we could tag 27 SNPs between base
pair positions 61234329 and 61372379 of FADS1 FADS2.
The efﬁciency was 10.7-fold although the two further SNPs
rs174561 and rs3834458 could not be included as these are
not included in the HapMap database. Genotyping of SNPs
was realized with the iPLEX (Sequenom, San Diego, CA,
USA) method by means of matrix-assisted laser desorption
ionization–time of ﬂight mass spectrometry method
(MALDI-TOF MS, Mass Array; Sequenom) in one labora-
tory according to the manufacturer’s instructions. Standard
genotyping quality control included 10% duplicate and nega-
tive samples. Genotyping discordance rate was below 0.3%.
Definition of outcome variables
Information on ever having physician-diagnosed asthma was
collected using self-administered questionnaires completed by
the parents. The questionnaires were completed at 6, 12, 18
and 24 months and 4, 5, 6 and 10 years of age in the LISA-
plus study and 1, 2, 3, 4, 6 and 10 years in the GINIplus
study. Each questionnaire asked for information pertaining
to the timeframe since the previous follow-up. Based on these
questions for asthma for each year of age up to 10 years, a
binary outcome variable for ever having a diagnosis was
deﬁned. Blood was collected at age 6 and 10 years. Speciﬁc
serum IgE concentrations were assayed by the CAP-RAST
FEIA system (Pharmacia Diagnostics, Freiburg, Germany)
according to the manufacturer’s instructions. Screening tests
were used to test allergic sensitization against food allergens
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(fx5: egg, cow milk, wheat, peanut, soybean and codﬁsh) and
inhalant allergens (sx1: Dermatophagoides pteronyssinus, cat,
dog, rye, timothy grass, Cladosporium herbarum, birch and
mugwort). The limit of detection for allergen-speciﬁc IgE was
0.35 kU/l.
Atopic asthma was deﬁned as ever having physician-diag-
nosed asthma and having an IgE value exceeding the detection
limit in at least one of both RAST tests at 6 or 10 years of age.
Nonatopic asthma was deﬁned as ever having physician-diag-
nosed asthma and having an IgE value below the detection
limit in both RAST tests administered at 6 and 10 years of age.
Statistical analysis
Preliminary analyses showed similar results for the homozy-
gous and heterozygous minor allele carriers. Therefore, we
assumed a dominant model and compared homozygous or
heterozygous minor allele carriers with homozygous major
allele carriers.
Multiple logistic regression analysis stratiﬁed by genotype
was applied to estimate the adjusted odds ratios (aOR) with
95% conﬁdence intervals (CI) for the association between
exclusive BF and asthma. Additionally, the interaction
between FADS genotype and category of BF was tested.
Statistical signiﬁcance was deﬁned by a two-sided alpha
level of 5%. According to Nyholt (18), the number of effec-
tive loci of the six SNPs in the FADS gene cluster was com-
puted as 2. To correct for multiple testing, the alpha level is
divided by the number of effective loci, which leads to a cor-
rected two-sided alpha level of 5%/2 = 2.5%.
All models are adjusted for gender, age, maternal educa-
tion level (low, medium and high), study centre (Munich,
Leipzig, Wesel and Bad Honnef), presence of older siblings
(yes/no) and study (GINI intervention, GINI noninterven-
tion, LISA). In bivariate analyses, testing was performed
using Pearson’s chi-squared test. Statistical analysis was per-
formed using the statistical software R, version 2.13.1 (http://
www.R-project.org) (19).
Results
Complete information on BF, FADS1 FADS2 genotype and
asthma was available for 2245 children [1456 (65%) children
from the GINIplus study and 789 (35%) children from the
LISAplus study]. Basic characteristics of the study population
are presented in Table 1. Forty-nine per cent of the neonates
were exclusively breastfed for at least 5 months after birth.
The prevalence for doctor-diagnosed asthma up to 10 years
of age is in total 11%.
The genotype and allele frequencies of the six SNPs that
were included in the analysis are shown in Table 2. Five of
the six SNPs (rs174545, rs174546, rs174556, rs174561 and
rs3834458) are in high LD with each other. For these ﬁve
SNPs, the pairwise squared correlations r2 ranged between
0.84 and 0.99 and Lewontin’s D’ ranged between 0.99 and 1.
For rs174575, the LB is lower. The pairwise correlation r2 for
this SNP ranged between 0.49 and 0.64 and Lewontin’s D’
ranged between 0.77 and 0.95.
The association between asthma and exclusive BF is
presented in Table 3. Asthma prevalence is decreasing with
increasing duration of exclusive BF (P = 0.0172). Table 4
shows the asthma prevalence stratiﬁed by genotype. The
asthma prevalence is lower in minor allele carriers than in
homozygous major allele carriers, although this effect is non-
signiﬁcant.
Figure 1 shows the association between asthma prevalence
and the number of months of exclusive BF stratiﬁed by geno-
type for each of the six SNPs. The asthma prevalence is
reduced in children who were exclusively breastfed for at
least 3 months and are carrying the minor allele, whereas no
effect is observed in homozygous major allele carriers.
The results of logistic regression models of exclusive BF
on asthma stratiﬁed by genotype show similar effects
(Table 5). Individuals carrying the minor allele have a signiﬁ-
cant decreased asthma risk if they are exclusively breastfed
for 3 or 4 months [aOR between 0.37 (95% CI: 0.18–0.80)
and 0.42 (95% CI: 0.20–0.88)] or more than 5 months [0.32
(0.18–0.57) to 0.47 (0.27–0.81)]. These associations remained
signiﬁcant after correction for multiple testing
(acorr = 0.025).
In children carrying at least one minor allele of the FADS
variants rs174545, rs174546, rs174556, rs174561 and
rs3834458, asthma risk reduction is strongest for exclusive
BF for 3 or 4 months after birth. Only for minor allele carri-
ers of one SNP, rs174575, the asthma risk is further
decreased for further extended exclusive BF. Additionally,
adjusting for parental atopy did not modify these associa-
tions substantially.
The results of a stratiﬁed analysis for atopic (Supplemen-
tary Table S2) and nonatopic asthma (Supplementary Table
S3) did not change substantially. In an additional model, the
Table 1 Basic characteristics of the study population
LISAplus
(n = 789)
GINIplus
(n = 1456)
Total
(n = 2245)
Boys 56% 50% 52%
Intervention group 0% 50% 32%
High maternal
education
58% 50% 53%
Presence of
older siblings
47% 48% 48%
Study centre
Mu¨nchen 53% 56% 55%
Leipzig 25% 0% 9%
Bad Honnef 13% 0% 5%
Wesel 9% 44% 32%
Breastfeeding (BF)
Number of months
of exclusive BF
18% 26% 23%
1–2 13% 11% 12%
3–4 18% 16% 17%
5–6 51% 47% 48%
Asthma (DD) 9% 12% 11%
Atopic asthma (DD) 7% 8% 8%
Nonatopic asthma (DD) 1% 3% 2%
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interaction between FADS genotype and exclusive BF was
tested. In Supplementary Table S1, only the interactive
effects are presented. These effects also show a highly
decreased risk of asthma in children carrying at least one
minor allele who are breastfed for more than 3 months. After
correction for multiple testing (acorr = 0.025), the interaction
is signiﬁcant for children breastfed for 3 to 4 months for all
of the six tested SNPs [interaction effect ranging from )1.17
(P = 0.015) to )1. 33 (P = 0.0066)]. The asthma risk is also
decreased in minor allele carriers who are breastfed for more
than 5 months [)0.64 (P = 0.0861) to )1.33 (P = 0.0005)].
After correction for multiple testing, the interaction is signiﬁ-
cant for four SNPs (rs174545, rs174546, rs174575 and
rs3834458).
Discussion
The present study investigated the modulating effect of the
FADS gene cluster on the association between exclusive BF
and the development of asthma up to 10 years of age. Exclu-
sive BF for more than 3 months was found to reduce the risk
of asthma in homozygous or heterozygous carriers of the
minor allele. In homozygous major allele carriers, no effect
of the duration of exclusive BF on the development of
asthma was observed. We identiﬁed a strong interaction of
the association between exclusive BF and asthma by FADS
gene polymorphism in children.
Comparison with other studies
We could not ﬁnd another study that investigated the associ-
ation between BF, FADS genotype and atopy. Two studies
reported a modulating effect of the FADS genotype on the
association between BF and IQ (20, 21). Caspi et al. (20)
Table 2 Characteristics of the SNPs in the FADS gene cluster
SNP
Alleles
(major/minor)
1/2 N
Number of subjects with
Genotype (%) Allele (%)
11 12/22 1 2
rs174545 G/C 2047 931 (45%) 1116 (55%) 2757 (67%) 1337 (33%)
rs174546 G/A 2076 946 (46%) 1130 (54%) 2799 (67%) 1353 (33%)
rs174556 G/A 2069 1033 (50%) 1036 (50%) 2927 (71%) 1211 (29%)
rs174561 A/G 2082 1040 (50%) 1042 (50%) 2951 (71%) 1213 (29%)
rs174575 C/G 2212 1236 (56%) 976 (44%) 3300 (75%) 1124 (25%)
rs3834458 T/del 2211 1016 (46%) 1195 (54%) 2995 (68%) 1427 (32%)
SNP, single-nucleotide polymorphisms.
Table 3 Prevalence of doctor-diagnosed asthma stratified by number of months of exclusive breastfeeding
Number of months of exclusive BF 1–2 3–4 5–6
P-value*% (n/N) % (n/N) % (n/N) % (n/N)
Asthma ever (DD)
No 86.0 (442/513) 87.0 (233/268) 89.0 (338/379) 91.0 (988/1085) 0.0172
Yes 14.0 (71/513) 13.0 (35/268) 11.0 (41/379) 9.0 (97/1085)
BF, breastfeeding.
*Chi-squared test.
Table 4 Prevalence of doctor-diagnosed asthma stratified by geno-
type
Asthma ever (DD)
% (n/N) P-value*
rs174545
Allele 12/22 10.5 (117/1116) 0.3372
Allele 11 11.9 (111/931)
rs174546
Allele 12/22 10.4 (118/1130) 0.3105
Allele 11 11.9 (113/946)
rs174556
Allele 12/22 10.0 (104/1036) 0.1190
Allele 11 12.3 (127/1033)
rs174561
Allele 12/22 10.1 (105/1042) 0.1790
Allele 11 12.0 (125/1040)
rs174575
Allele 12/22 10.2 (100/976) 0.4944
Allele 11 11.2 (139/1236)
rs3834458
Allele 12/22 10.0 (120/1195) 0.2062
Allele 11 11.8 (120/1016)
*Chi-squared test.
FADS genes, breastfeeding and asthma Standl et al.
86 Allergy 67 (2012) 83–90 ª 2011 John Wiley & Sons A/S
found no signiﬁcant differences in IQ in homozygous minor
allele carriers of rs174575 but a beneﬁcial effect of BF on
IQ scores in homozygous or heterozygous major allele carri-
ers. In contrast, Steer et al. (21) could not replicate the
results by Caspi et al. In this study, BF was associated with
higher IQ scores at 8 years of age in homozygous minor
allele carriers.
While the association between FADS genotype and fatty
acid composition in serum phospholipids or plasma is well
established (7), the association between FADS variants and
atopic diseases or other fatty acid-related phenotypes is less
clear (22, 23). Singmann et al. (24) investigated the associa-
tion between ﬁve SNPs in the FADS1 FADS2 gene cluster
and doctor-diagnosed atopic diseases in 6-year-old children
from the GINIplus and LISAplus birth cohort studies. Scha-
effer et al. (8) reported a decreased risk of allergic rhinitis
and atopic eczema in minor allele carriers in adults, although
the associations did not reach the signiﬁcance level after
adjusting for multiple testing.
More than 3 months of exclusive BF was protective for
the development of asthma in minor allele carriers, but there
was no signiﬁcant difference whether minor allele carriers
were exclusively breastfed for 3–4 months or more than
4 months. This is in line with the results of the review by
Kramer et al. (1). There was no difference in the development
of allergies after exclusive BF for 6 months compared with
3–4 months. We did not ﬁnd a signiﬁcant association for
only 1 or 2 months of exclusive BF in our study. As the
reference group is not deﬁned by exclusive bottle-feeding
only, the difference between these two groups may be too
small to be detected as statistical signiﬁcant.
Additionally, the innate immune system of neonates is
skewed towards Th2 responses. The stimulation of the
immune system in early childhood redirects the balance
between Th1 and Th2 cells (25). So, it might be possible that
the beneﬁcial effects of BF occur during the development of
the immune system after the third month.
The sensitivity analysis for atopic and nonatopic asthma
did not show different effects for atopic and nonatopic
asthma. Looking at the point estimates for both outcomes,
there seems to be a stronger protective effect in particular for
minor allele carriers exclusively breastfed for 3–4 months for
nonatopic asthma, but the numbers are much too small for
statistical approval.
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Figure 1 Asthma prevalence stratified by FADS genotype and breastfeeding (1: major allele, 2: minor allele).
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The underlying biological mechanism that causes the asso-
ciation between BF, FADS1 FADS2 genotype and asthma is
not completely clear although there are a number of biologi-
cally plausible indicators (3, 26). Minor allele carriers have a
lower proportion of products of the fatty acid metabolism
and therefore a lower proportion of AA, a product of the
n-6 pathway which may reduce the risk of asthma. But this is
highly speculative as the underlying biological mechanisms
that cause these associations are unknown.
Strength and limitations
The fatty acid composition of the breast milk varies depend-
ing on the FADS genotype of the mother (9, 12, 13). The
breast milk of women carrying the homozygous minor allele
contains lower proportions of products of the fatty acid
metabolism compared to the breast milk of woman carrying
the major allele. As we do not know the genotype of the
mother, we cannot take the variation of the fatty acid
composition in the breast milk into account.
The prevalence of doctor-diagnosed asthma is in total 11%
up to 10 years of age. Owing to this low prevalence, the out-
come variable was deﬁned as ever having a diagnosis, and it was
not possible to apply a more appropriate longitudinal model.
Indeed, Scholtens et al. (27) could show in a longitudinal analy-
sis that BF for more than 16 weeks decreases the risk of asthma
until 8 years of age, but no age-dependent differences.
Additionally, the percentage of exclusively bottle-fed neo-
nates was very low in our study. Therefore, the reference
category ‘No exclusive BF’ covers all children that were
exclusively bottle-fed and both breastfed and bottle-fed after
birth. Thus, the effect estimates of our study might even
underestimate the true magnitude, if a bottle-fed-only group
could have been used. Further, the asthma deﬁnition is based
on parental report of a doctor diagnosis for each year up to
10 years of age, but there was no clinical ascertainment of
the parentally reported diagnosis. A major strength of our
study is the prospective design and the long-term follow-up
until 10 years of a large study population.
Conclusion
The association between exclusive BF and asthma is modiﬁed
by the genetic variants of FADS genotypes in children. Our
results suggest that only minor allele carriers beneﬁt from
exclusive BF in regard to asthma development, while homo-
zygous major allele carriers have no advantage in this respect.
This might explain the partly inconsistent results from previ-
ous studies on BF and asthma prevalence, which suggests the
inclusion of genetic data in future studies.
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Supplementary Table 1  Results of logistic regression models of exclusive breastfeeding (BF) and SNP interaction on asthma, adjusted for gender, study centre, maternal 
education level, study (GINI intervention, GINI non‐intervention, LISA) and presence of older siblings (reference category: never excl. BF and major allele)  
  1‐2 months excl. bf    3‐4 months excl. bf    5‐6 months excl. bf 
   Estimate Sd  p‐value$   Estimate Sd  p‐value$   Estimate Sd  p‐value$
rs174545 
Allele 12 /22 vs. Allele 11 ‐0.34  0.50 0.4914  ‐1.33  0.49  0.0066  ‐0.91  0.38 0.0168 
rs174546 
Allele 12 /22 vs. Allele 11 ‐0.34  0.50 0.4964  ‐1.31  0.49  0.0069  ‐0.95  0.38 0.0122 
rs174556 
Allele 12 /22 vs. Allele 11 ‐0.13  0.49 0.7858  ‐1.30  0.50  0.0087  ‐0.79  0.38 0.0365 
rs174561 
Allele 12 /22 vs. Allele 11 ‐0.07  0.49 0.8861  ‐1.27  0.50  0.0108  ‐0.64  0.37 0.0861 
rs174575 
Allele 12 /22 vs. Allele 11 ‐0.56  0.48 0.2414  ‐1.17  0.48  0.0150  ‐1.33  0.38 0.0005 
rs3834458 
Allele 12 /22 vs. Allele 11 ‐0.26  0.49 0.5984    ‐1.24  0.48  0.0095    ‐0.87  0.37 0.0187 
$ Significance level after correcting for multiple testing: αcorr=0.05/2=0.025 
1: major allele, 2: minor allele 
Supplementary Table 2  Results of  logistic regression models of breastfeeding (BF) on atopic asthma stratified by genotype, adjusted for gender, study centre, maternal 
education level, study (GINI intervention, GINI non‐intervention, LISA) and presence of older siblings (reference category: never exclusive breastfeeding) 
      never excl. BF 1‐2 months excl. BF 3‐4 months excl. BF 5‐6 months excl. BF
   N  aOR    aOR 95%‐CI  p‐value$   aOR 95%‐CI  p‐value$   aOR 95%‐CI  p‐value$
rs174545 
Allele 12 / 22  1039  1  0.74 (0.34,1.63) 0.4548 0.43 (0.19,0.96) 0.0394 0.44 (0.23,0.81) 0.0082
Allele 11  885  1  1.33 (0.57,3.08) 0.5060 1.05 (0.47,2.30) 0.9127 1.11 (0.59,2.08) 0.7442
rs174546 
Allele 12 / 22  1051  1  0.75 (0.34,1.66) 0.4794 0.44 (0.19,0.98) 0.0446 0.43 (0.23,0.80) 0.0078
Allele 11  899  1  1.33 (0.58,3.08) 0.5000 1.05 (0.48,2.32) 0.8955 1.13 (0.61,2.12) 0.6948
rs174556 
Allele 12 / 22  967  1  0.72 (0.31,1.65) 0.4332 0.42 (0.18,0.98) 0.0453 0.38 (0.20,0.74) 0.0045
Allele 11  976  1  1.29 (0.58,2.84) 0.5337 1.07 (0.51,2.27) 0.8573 1.10 (0.61,1.98) 0.7440
rs174561 
Allele 12 / 22  973  1  0.72 (0.31,1.66) 0.4390 0.42 (0.18,0.98) 0.0446 0.41 (0.21,0.78) 0.0070
Allele 11  984  1  1.27 (0.58,2.79) 0.5548 1.08 (0.51,2.30) 0.8328 1.08 (0.60,1.95) 0.7951
rs174575 
Allele 12 / 22  905  1  0.79 (0.34,1.84) 0.5881 0.56 (0.24,1.32) 0.1850 0.35 (0.17,0.71) 0.0037
Allele 11  1175  1  1.24 (0.59,2.60) 0.5690 0.93 (0.46,1.88) 0.8482 1.10 (0.64,1.90) 0.7333
rs3834458 
Allele 12 / 22  1112  1  0.85 (0.39,1.83) 0.6698 0.47 (0.21,1.07) 0.0715 0.44 (0.23,0.83) 0.0110
Allele 11  967  1  1.17 (0.52,2.64) 0.7028 1.03 (0.49,2.15) 0.9420 1.02 (0.56,1.84) 0.9513
$ Significance level after correcting for multiple testing: αcorr=0.05/2=0.025 
1: major allele, 2: minor allele 
Supplementary Table 3  Results  of  logistic  regression  models  of  breastfeeding  (BF)  on  non‐atopic  asthma  stratified  by  genotype,  adjusted  for  gender,  study  centre, 
maternal education level, study (GINI intervention, GINI non‐intervention, LISA) and presence of older siblings (reference category: never exclusive breastfeeding) 
      never excl. BF 1‐2 months excl. BF 3‐4 months excl. BF 5‐6 months excl. BF
   N  aOR    aOR 95%‐CI  p‐value$   aOR 95%‐CI  p‐value$   aOR 95%‐CI  p‐value$
rs174545 
Allele 12 / 22  997  1  1.08 (0.35,3.38)  0.8893 0.30 (0.06,1.47)  0.1384 0.50 (0.19,1.33)  0.1645
Allele 11  814  1  1.27 (0.11,14.83) 0.8470 4.87 (0.87,27.16) 0.0712 1.42 (0.26,7.76) 0.6871
rs174546 
Allele 12 / 22  1009  1  1.09 (0.35,3.40)  0.8797 0.31 (0.06,1.49)  0.1439 0.49 (0.18,1.31)  0.1538
Allele 11  827  1  1.28 (0.11,14.86) 0.8431 4.80 (0.86,26.74) 0.0734 1.43 (0.26,7.84)  0.6817
rs174556 
Allele 12 / 22  929  1  1.74 (0.50,6.03)  0.3811 0.25 (0.03,2.11)  0.2005 0.80 (0.27,2.39)  0.6915
Allele 11  900  1  0.48 (0.05,4.33)  0.5160 2.11 (0.58,7.59)  0.2543 0.53 (0.14,1.95)  0.3397
rs174561 
Allele 12 / 22  934  1  2.17 (0.59,7.95)  0.2413 0.32 (0.04,2.83)  0.3052 1.16 (0.37,3.64)  0.8004
Allele 11  909  1  0.47 (0.05,4.23)  0.5033 2.10 (0.58,7.56)  0.2581 0.53 (0.14,1.94)  0.3369
rs174575 
Allele 12 / 22  873  1  0.85 (0.25,2.94) 0.8027 0.16 (0.02,1.32)  0.0880 0.36 (0.12,1.05) 0.0622
Allele 11  1094  1  2.42 (0.33,17.81) 0.3862 5.07 (0.98,26.16) 0.0523 2.89 (0.61,13.66) 0.1807
rs3834458 
Allele 12 / 22  1075  1  0.98 (0.32,2.99)  0.9686 0.29 (0.06,1.39)  0.1226 0.54 (0.22,1.36)  0.1914
Allele 11  890  1  2.52 (0.15,42.45) 0.5202 8.55 (0.93,78.24) 0.0574 3.62 (0.42,31.22) 0.2411
$ Significance level after correcting for multiple testing: αcorr=0.05/2=0.025 
1: major allele, 2: minor allele 
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Atopic dermatitis (AD) is a commonly occurring chronic skin 
disease with high heritability. Apart from filaggrin (FLG), the 
genes influencing atopic dermatitis are largely unknown. We 
conducted a genome-wide association meta-analysis of 5,606 
affected individuals and 20,565 controls from 16 population-
based cohorts and then examined the ten most strongly 
associated new susceptibility loci in an additional 5,419 
affected individuals and 19,833 controls from 14 studies. Three 
SNPs reached genome-wide significance in the discovery and 
replication cohorts combined, including rs479844 upstream 
of OVOL1 (odds ratio (OR) = 0.88, P = 1.1 × 10−13) and 
rs2164983 near ACTL9 (OR = 1.16, P = 7.1 × 10−9), both of 
which are near genes that have been implicated in epidermal 
proliferation and differentiation, as well as rs2897442 in  
KIF3A within the cytokine cluster at 5q31.1 (OR = 1.11,  
P = 3.8 × 10−8). We also replicated association with the FLG 
locus and with two recently identified association signals at 
11q13.5 (rs7927894; P = 0.008) and 20q13.33 (rs6010620; 
P = 0.002). Our results underline the importance of both 
epidermal barrier function and immune dysregulation in 
atopic dermatitis pathogenesis.
Atopic dermatitis, or eczema, is one of the most common chronic 
inflammatory skin diseases, with prevalence rates of up to 20% in chil-
dren and 3% in adults. It commonly starts during infancy and frequently 
precedes or co-occurs with food allergy, asthma and rhinitis1.
Atopic dermatitis has a broad spectrum of clinical manifesta-
tions and is characterized by dry skin, intense pruritus and a typical 
age-related distribution of inflammatory lesions that are frequently 
superinfected by bacteria and viruses1. Profound alterations in skin 
barrier function and immunologic abnormalities are considered to 
be key components affecting the development and severity of atopic 
dermatitis, but the exact cellular and molecular mechanisms remain 
incompletely understood1.
There is substantial evidence supporting the idea of a strong genetic 
component in atopic dermatitis; however, it is not well understood 
how genetic susceptibility contributes to the development of this con-
dition2,3. To date, only null mutations in the FLG gene encoding the 
epidermal structural protein filaggrin have been established as major 
risk factors4,5.
The only genome-wide association study (GWAS) of atopic derma-
titis in European populations identified a new susceptibility locus at 
11q13.5 downstream of C11orf30 (ref. 6). A second GWAS, recently 
carried out in a Chinese Han population, identified two new sus-
ceptibility loci, one of which (rs6010620 at 20q13.33) also showed 
evidence for association in a German sample7. In a collaborative effort 
to identify additional risk genes for atopic dermatitis, we conducted a 
well-powered, two-stage genome-wide association meta-analysis for 
the EAGLE Consortium.
In the discovery analysis of 5,606 individuals with atopic dermati-
tis (cases) and 20,565 controls from 16 population-based cohorts of 
European descent (Supplementary Tables 1 and 2), there was little 
evidence for population stratification at the study level (genomic infla-
tion factor, λGC ≤ 1.08) or at the meta-analysis level (λGC = 1.02), and 
we detected an excess of association signals beyond those expected 
by chance (Supplementary Figs. 1 and 2).
SNPs from two regions reached genome-wide significance (P < 5 × 
10−8) in the discovery meta-analysis (Fig. 1 and Supplementary 
Table 3): rs7000782 (8q21.13 near ZBTB10; OR = 1.14, P = 1.6 × 10−8) 
and rs9050 (1q21.3 near TCHH; OR = 1.33, P = 1.9 × 10−8). Given the 
proximity of rs9050 to the well-established atopic dermatitis suscepti-
bility gene FLG4,5, we evaluated whether the observed association was 
due to linkage disequilibrium (LD) with FLG mutations. Despite low 
correlation between rs9050 and the two most prevalent FLG mutations 
in ALSPAC cases (r2 = 0.257 for p.Arg501* (c.1501C>T) and r2 = 0.001 
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Figure 1 Manhattan plot for the discovery genome-wide association meta-
analysis of atopic dermatitis after excluding all SNPs with minor allele 
frequency (MAF) <1% and r2 <0.3 or proper info <0.4. λGC = 1.017. 
SNPs with P < 1 × 10−5 are shown in red.
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After excluding the rs9050 SNP, we attempted to replicate the 
remaining 10 most strongly associated loci (P < 1 × 10−5 in the dis-
covery meta-analysis) (Fig. 2, Table 1, Supplementary Fig. 5 and 
Supplementary Table 3) in 5,419 cases and 19,833 controls from 
14 studies (Supplementary Tables 1 and 2). Three of the ten SNPs 
showed significant association after conservative Bonferroni correc-
tion (P < 0.05/10 = 0.005) in the replication meta-analysis (with the 
same direction of effect as in the discovery meta-analysis), includ-
ing rs479844 near OVOL1, rs2164983 near ACTL9 and rs2897442 
in intron 8 of KIF3A (Fig. 2 and Table 1). All three SNPs reached 
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Figure 2 Forest plots for the association of SNP markers with atopic 
dermatitis. (a–c) Data are shown for rs479844 (a), rs2164983 (b) and 
rs2897442 (c). Black circles, ORs; horizontal lines, 95% CIs. Arrows 
indicate where a CI extends beyond the range of the plot. Blue boxes, 
imputed SNPs; red boxes, SNPs on the genotyping chip in the discovery 
cohorts and either on the genotyping chip or individually genotyped in 
the replication cohorts. The sizes of the red and blue boxes indicate the 
relative weight of each study (using inverse variance weighting). All ORs 
are reported with the minor allele (in parentheses) as the effect allele. 
The subtotals (for discovery and replication) and overall ORs and CIs 
are indicated by the center and range of the diamonds. rs2164983 was 
not included in HapMap release 21 and was therefore missing for some 
discovery cohorts. *MoBa imputation quality score was ‘info’ from PLINK. 
GENR, Generation R. Only Health2006, KORA/GENEVA and NFBC86 
underwent individual SNP genotyping. 
for c.2282del4) and high levels of recombination between the TCHH 
and FLG regions (peak of 20 cM/Mb at ~150.4 Mb in HapMap), in a 
meta-analysis across eight studies conditional on the two FLG mutations, 
rs9050 was no longer associated with atopic dermatitis (OR = 0.98, 
P = 0.88) (Supplementary Fig. 3) and was therefore not investigated 
further. rs9050 might represent a far-reaching haplotype of the FLG 
null mutations, but we cannot exclude the possibility that there are 
additional atopic dermatitis risk variants in this complex region.
The 11q13.5 locus previously reported to be associated in the only 
other European GWAS on atopic dermatitis to date6 was confirmed 
in our meta-analysis (rs7927894: OR = 1.07, 95% confidence interval 
(CI)1.02–1.12, P = 0.008) (Supplementary Fig. 4). Association with 
the rs6010620 variant, which was reported in a recent Chinese GWAS7, 
was similarly confirmed (OR = 1.09, 95% CI 1.03–1.15, P = 0.002).
Of the 15 loci reported to be associated with asthma or total serum 
immunoglobulin E (IgE) levels in a recent GWAS8, two showed 
suggestive evidence for association with atopic dermatitis (IL13: 
rs1295686, P = 0.0008 and rs20541, P = 0.0007; STAT6: rs167769, P = 
0.0379) (Supplementary Table 4).
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remodeling and extracellular matrix turnover20,21. Actin proteins 
have well-characterized cytoskeletal functions, are important for the 
maintenance of epithelial morphology and cell migration and have 
also been implicated in nuclear activities22–24. The low recombina-
tion rate between rs2164983 and ACTL9 and the recombination peak 
between this SNP and ADAMTS10 in the HapMap reference set of 
Utah residents of Northern and Western European descent (CEU) 
(Supplementary Fig. 2) suggests the functional variant may be located 
within the ACTL9 region. There was no evidence for association 
between rs2164983 and altered expression of genes within 500 kb of 
this marker in either the ALSPAC LCL eQTL analysis or the MuTHER 
skin eQTL data (Supplementary Fig. 6).
rs2897442 is located in intron 8 of KIF3A, which encodes a sub-
unit of the kinesin II complex required for the assembly of primary 
cilia, which are essential for Hedgehog signaling and are implicated in 
β-catenin–dependent Wnt signaling to induce expression of a variety 
of genes that influence proliferation and apoptosis25,26. Of note, KIF3A 
is located at 5q31, which is characterized by a complex LD pattern 
and contains a cluster of cytokine and immune-related genes. This 
chromosomal location has been linked to several autoimmune and 
inflammatory diseases, including psoriasis27,28, Crohn’s disease29,30 
and asthma8,29,31 (Supplementary Table 4). In particular, distinct 
functional IL13 (interleukin 13) variants have been associated with 
asthma susceptibility32. Although rs2897442 is within the KIF3A 
gene, there is little recombination between this locus and IL4 (encod-
ing interleukin 4). There is a recombination peak between this region 
and IL13 (Supplementary Fig. 7a); however, there also seems to be 
a secondary association signal in the IL13-RAD50 region, and when 
making association conditional on rs2897442 in the discovery meta-
analysis, the signal in the IL13-RAD50 region is still present, provid-
ing evidence of two independent signals (Supplementary Fig. 7b). In 
an attempt to further refine the association at this locus, we analyzed 
Immunochip data from 1,553 German atopic dermatitis cases and 
3,640 population controls, of whom 767 cases and 983 controls were 
part of the replication stage. The Immunochip is a custom-content 
Illumina iSelect array that focuses on genes involved in autoimmune 
disorders and offers an increased resolution at 5q31. In the population 
tested, the strongest association signal was seen for the rs848 SNP 
in IL13 (P = 1.93 × 10−10), which is in high LD with the functional 
IL13 variant rs20541 (r2 = 0.979; D′ = 0.995). Additional significantly 
associated signals were observed for a cluster of tightly linked variants 
in IL4 (lead SNP rs66913936: P = 2.58 × 10−8) and KIF3A (rs2897442: 
P = 8.84 × 10−7) (Supplementary Fig. 8 and Supplementary 
Tables 6 and 7). Whereas rs2897442 showed only weak LD with rs848 
genome-wide significance in the combined meta-analysis of the 
discovery and replication sets: rs479844 with OR = 0.88, P = 1.1 × 
10−13; rs2164983 with OR = 1.16, P = 7.1 × 10−9; and rs2897442 with 
OR = 1.11, P = 3.8 × 10−8. In contrast, rs7000782, which had reached 
genome-wide significance in the discovery analysis, showed no evi-
dence of association in the replication cohort (P = 0.296). There 
was no evidence of interaction between the three replicated SNPs 
(Supplementary Table 5).
rs479844 (at 11q13.1) is located <3 kb upstream of OVOL1. The 
pattern of LD is complex at this locus, but there is a low recombination 
rate between rs479844 and OVOL1 in Europeans (Supplementary 
Fig. 2). OVOL1 belongs to a highly conserved family of genes involved 
in regulation of the development and differentiation of epithelial tis-
sues and germ cells9–11. The encoded OVOL1 protein functions as 
a c-Myc repressor in keratinocytes, is activated by the β-catenin–
LEF1 complex during epidermal differentiation and is a downstream 
target of the Wg-Wnt and TGF-β–BMP7–Smad4 developmental 
signaling pathways10,12,13. Apart from their role in the organogenesis 
of skin and skin appendages14,15, these pathways are also implicated 
in postnatal regulation of epidermal proliferation and differentia-
tion16–18. Disruption of Ovol1 in mice leads to keratinocyte hyper-
proliferation, hair shaft abnormalities, kidney cysts and defective 
 spermatogenesis10,11. In addition, OVOL1 regulates loricrin (LOR) 
expression, thereby preventing premature terminal differentiation10. 
Thus, it is reasonable to speculate that variation at this locus might 
influence epidermal proliferation and/or differentiation, which are 
known to be disturbed in atopic dermatitis. Analysis of transcript 
levels of all genes within 500 kb of rs479844 in Epstein-Barr virus 
(EBV)-transformed lymphoblastoid cell lines (LCLs) from 949 
ALSPAC individuals revealed a significant association (P = 7 × 10−5) 
between rs479844 and the nearby DKFZp761E198 locus, which 
encodes a hypothetical protein. Likewise, analysis of SNP-transcript 
pairs in the Multiple Tissue Human Expression Resource (MuTHER) 
pilot database of skin genome-wide expression quantitative trait loci 
(eQTL) from 160 samples19 provided suggestive evidence for an asso-
ciation with DKFZp761E198 in the same direction in one of the twin 
sets (Supplementary Fig. 6). Further investigations are needed to 
clarify whether the causal variant(s) at this locus exerts its effect by 
regulating the expression of the DKFZp761E198 transcript.
rs2164983 (at 19p13.2) is located in an intergenic region 70 kb 
upstream of ADAMTS10 and 18 kb downstream of ACTL9 (encoding 
a hypothetical protein). ADAMTS proteins are a group of complex, 
secreted zinc-dependent metalloproteinases, which bind to and cleave 
extracellular matrix components and are involved in connective tissue 
table 1 Discovery and replication results for loci associated with atopic dermatitis
Chr. SNP Position (bp) Gene
Effect  
allele
Other  
allele
Effect  
allele freq. Stage N OR (95% CI) P value Phet
11 rs479844 65,308,533 OVOL1 A G 0.44 I 26,151 0.89 (0.85–0.93) 7.8 × 10–7
II 25,098 0.87 (0.83–0.92) 2.4 × 10–8
I + II 51,249 0.88 (0.85–0.91) 1.1 × 10–13 0.23
19 rs2164983a 8,650,381 ACTL9 A C 0.15 I 17,403 1.22 (1.13–1.32) 1.8 × 10–7
II 22,996 1.11 (1.04–1.19) 0.002
I + II 40,399 1.16 (1.10–1.22) 7.1 × 10–9 0.004
5 rs2897442 132,076,926 KIF3A C T 0.29 I 26,164 1.12 (1.07–1.18) 7.8 × 10–6
II 25,064 1.09 (1.04–1.15) 0.001
I + II 51,228 1.11 (1.07–1.15) 3.8 × 10–8 0.52
Results are for the fixed-effect, inverse variance meta-analysis, with genomic control applied to the individual studies in the discovery meta-analysis. Chr., chromosome; Stage I, 
discovery screen; stage II, replication; stages I + II, combined analysis; N, number of subjects in each analysis. The heterogeneity P value (Phet) for overall heterogeneity between 
all discovery and replication studies was generated using Cochran’s Q test for heterogeneity. All ORs are given with the minor allele representing the effect allele.
ars2164983 was not included in HapMap release 21 and was therefore missing for some discovery cohorts. This SNP showed evidence of heterogeneity (P = 0.004). The random-effects  
combined (I + II) result for this SNP was OR = 1.14 (95%CI 1.05–1.24), P = 0.001.
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(r2 = 0.160; D′ = 0.483), it was strongly correlated with rs66913936 
(r2 = 0.858; D′ = 0.982). Likewise, pairwise genotype-conditioned ana-
lyses showed that the significant association of rs2897442 with atopic 
dermatitis was abolished upon conditioning for rs66913936, whereas 
there an association signal remained after conditioning for rs848 
(Supplementary Tables 6 and 7). Analysis of the expression levels of 
all genes within 500 kb of rs2897442 in LCLs derived from ALSPAC 
individuals revealed a modest association between rs2897442 and IL13 
transcript levels (P = 2.7 × 10−3). No association with transcript levels 
for any gene within 500 kb of the proxy variant, rs2299009, (r2 = 1) 
was seen in the MuTHER skin eQTL data (Supplementary Fig. 6). 
However, this result does not exclude the possibilities that this vari-
ation may cause a regulatory effect in another tissue or physiological 
state, that this variant or causative variants in LD may be involved in 
long-range control of more distant genes33 or that different functional 
effects, such as alternative splicing, may be affected.
It is well known that genes that participate in the same pathway 
tend to be located adjacent to one another in the human genome and 
are coordinately regulated34. Thus, our results and previous findings 
suggest that there are distinct effects at the 5q31 locus, which might 
involve loci that are part of a regulatory block in this region. Further 
efforts, including detailed sequencing and functional exploration, are 
necessary to fully explore this locus.
The rs2164983, rs1327914 and rs10983837 variants showed evi-
dence of heterogeneity in the meta-analysis (P < 0.01). The over-
all random-effects results for these variants were OR = 1.14 (95% 
CI 1.05–1.24), P = 0.001; OR = 1.06 (95% CI 1.00–1.13), P = 0.058; 
and OR = 1.11 (95% CI 0.98–1.20), P = 0.155, respectively. Stratified 
analysis showed that the effects of rs2164983 and rs1327914 were 
stronger in the childhood atopic dermatitis cohorts (OR = 1.23, P =  
2.9 × 10−9 and OR = 1.12, P = 2.5 × 10−4) than in studies that 
included atopic dermatitis cases of any age (OR = 1.17, P = 0.002 and 
OR = 1.02, P = 0.584; P values for the differences = 0.031 and 
0.028, respectively) (Supplementary Fig. 9). This stratification 
did not fully explain the heterogeneity for rs2164983 (in the 
 childhood-only cohorts, the P value for heterogeneity was still <0.01). 
In the COPSAC cohort, results were noticeably in the opposite direc-
tion, and excluding this study gave a heterogeneity P value of 0.069 
(OR = 1.17, P = 8.1 × 10−10). However, the COPSAC cases are diagnos-
tically and demographically comparable to those in the other cohorts, 
and, thus, there is no obvious reason why this cohort should give 
such a different result. Neither stratification by age of diagnosis nor 
by whether a physician’s diagnosis was required for definition as a 
case explained the heterogeneity observed for rs10983837. Stratified 
analyses also indicated a stronger effect of rs2897442 in studies with 
a more stringent definition of atopic dermatitis (reported physician’s 
diagnosis) (OR = 1.14, P = 7.0 × 10−9) compared to studies in which 
atopic dermatitis was defined using only self-reported histories of the 
disease (OR = 1.05, P = 0.119) (Supplementary Fig. 9). These obser-
vations highlight the importance of careful phenotyping and support 
the claim that atopic dermatitis encompasses distinct disease entities 
rather than being one illness, as is reflected by the current, relatively 
broad and inclusive concept of this condition. It is anticipated that the 
results of molecular studies will enable a more precise classification 
of atopic dermatitis.
In summary, in this large-scale GWAS of 11,025 atopic dermatitis 
cases and 40,398 controls, we have identified and replicated two newly 
identified risk loci for atopic dermatitis near genes that have annota-
tions suggesting roles in epidermal proliferation and differentiation, 
supporting the importance of abnormalities in skin barrier function 
in the pathobiology of atopic dermatitis. In addition, we observed 
an association signal of genome-wide significance from within the 
cytokine cluster at 5q31.1, which seemed to be composed of two dis-
tinct signals, one centered at IL13-RAD50 and the other at IL4-KIF3A, 
both of which showed moderate association with IL13 expression. 
We further observed a signal in the epidermal differentiation com-
plex, representing the FLG locus, and replicated the association with 
the 11q13.5 variant identified in the only other (smaller) published 
European GWAS of atopic dermatitis to date. Our results are con-
sistent with the hypothesis that atopic dermatitis is caused by both 
epidermal barrier abnormalities and immunological features. Further 
studies are needed to identify the causal variants at the associated loci 
and to understand the mechanisms through which they confer risk 
for atopic dermatitis.
MeThODS
Methods and any associated references are available in the online 
 version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
Acknowledgments
The full list of acknowledgments for each study is provided in the  
Supplementary Note.
AUtHoR contRIBUtIons
Study-level data analysis: L.P., M.S., A.R., K.B., L.D., M.A.F., A.C.A., J.P.T., E.A.,  
H. Baurecht, B.F., P.H., N.M.W., I.C., R.M., J.A.C., M.M.G.-B., M. Kerkhof, A. Sääf,  
A.F., D.E., S.B.M., B.S.P., J.P.K., N.J.T., M.M.-N., F.G., M. March, M. Mangino, 
T.D.S., V.B., C.M.T.T., E.T., M.I., A. Simpson, J.-J.H., H.A.S., B.C., E.K.-M.,  
E.M., A.C., B.J., N.M.P.-H., D.G., D.L.J., H.P., K.H. and D.P.S. Study design: L.P.,  
M.S., C.-M.C., L.D., J.P.T., B.F., P.M.A.S., M. Kerkhof, E.D., A.-L.H., A.P., J.P.,  
M. Kaakinen, G.D.S., J. Henderson, H.-E.W., N.N., A.L., T.M., E.A.N., A.H., 
A.G.U., C.M.v.D., F.R., J.C.d.J., R.J.P.v.d.V., H.A.B., J.C.M., T.D.S., P.S., W.N.,  
A. Simpson, D.P., G.H.K., H.A.S., H. Bisgaard, D.I.B., A.C., N.M.P.-H., H.H.,  
M. Melbye, D.L.J., V.W.V.J., C.G., M.-R.J., J. Heinrich, D.M.E. and S.W. Manuscript 
writing: L.P., M.S., A.R., K.B., J. Heinrich, D.M.E. and S.W. Data collection: K.B., 
L.D., J.P.T., B.F., R.M., M. Kerkhof, R.F.-H., E.D., S.B.M., A.-L.H., A.P., J.P.,  
M. Kaakinen, D.L.D., P.A.M., A.C.H., G.W.M., P.J.T., M.C.M., P.L.S., J. Henderson, 
S.M.R., W.M., A.L., T.M., E.A.N., J.C.d.J., R.J.P.v.d.V., M.W., R.J., F.G., H.A.B., 
J.C.M., F.M., T.D.S., V.B., C.E.P., P.G.H., P.S., M.I., W.N., A. Simpson, D.P., G.H.K., 
H.A.S., B.C., E.K.-M., H. Bisgaard, E.M., D.I.B., A.C., B.J., N.M.P.-H., L.J.P.,  
M. Melbye, D.L.J., V.W.V.J., N.G.M., M.-R.J., J. Heinrich and S.W. Genotyping: R.M., 
A.F., A.I.F.B., J.L.B., P.D., S.M.R., N.K., E.R., W.M., A.L., A.G.U., F.R., M.W., C.K., 
C.E.P., T.I., C.S., B.J., L.J.P. and M.-R.J. Revising and reviewing paper: L.P., M.S.,  
C.-M.C., A.R., K.B., L.D., M.A.F., A.C.A., J.P.T., E.A., H. Baurecht, B.F., P.M.A.S., 
P.H., N.M.W., I.C., R.M., J.A.C., M.M.G.-B., M. Kerkhof, A. Sääf, A.F., D.E., R.F. -H., 
E.D., S.B.M., A.-L.H., A.P., J.P., A.I.F.B., J.L.B., M. Kaakinen, D.L.D., P.A.M., A.C.H., 
G.W.M., P.J.T., M.C.M., P.L.S., B.S.P., G.D.S., J. Henderson, J.P.K., N.J.T., P.D., 
S.M.R., H.-E.W., M.M.-N., N.N., N.K., E.R., W.M., A.L., T.M., E.A.N., A.H., A.G.U., 
C.M.v.D., F.R., J.C.d.J., R.J.P.v.d.V., M.W., R.J., F.G., H.A.B., J.C.M., C.K., F.M.,  
M. March, M. Mangino, T.D.S., V.B., C.E.P., P.G.H., P.S., C.M.T.T., E.T., T.I., M.I., 
W.N., A. Simpson, J.-J.H., D.P., G.H.K., H.A.S., C.S., B.C., E.K.-M., H. Bisgaard, 
E.M., D.I.B., A.C., B.J., N.M.P.-H., L.J.P., D.G., H.H., M. Melbye, D.L.J., V.W.V.J., 
C.G., D.P.S., N.G.M., M.-R.J., J. Heinrich, D.M.E., H.P., K.H. and S.W.
AAGC provided results for the replication analysis, and GOYA provided results 
for the discovery analysis.
COMPETING FINANCIAL INTERESTS
The authors declare competing financial interests: details accompany the full-text 
HTML version of the paper at http://www.nature.com/naturegenetics/. 
Published online at http://www.nature.com/naturegenetics/.  
Reprints and permissions information is available online at http://www.nature.com/
reprints/index.html.
1. Bieber, T. Atopic dermatitis. N. Engl. J. Med. 358, 1483–1494 (2008).
2. Brown, S.J. & McLean, W.H.I. Eczema genetics: current state of knowledge and 
future goals. J. Invest. Dermatol. 129, 543–552 (2009).
3. Morar, N., Willis-Owen, S.A.G., Moffatt, M.F. & Cookson, W.O. The genetics of 
atopic dermatitis. J. Allergy Clin. Immunol. 118, 24–34 (2006).
np
g
© 
20
12
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
Nature GeNetics  VOLUME 44 | NUMBER 2 | FEBRUARY 2012 191
l e t t e r s
4. Palmer, C.N.A. et al. Common loss-of-function variants of the epidermal barrier 
protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38, 
441–446 (2006).
5. Rodríguez, E. et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: 
robust risk factors in atopic disease. J. Allergy Clin. Immunol. 123, 1361–1370 
e7 (2009).
6. Esparza-Gordillo, J. et al. A common variant on chromosome 11q13 is associated 
with atopic dermatitis. Nat. Genet. 41, 596–601 (2009).
7. Sun, L.D. et al. Genome-wide association study identifies two new susceptibility 
loci for atopic dermatitis in the Chinese Han population. Nat. Genet. 43, 690–694 
(2011).
8. Moffatt, M.F. et al. A large-scale, consortium-based genomewide association study 
of asthma. N. Engl. J. Med. 363, 1211–1221 (2010).
9. Li, B. et al. Ovol1 regulates meiotic pachytene progression during spermatogenesis 
by repressing Id2 expression. Development 132, 1463–1473 (2005).
10. Nair, M. et al. Ovol1 regulates the growth arrest of embryonic epidermal progenitor 
cells and represses c-myc transcription. J. Cell Biol. 173, 253–264 (2006).
11. Dai, X. et al. The ovo gene required for cuticle formation and oogenesis in flies is 
involved in hair formation and spermatogenesis in mice. Genes Dev. 12, 
3452–3463 (1998).
12. Kowanetz, M., Valcourt, U., Bergström, R., Heldin, C.H. & Moustakas, A. Id2 and 
Id3 define the potency of cell proliferation and differentiation responses to 
transforming growth factor β and bone morphogenetic protein. Mol. Cell. Biol. 24, 
4241–4254 (2004).
13. Li, B. et al. The LEF1/β-catenin complex activates movo1, a mouse homolog of 
Drosophila ovo required for epidermal appendage differentiation. Proc. Natl. Acad. 
Sci. USA 99, 6064–6069 (2002).
14. Owens, P., Han, G., Li, A.G. & Wang, X.J. The role of Smads in skin development. 
J. Invest. Dermatol. 128, 783–790 (2008).
15. Widelitz, R.B. Wnt signaling in skin organogenesis. Organogenesis 4, 123–133 
(2008).
16. Buschke, S. et al. A decisive function of transforming growth factor-β/Smad 
signaling in tissue morphogenesis and differentiation of human HaCaT keratinocytes. 
Mol. Biol. Cell 22, 782–794 (2011).
17. Maganga, R. et al. Secreted Frizzled related protein-4 (sFRP4) promotes epidermal 
differentiation and apoptosis. Biochem. Biophys. Res. Commun. 377, 606–611 
(2008).
18. Romanowska, M. et al. Wnt5a exhibits layer-specific expression in adult skin, is 
upregulated in psoriasis, and synergizes with type 1 interferon. PLoS ONE 4, e5354 
(2009).
19. Nica, A.C. et al. The architecture of gene regulatory variation across multiple human 
tissues: the MuTHER study. PLoS Genet. 7, e1002003 (2011).
20. Apte, S.S. A disintegrin-like and metalloprotease (reprolysin-type) with 
thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. 
J. Biol. Chem. 284, 31493–31497 (2009).
21. Porter, S., Clark, I.M., Kevorkian, L. & Edwards, D.R. The ADAMTS metalloproteinases. 
Biochem. J. 386, 15–27 (2005).
22. Pollard, T.D. The cytoskeleton, cellular motility and the reductionist agenda. 
Nature 422, 741–745 (2003).
23. Pollard, T.D. & Borisy, G.G. Cellular motility driven by assembly and disassembly 
of actin filaments. Cell 112, 453–465 (2003).
24. Winder, S.J. Structural insights into actin-binding, branching and bundling proteins. 
Curr. Opin. Cell Biol. 15, 14–22 (2003).
25. Goetz, S.C. & Anderson, K.V. The primary cilium: a signalling centre during 
vertebrate development. Nat. Rev. Genet. 11, 331–344 (2010).
26. Mosimann, C., Hausmann, G. & Basler, K. β-catenin hits chromatin: regulation of 
Wnt target gene activation. Nat. Rev. Mol. Cell Biol. 10, 276–286 (2009).
27. Chang, M. et al. Variants in the 5q31 cytokine gene cluster are associated with 
psoriasis. Genes Immun. 9, 176–181 (2008).
28. Nair, R.P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and 
NF-κB pathways. Nat. Genet. 41, 199–204 (2009).
29. Li, Y. et al. The 5q31 variants associated with psoriasis and Crohn’s disease are 
distinct. Hum. Mol. Genet. 17, 2978–2985 (2008).
30. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 
cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678 
(2007).
31. Weidinger, S. et al. Genome-wide scan on total serum IgE levels identifies FCER1A 
as novel susceptibility locus. PLoS Genet. 4, e1000166 (2008).
32. Vercelli, D. Discovering susceptibility genes for asthma and allergy. Nat. Rev. 
Immunol. 8, 169–182 (2008).
33. Kleinjan, D.A. & van Heyningen, V. Long-range control of gene expression: emerging 
mechanisms and disruption in disease. Am. J. Hum. Genet. 76, 8–32 (2005).
34. Sproul, D., Gilbert, N. & Bickmore, W.A. The role of chromatin structure in regulating 
the expression of clustered genes. Nat. Rev. Genet. 6, 775–781 (2005).
lavinia Paternoster1,75, marie standl2,75, chih-mei chen3, Adaikalavan Ramasamy4–6, klaus Bønnelykke7,  
liesbeth duijts8–10, manuel A Ferreira11, Alexessander couto Alves5, Jacob P thyssen12, eva Albrecht13,  
Hansjörg Baurecht14–16, Bjarke Feenstra17, Patrick m A sleiman18, Pirro Hysi19, nicole m warrington20,  
Ivan curjuric21,22, Ronny myhre23, John A curtin24, maria m groen-Blokhuis25, marjan kerkhof26,  
Annika sääf27, Andre Franke28, david ellinghaus28, Regina Fölster-Holst15, emmanouil dermitzakis29,30,  
stephen B montgomery29,30, Holger Prokisch31,32, katharina Heim32, Anna-liisa Hartikainen33, Anneli Pouta33,34, 
Juha Pekkanen34,35, Alexandra I F Blakemore36, Jessica l Buxton36, marika kaakinen37, david l duffy11,  
Pamela A madden38, Andrew c Heath38, grant w montgomery11, Philip J thompson39,40, melanie c matheson41, 
Peter le souëf42, Australian Asthma genetics consortium (AAgc)43, Beate st. Pourcain44, george davey smith1,  
John Henderson44, John P kemp1, nicholas J timpson1, Panos deloukas30, susan m Ring44, H-erich wichmann2,45,46, 
martina müller-nurasyid13,45,47,48, natalija novak49, norman klopp50, elke Rodríguez15,51, wendy mcArdle52,  
Allan linneberg53, torkil menné12, ellen A nohr54, Albert Hofman8,9, André g Uitterlinden8,9,55,  
cornélia m van duijn9, Fernando Rivadeneira8,9,55, Johan c de Jongste10, Ralf J P van der Valk8–10,  
matthias wjst56, Rain Jogi57, Frank geller17, Heather A Boyd17, Jeffrey c murray58, cecilia kim18, Frank mentch18,  
michael march18, massimo mangino19, tim d spector19, Veronique Bataille19, craig e Pennell20, Patrick g Holt59, 
Peter sly60, carla m t tiesler2,61, elisabeth thiering2, thomas Illig50,62, medea Imboden21,22, wenche nystad63,  
Angela simpson24, Jouke-Jan Hottenga25, dirkje Postma64, gerard H koppelman65, Henriette A smit66,  
cilla söderhäll67, Bo chawes7, eskil kreiner-møller7, Hans Bisgaard7, erik melén27,68, dorret I Boomsma25,  
Adnan custovic24, Bo Jacobsson23,69, nicole m Probst-Hensch21,22, lyle J Palmer70, daniel glass19,  
Hakon Hakonarson18,71, mads melbye17, deborah l Jarvis4, Vincent w V Jaddoe8,9,72, christian gieger13,  
the genetics of overweight Young Adults (goYA) consortium43, david P strachan73, nicholas g martin11,  
marjo-Riitta Jarvelin5,34,37,74, Joachim Heinrich2,76, david m evans1,76 & stephan weidinger15,76 for the eArly 
genetics & lifecourse epidemiology (eAgle) consortium43
1Medical Research Council (MRC) Centre for Causal Analyses in Translational Epidemiology (CAiTE), School of Social & Community Medicine, University of Bristol, 
Bristol, UK. 2Institute of Epidemiology I, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. 3Department for 
Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany. 4Respiratory Epidemiology and Public Health, Imperial College 
London, London, UK. 5Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. 6Department of Medical and 
np
g
© 
20
12
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
192  VOLUME 44 | NUMBER 2 | FEBRUARY 2012 Nature GeNetics
Molecular Genetics, King’s College London, Guy’s Hospital, London, UK. 7Copenhagen Prospective Studies on Asthma in Childhood (COPSAC), Health Sciences, 
University of Copenhagen and Copenhagen University Hospital, Gentofte, Denmark. 8The Generation R Study Group, Erasmus Medical Center, Rotterdam, The 
Netherlands. 9Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands. 10Department of Pediatrics, Division of Respiratory Medicine, 
Erasmus Medical Center, Rotterdam, The Netherlands. 11Queensland Institute of Medical Research, Brisbane, Queensland, Australia. 12Department of Dermato-
Allergology, National Allergy Research Centre, Gentofte Hospital, University of Copenhagen, Copenhagen. Denmark. 13Institute of Genetic Epidemiology, Helmholtz 
Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. 14Department of Dermatology and Allergy, Technische Universität 
München, Munich, Germany. 15Department of Dermatology, Allergology, and Venerology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. 
16Graduate School of Information Science in Health, Technische Universität München, Munich, Germany. 17Department of Epidemiology Research, Statens Serum 
Institut, Copenhagen, Denmark. 18The Center for Applied Genomics, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 19Department of Twin 
Research and Genetic Epidemiology, King’s College London, London, UK. 20School of Women’s and Infants’ Health, The University of Western Australia, Perth, 
Western Australia, Australia. 21Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland. 22University of Basel, Basel, Switzerland. 23Department of 
Genes and Environment, Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway. 24Manchester Academic Health Science Centre, National 
Institute for Health Research (NIHR) Translational Research Facility in Respiratory Medicine, The University of Manchester, University Hospital of South Manchester 
National Health Service Foundation Trust, Manchester, UK. 25Department of Biological Psychology, VU University Amsterdam, Amsterdam, The Netherlands. 
26Department of Epidemiology, Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, 
Groningen, The Netherlands. 27Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 28Institute of Clinical Molecular Biology, Christian-
Albrechts-Universität zu Kiel, Kiel, Germany. 29Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland. 
30Wellcome Trust Sanger Institute, Cambridge, UK. 31Institute of Human Genetics, Technische Universität München, Munich, Germany. 32Institute of Human 
Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. 33Department of Obstetrics and Gynaecology, 
University of Oulu, Oulu, Finland. 34National Institute for Health and Welfare (THL), Kuopio & Oulu, Finland. 35Department of Public Health and Clinical Nutrition, 
University of Eastern Finland, Kuopio, Finland. 36Department of Genomics of Common Disease, Imperial College London, London, UK. 37Institute of Health Sciences, 
Biocenter Oulu, University of Oulu, Oulu, Finland. 38Washington University School of Medicine, Saint Louis, Missouri, USA. 39Lung Institute of Western Australia, 
Perth, Western Australia, Australia. 40Centre for Asthma, Allergy and Respiratory Research, University of Western Australia, Perth, Western Australia, Australia. 
41Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Victoria, Australia. 42School of Paediatrics and 
Child Health, Princess Margaret Hospital for Children, Perth, Western Australia, Australia. 43A full list of consortium members is provided in the supplementary Note. 
44The School of Social & Community Medicine, University of Bristol, Bristol, UK. 45Chair of Epidemiology, Institute of Medical Informatics, Biometry and 
Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany. 46Klinikum Grosshadern, Munich, Germany. 47Chair of Genetic Epidemiology, Institute of 
Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany. 48Department of Medicine I, University Hospital 
Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany. 49Department of Dermatology and Allergy, University of Bonn Medical Center, Bonn, 
Germany. 50Unit for Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. 51ZAUM–
Center for Allergy and Environment, Helmholtz-Zentrum and Technische Universität, Munich, Germany. 52Avon Longitudinal Study of Parents and Children (ALSPAC) 
Laboratory, School of Social & Community Medicine, University of Bristol, Bristol, UK. 53Research Center for Prevention and Health, Glostrup University Hospital, 
Copenhagen, Denmark. 54Institute of Public Health, Aarhus University, Aarhus, Denmark. 55Department of Internal Medicine, Erasmus Medical Center, Rotterdam, 
The Netherlands. 56Comprehensive Pneumology Center and Institute of Lung Biology and Disease, Helmholtz Zentrum München, German Research Center for 
Environmental Health, Neuherberg, Germany. 57Lung Clinic, Tartu University Hospital, Tartu, Estonia. 58Department of Pediatrics, University of Iowa, Iowa City, Iowa, 
USA. 59Telethon Institute for Child Health Research and Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia. 
60Queensland Children’s Medical Research Institute, University of Queensland, World Health Organization (WHO) Collaborating Centre for Research on Children’s 
Environmental Health, Brisbane, Queensland, Australia. 61Division of Metabolic Diseases and Nutritional Medicine, Dr von Hauner Children’s Hospital, Ludwig-
Maximilians-Universität München, Munich, Germany. 62Hannover Unified Biobank, Hannover Medical School, Hannover, Germany. 63Division of Epidemiology, 
Norwegian Institute of Public Health, Oslo, Norway. 64Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen,  
The Netherlands. 65Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children’s Hospital, GRIAC, University Medical Center Groningen, 
University of Groningen, Groningen, The Netherlands. 66Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht,  
The Netherlands. 67Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden. 68Astrid Lindgren Children’s Hospital, Karolinska  
University Hospital, Stockholm, Sweden. 69Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Sahlgrenska Academy, Göteborg University, 
Göteborg, Sweden. 70Ontario Institute for Cancer Research, Toronto, University of Toronto, Toronto, Canada. 71Department of Pediatrics, University of Pennsylvania 
School of Medicine, Philadelphia, Pennsylvania, USA. 72Department of Pediatrics, Erasmus Medical Center, Rotterdam, The Netherlands. 73Division of Population 
Health Sciences and Education, St George’s University of London, London, UK. 74MRC-HPA Centre for Environment and Health, Faculty of Medicine, Imperial  
College London, London, UK. 75These authors contributed equally to this work. 76These authors jointly directed this work. Correspondence should be addressed to  
L.P. (l.paternoster@bristol.ac.uk).
l e t t e r s
np
g
© 
20
12
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
Nature GeNeticsdoi:10.1038/ng.1017
ONLINe MeThODS
Discovery analysis. For the discovery analysis, we used 5,606 atopic derma-
titis cases and 20,565 controls of European descent from 16 population-based 
cohorts, 10 of which were birth cohorts. Local research ethics committees 
approved the individual studies, and informed consent was obtained from all 
participants when necessary (see the Supplementary Note for full details of 
ethics and consent procedures for each study). Additional details on sample 
recruitment and phenotypes and summary details for each collection are 
given in the Supplementary Note and in Supplementary Table 1. Genome-
wide genotyping was performed independently in each cohort with the use 
of various standard genotyping technologies (see Supplementary Table 2). 
Imputation was independently conducted for each study with reference to 
HapMap release 21 or 22 CEU phased genotypes, and association analysis 
was performed using logistic regression models based on an expected allelic 
dosage model for SNPs, adjusting for sex- and ancestry-informative principal 
components as necessary. SNPs with MAF <1% and poor imputation quality 
(r2 <0.3, if using MACH, or proper info <0.4, if using the IMPUTE imputation 
algorithm) were excluded. After genomic control at the level of the individual 
studies, we combined association data for ~2.5 million imputed and genotyped 
autosomal SNPs into an inverse variance fixed-effects additive model meta-
analysis. There was little evidence for population stratification at the study 
level (λGC ≤ 1.08; Supplementary Table 2) or at the meta-analysis level (λGC = 
1.02), and the quantile-quantile plot of the meta-statistic showed a marked 
excess of detectable association signals well beyond those expected by chance 
(Supplementary Fig. 1).
Replication analysis. For replication, we selected the most strongly associ-
ated SNPs from the 10 most strongly associated loci in the discovery meta-
analysis (all with P < 1 × 10−5 in stage I; Table 1). These SNPs were analyzed 
using in silico data from 11 GWAS sample sets not included in the discov-
ery meta-analysis and de novo genotyping data from an additional 3 studies 
(Supplementary Tables 1 and 2), for a maximum possible replication sample 
size of 5,419 cases and 19,833 controls, all of European descent. Association 
analyses were again conducted for each study using a logistic regression model 
with similar covariate adjustments, based on expected allelic dosage for the 
in silico studies and allele counts in the de novo genotyping studies, and the 
results underwent meta-analysis with Stata 11.1 software (Statacorp LP). We 
applied a threshold of P < 5 × 10−8 for genome-wide significance and tested 
for overall heterogeneity of the discovery and replication studies using the 
Cochran’s Q statistic.
Immunochip analysis. In this analysis, we evaluated 1,553 German atopic 
dermatitis cases and 3,640 German population controls. Cases were obtained 
from German university hospitals (Technical University Munich, as part of 
the GENEVA study, and University of Kiel). Atopic dermatitis was diagnosed 
on the basis of a skin examination by experienced dermatologists according to 
standard criteria, which included the presence of chronic or chronically relaps-
ing pruritic dermatitis with the typical morphology and distribution6. Controls 
were derived from the Kooperative Gesundheitsforschung in der Region 
Augsburg (KORA) population-based surveys35 and the previously described 
population-based Popgen Biobank36. Of these samples, 767 of the cases and 
983 of the controls were also part of the replication stage. Samples with >10% 
missing data, individuals from pairs of unexpected duplicates or relatives and 
individuals with outlier heterozygosities of greater than ±5 s.d. from the mean 
were excluded. The remaining Immunochip samples were tested for popula-
tion stratification using the principal-components stratification method, as 
implemented in EIGENSTRAT37. The results of principal-component analysis 
revealed no evidence for population stratification. SNPs that had >5% missing 
data, MAF <1% or exact Hardy-Weinberg equilibrium (Pcontrols <1 × 10−4) 
were excluded. Association P values were calculated using χ2 tests (degree of 
freedom (d.f.) = 1) and conditional association was analyzed using logistic 
regression, with both implemented in PLINK38, from which we also derived 
OR values and their respective CIs.
ALSPAC expression analysis. RNA was extracted from LCLs generated from 
997 unrelated ALSPAC individuals using an RNeasy extraction kit (Qiagen) 
and was amplified using the Illumina TotalPrep-96 RNA Amplification kit 
(Ambion). Expression was evaluated using Illumina HT-12 v3 BeadChip 
arrays. Each individual sample was run with two replicates. Expression data 
were normalized by quantile normalization between replicates and then 
by median normalization across individuals. For 949 ALSPAC individuals, 
both expression levels and imputed genome-wide SNP data were available 
(see ALSPAC replication cohort genotyping). For each of the three replicated 
SNPs that were associated with atopic dermatitis (rs479844, rs2164983 and 
rs2897442), we used linear regression in Mach2QTL to investigate the associa-
tion between each SNP and any transcript within 500 kb of this SNP.
35. Holle, R., Happich, M., Löwel, H. & Wichmann, H.E. & MONICA/KORA Study 
Group. KORA—a research platform for population based health research. 
Gesundheitswesen 67 (suppl. 1), S19–S25 (2005).
36. Krawczak, M. et al. PopGen: population-based recruitment of patients and controls 
for the analysis of complex genotype-phenotype relationships. Community Genet. 9, 
55–61 (2006).
37. Price, A.L. et al. Principal components analysis corrects for stratification in genome-
wide association studies. Nat. Genet. 38, 904–909 (2006).
38. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-
based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
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SUPPLEMENTARY NOTE 
 
Note on nomenclature 
The extant nosology of atopic disease is confusing, and terms such as atopic dermatitis, eczema, atopic 
eczema, endogenous eczema and flexural dermatitis are frequently used interchangeably in the literature. 
Recently, a World Allergy Organization (WAO) report suggested the use of eczema as preferable to atopic 
dermatitis
1
.
 
However, in this article, we continued to use the term atopic dermatitis, as many studies used for 
this project were designed prior to the WAO report and because this is the term used in many questionnaires 
on which the results presented here are based.  
 
STUDY SAMPLE DESCRIPTIONS 
 
Australian Asthma Genetics Consortium (AAGC) replication cohort 
As part of the AAGC, we performed a GWAS of asthma in 7,197 unrelated individuals of European ancestry 
ascertained from the Australian population as described in detail elsewhere {Ferreira, submitted}. For this 
analysis, we tested 10 SNPs for association with AD status in 3,881 individuals (49% males, mean age 35 years, 
range 3 to 89), including 269 who reported having had AD at any point in their lifetime diagnosed by a doctor 
and 3,612 AD-free controls. These individuals participated in one of five studies: QIMR (N=3,132), CAPS (N=53), 
LIWA (N=474), MESCA (N=64) or TAHS (N=158). The QIMR individuals included in the AAGC analysis are 
unrelated to those included in the QIMR discovery cohort described below. Genotyping was performed with 
Illumina 610K or 370K arrays and stringent quality control filters applied as described in Supplementary Table 
2. Imputation to HapMap 3 (all 11 populations, Feb 2009 release) and 1000 Genomes Project (CEU, Mar 2010 
release) SNPs was performed with Impute2 and SNPs tested for association with disease status using logistic 
regression in PLINK, with sex and array type included as a covariate. Participants provided informed consent to 
participate in this study, which was approved by the respective ethics committees.  
 
The Avon Longitudinal Study of Parents and Children (ALSPAC)  
The Avon Longitudinal Study of Parents and their Children (ALSPAC) is a longitudinal population-based birth 
cohort that recruited pregnant women residing in Avon, UK, with an expected delivery data between 1st April 
1991 and 31st December 1992. 14,541 pregnant women were initially enrolled with 14,062 children born (see 
2
 and website http://www.alspac.bris.ac.uk). Biological samples including DNA have been collected for 10,121 
of the children from this cohort. Ethical approval was obtained from the ALSPAC Law and Ethics committee 
and relevant local ethics committees, and written informed consent provided by all parents. Questionnaire 
data has been collected regularly, with extensive questions, including those relating to AD. In this study we 
included data from the following questions, asked when the children were approximately 81, 91, 103 months, 
10, 13 and 14 years [possible answers]: 
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1. Has your child in the past 12 months had eczema? [yes, saw a Dr; Yes, but did not see a Dr; No, did 
not have] 
2. Has a doctor ever actually said that your child has eczema? (10 & 14 years only) [yes; no] 
We defined cases as those individuals who answered ‘Yes, and saw a Dr’ to Q1 or ‘yes’ to Q2. We defined 
controls as those individuals who answered ‘no’ to Q2 at age 14 years.  
 
Discovery Cohort Genotyping and Statistical Analysis 
Subjects were genotyped using either Illumina 317K or 610K genome-wide SNP genotyping platforms by the 
Wellcome Trust Sanger Institute, Cambridge, UK and the Centre National de Génotypage, Evry, France. A 
common set of SNPs were extracted and the resulting raw genome-wide data was subjected to standard 
quality control methods. Individuals were excluded on the basis of having incorrect gender assignments; 
minimal (0.34) or excessive (0.36) heterozygosity; disproportionate levels of individual missingness (>3%) and 
evidence of cryptic relatedness (PI HAT > 0.11). The remaining individuals were assessed for evidence of 
population stratification by multidimensional scaling analysis, using CEU, Yoruba, Japanese and Chinese 
individuals as reference ethnic groups. The underlying population stratification was thereafter controlled for 
by using EIGENSTRAT derived ancestry informative covariates. SNPs with a minor allele frequency of < 0.5% 
and call rate of < 97% were removed. Furthermore, only SNPs which passed an exact test of Hardy-Weinberg 
equilibrium (P > 5E-7) were considered for analysis. The resulting dataset consisted of 3233 individuals and 
285,531 SNPs. Missing genotypes were subsequently imputed with MACH 1.0 Markov Chain Haplotyping 
software, using CEPH individuals from phase two of the HapMap project as a reference set (release 22). The 
final imputed dataset consisted of 3233 subjects, each with 2,483,534 imputed markers. 2811 of which also 
had AD phenotype information (909 cases and 1902 controls).  
 
Genome-wide association analysis of AD was carried out in MACH2DAT 
3,4
 regressing expected allelic dosage 
on case-control status, including sex as a covariate.  
R501X and 2282del4 have been genotyped in a previous study on 2634 subjects
5. In the FLG adjusted analysis, 
these were included as covariates (using an additive model).  
 
Replication Cohort Genotyping and Statistical Analysis 
Subjects were genotyped using the Illumina HumanHap550 quad genome-wide SNP genotyping platform by 
23andMe subcontracting the Wellcome Trust Sanger Institute, Cambridge, UK and the Laboratory Corporation 
of America, Burlington, NC, US. Individuals were excluded on the basis of having incorrect gender assignments; 
minimal or excessive heterozygosity (<0.32 and >0.345 for the Sanger data and <0.31 and >0.33 for the 
LabCorp data); disproportionate levels of individual missingness (>3%); evidence of cryptic relatedness (>10% 
IBD) and being of non-European ancestry. The resulting dataset consisted of 9233 individuals. SNPs with a 
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minor allele frequency of < 1% and call rate of < 95% were removed. Furthermore, only SNPs which passed an 
exact test of Hardy-Weinberg equilibrium (P > 5E-7) were considered for analysis. Genotypes were 
subsequently imputed with MACH 1.0.16 Markov Chain Haplotyping software, using CEPH individuals from 
phase 2 of the HapMap project as a reference set (release 22). Of the 9233 ALSPAC genotyped individuals, 
2903 also had AD phenotype information (895 cases and 2008 controls) and were not included in the ALSPAC 
discovery set.  
Replication association analysis of the 10 SNPs was carried out as per the discovery cohort methods.  
 
BAMSE 
BAMSE is a Swedish birth cohort study. A total number of 4,089 newborn infants were recruited between 1994 
and 1996 in the Stockholm area
6. The first questionnaire data, dealing with parental allergic diseases, socio-
economic status and residential characteristics, was obtained when the children were about 2 months. Similar 
questionnaires with a focus on the children’s symptoms related to asthma and allergic diseases including 
eczema were answered by the parents when the children were approximately 1, 2, 4 and 8 years old. At 8 
years of age, all children were invited to clinical testing, and blood samples were obtained from 2,480 children 
(~60%). DNA was extracted from 2,033 samples after exclusion of samples with too little blood, lack of 
questionnaire data, or if parental consent to genetic analysis of the sample was not obtained. From these 
samples, all children with a doctor’s diagnosis of asthma (ever) and children with no history of eczema or other 
allergic diseases (controls) underwent GWAS genotyping
7. Among asthmatics, all children with doctor’s 
diagnosis of eczema (ever) were identified and after QC, a total of 100 eczema (ever) cases and 246 controls 
were included in this study.  
BAMSE genotyping was conducted as part of the GABRIEL consortium. Genotyping in GABRIEL was carried out 
at Centre National de Génotypage (Evry, France) using the Illumina Human610 quad array (Illumina, Inc., San 
Diego, CA)
7. An ancestry analysis was performed using EIGENSTRAT, and putative non-Caucasian samples were 
flagged as outliers and eliminated from subsequent analyses. Imputation to HapMap CEU release 22 was 
conducted using MACH v.1.0.16 with option MLE (original genotypes were only replaced if the underlying 
reference haplotypes strongly contradict the input genotypes). Samples from the British 1958 birth cohort 
(B58C) with greater than 95% genotyping success rate were selected to estimate model parameters of error 
rates and recombination rates for step 1 of the imputation procedure. In step 2, all GABRIEL cohorts were 
imputed, no SNP/sample QC filters were applied to individual cohorts prior to this.  
Genome-wide association analysis of AD was carried out in ProbAbel
8
 regressing expected allelic dosage on 
case-control status, including sex as a covariate. The study was approved by the Ethics Committee of 
Karolinska Institutet, Stockholm, Sweden.  
 
British 1958 birth cohort (B58C) 
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The British 1958 birth cohort is an ongoing follow-up of all persons born in England, Scotland and Wales during 
one week in 1958. At age 7 years, a history of eczematous rashes was obtained by interview with a parent, and 
the presence of visible AD on skin examination was recorded by a school medical officer
9. For the purpose of 
this meta-analysis, cases were defined by a positive interview response for either AD during the first year of 
life, or AD after the first year (ie. ages 1-7), or both. (The results of skin examination were not used to define 
cases.) Controls were defined as children with no parentally reported history of AD by age 7, and no record of 
AD on skin examination at age 7.  
 
At the age of 44-45 years, the cohort were followed up with a biomedical examination and blood sampling 
10
, 
from which a DNA collection was established as a nationally representative reference panel 
(http://www.b58cgene.sgul.ac.uk/). The discovery phase of the analysis used two non-overlapping subsets of 
the DNA collection which were selected as controls for use by the Wellcome Trust Case-Control Consortium 
(WTCCC) 
11
 and the Type 1 Diabetes Genetics Consortium (T1DGC)
12. Genotyping by the WTCCC used the 
Affymetrix 500K array and the T1DGC used the Illumina 550K array. Imputations using the HapMap 2 (release 
21) template were performed using SNPTEST for the WTCCC subset and MACH for the T1DGC subset. Within-
cohort logistic regression analyses for AD were performed using Quicktest for the WTCCC subset and ProbAbel 
for the T1DGC subset.  
 
In silico replication analyses were performed using Illumina 550K/610K genotypes deposited by the GABRIEL 
consortium 
7
 and by the WTCCC on cohort members that had not been included in the discovery sets. 
Imputations for the replication set using the HapMap 2 (release 21) template were performed using MACH and 
within-cohort logistic regression analyses for eczema were performed using ProbAbel.  
 
CHOP 
CHOP patients and controls were recruited at the Children’s Hospital of Philadelphia between 2006 and 2010. 
All subjects were of self-reported Caucasian origin and resident in the Greater Philadelphia area. Ethical 
approval for this study was obtained from the Institutional Revue Board of the Children’s Hospital of 
Philadelphia. The study included 519 patients with physician-diagnosed eczema and 1004 disease-free controls 
without eczema. Cases were defined by the presence of the ICD9 code for eczema (691.8) in their electronic 
medical records. All CHOP samples were genotyped on either the Illumina HH550 or HH610 BeadChips 
(Illumina, San Diego) at the Center for Applied Genomics.  
In addition to self-reported ancestry, Principal Component Analysis was carried on all cases and controls using 
smartPCA to reduce the risk of population stratification. Mean age of the case cohort was 9 years and 51% 
were males and 49% females.  
 
Genotyping QC measures, imputation, analysis 
Prior to imputation, quality control was carried out in plink resulting in the exclusion of 10,930 SNPs with call 
rates <95%, 22,252 SNPs with a minor allele frequency (MAF) <1% and 13,181 SNPs with Hardy Weinberg 
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equilibrium P<10
-5
; the genomic inflation factor (GIF) was 1.05. Imputation was carried out using Impute 
version 1, and the HapMap release 22 haplotypes as a reference. Statistical analysis was carried out using 
SNPTEST, assuming an additive model and taking genotype uncertainty into account.  
 
 
COPSAC 
The COPSAC birth cohort study is a prospective clinical study of a birth cohort of 411 infants born to mothers 
with a history of asthma. The newborns were enrolled at the age of 1 month, the recruitment of which was 
previously described in detail
13-15. The study was approved by the Ethics Committee for Copenhagen (KF 01-
289/96) and The Danish Data Protection Agency (2008-41-1754) and informed consent was obtained from 
both parents. The families used doctors employed at the clinical research unit, and not the family practitioner, 
for diagnosis and treatment of AD and other skin-related symptoms. Skin lesions were described at both 
scheduled visits at 6-monthly intervals and acute visits with skin symptoms according to pre-defined 
morphology and localization; AD was defined based on the Hanifin-Rajka criteria as previously detailed
16-18. 
High throughput genome-wide SNP genotyping were performed using the Illumina Infinium™ II HumanHap550 
v1, v3 or quad BeadChip platform (Illumina, San Diego), at the Children’s Hospital of Philadelphia’s Center for 
Applied Genomics, as described previously
19. 
Statistical analysis was carried out using SNPTEST, assuming an additive model and taking genotype 
uncertainty into account.  
 
Danish National Birth Cohort (DNBC)  
DNBC is a population-based cohort of more than 100,000 pregnancies, recruited in the years 1996-2002
20. 
Extensive phenotype information was collected by computer-assisted telephone interviews twice during 
pregnancy as well as 6 and 18 months after delivery. An additional questionnaire-based follow-up survey was 
conducted when the children reached 7 years of age. Cases with early onset AD were identified from the 18 
months telephone interview data using an algorithm specifically developed for this purpose
21. In addition, 
children with a positive response to both of the following two questions from the 7 year survey were included 
in the case group: 1) “Has a doctor ever said that your child had AD, also known as allergic rash?” and 2) “Has 
your child ever had an itchy rash which was coming and going for at least 6 months?”. Finally, children with 
ICD10 diagnosis code L20 in the Danish Hospital Discharge Register were also included in the case group. 
Controls were required not to have any AD or AD symptoms recorded in interview, questionnaire, or register 
data. GWAS data were generated for 3,840 individuals from the DNBC (mothers and their children) in a study 
of prematurity and its complications (Principal investigator Jeff Murray) within the Gene Environment 
Association Studies (GENEVA) consortium. AD information and genome-wide genotype and imputed data were 
available for 1,641 children. Imputation was carried out with MACH, using HapMap CEU release 22 as the 
reference panel. Logistic regression analysis for AD was performed with MACH2DAT, using imputed allele 
dosages and including sex as a covariate.  
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The DNBC study protocol was approved by the Danish Scientific Ethical Committee and the Danish Data 
Protection Agency.  
 
ECRHS 
Details of the methods of ECRHS I and ECRHS II, a multicentre international cohort study, have been published 
elsewhere
22,23. Participants within the ECRHS were eligible for inclusion in this analysis if they were identified 
by random sampling of those who fulfilled the following criteria 1) lived in centres that took part in genome-
wide genotyping initiative under the auspices of GABRIEL
7
 AND 2) were initially selected to take part in the 
ECRHS clinical measurements as part of the random sample (ie not specifically selected for inclusion because 
of any pre-existing disease). Cases were those answering positively to the questions ‘Have you ever had an 
itchy rash that was coming and going for at least 6 months?’ AND yes to ‘Have you had this itchy rash in the 
last 12 months?’ during ECRHS II (aged 27-58). Further information on the distribution of eczema within the 
cohort is available
24. 
Genotyping and imputation was carried out within the GABRIEL consortium, details in BAMSE methods (page 
S5). Genome-wide association analysis of AD was carried out in ProbABEL regressing expected allelic dosage on 
case-control status, adjusted for sex, recruitment centre and first two principal components informative of 
European ancestry.  
Each participating centre obtained ethical permission from the appropriate local committee.  
 
Generation R  
The Generation R Study is a population-based prospective cohort study of pregnant women and their children 
from fetal life onwards in Rotterdam, The Netherlands
25,26. All children were born between April 2002 and 
January 2006, and currently followed until young adulthood. Of all eligible children in the study area, 61% were 
participating in the study at birth
26. Cord blood samples including DNA have been collected at birth. Postnatal 
data about eczema was annually collected by questionnaires at the ages of 1 to 5 years. Response rates for the 
questionnaires were 71%, 76%, 72%, 73% and 74%, respectively
26. For the current study, 1,115 children were 
included in the discovery analysis (males, n = 594 (53%)). A total number of 620 children were available for the 
replication analyses (males, n = 299 (48%). Questions about eczema were ‘Has your child in the past 12 months 
had eczema [yes, saw a doctor; Yes, but did not see a doctor; No, did not have] (age 1 to 4 years)?’ and ‘Has 
your child ever had eczema [yes; no] (age 5)?’. We defined cases as those children of whom parents answered 
their child ‘Yes, had eczema and saw a doctor’ or ‘Yes, ever had eczema’. We defined controls as those children 
of whom parents answered their child ‘No, never had eczema’ and ‘Yes, had eczema but did not see a 
doctor/No, did not have eczema’. The current study used the first set of Generation R samples of Northern 
European Ancestry. Samples were genotyped using Illumina Infinium II HumanHap610 Quad Arrays following 
standard manufacturer's protocols. Intensity files were analyzed using the Beadstudio Genotyping Module 
software v.3.2.32 and genotype calling based on default cluster files. Any sample displaying call rates below 
97.5%, excess of autosomal heterozygosity (F<mean-4SD) and mismatch between called and phenotypic 
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gender were excluded. In addition, individuals identified as genetic outliers by the IBS clustering analysis (> 3 
standard deviations away from the HapMap CEU population mean) an one of 2 pairs of identical twins (IBD 
probabilities =1) were excluded from the analysis. After quality control (QC) 2,729 children were included in 
the analyses. Genotypes were imputed for all polymorphic SNPs from phased haplotypes in autosomal 
chromosomes of the HapMap CEU Phase II panel (release 22, build 36) oriented to the positive (forward) 
strand. Genotyped SNPs with minor allele frequency < 0.01, SNP Call Rate < 0.98 and HWE P-value < 1x10
-6
 
were filtered. After marker pruning 503,248 SNPs were used for imputation (MACH v 1.0.16) of 2,543,887 
SNPs. Association analysis for directly genotyped data were carried out in PLINK implemented on BCSNPmax 
and for imputed data were ran using MACH2DAT implemented in the GRIMP
27
 user interface platform. The 
study protocol was approved by the Medical Ethical Committee of the Erasmus Medical Centre, Rotterdam 
(MEC 217.595/2002/20). Written informed consent was obtained from all participants.  
 
Genetics of Overweight Young Adults (GOYA) women’s study 
In total, 91,387 pregnant women were recruited to the Danish National Birth Cohort during 1996-2002, 67,853 
of whom gave birth to a live born infant and had provided a blood sample during pregnancy. The GOYA study 
includes a subset of these women, selected for genome-wide genotyping according to their BMI and is 
described in full elsewhere
28,29. The 4% (2,451) of the women with the largest residuals from the regression of 
BMI on age and parity and a random sample of similar size (2,450) drawn from the remaining distribution were 
selected for genotyping. Pertinent to this study, the women were asked questions about eczema during a 
telephone interview at ~16 weeks of gestation. The questions were: 
1. Have you ever had any skin disease?  
2. Was the skin disease diagnosed by a doctor?  
3. What kind of skin disease?  
Cases were defined as those that answered “yes” to Qs 1 and 2, and ‘AD’ to Q3. Controls were defined as 
those that answered “no” to Q1.  
The GOYA study was approved by the regional scientific ethics committee and by the Danish Data Protection 
Board.  
 
Genome-wide genotyping on the Illumina 610k quad chip was carried out at the Centre National de 
Génotypage (CNG), Evry, France. We excluded SNPs with minor allele frequency <1%, >5% missing genotypes 
or which failed an exact test of Hardy-Weinberg equilibrium (HWE) in the controls (p<10-7). We also excluded 
any individual who did not cluster with the CEU individuals (Utah residents with ancestry from northern and 
western Europe) in a multidimensional scaling analysis seeded with individuals from the International HapMap 
release 22, who had >5% missing data, outlying heterozygosity of >35% or <30.2%, both samples in the case of 
genetic duplicates, one of each pair of genetically related individuals, individuals with sex discrepancies and 
individuals whose genotyping was discordant with a previous project. After data cleaning, 3,908 women and 
545,349 SNPs remained. We carried out imputation to HapMap release 22 (CEU individuals) using Mach 1.0, 
Markov Chain Haplotyping
3,4. 
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Logistic genome-wide association analysis for AD (with no covariates) was carried out in MACH2DAT
3,4. 
 
The Danish Glostrup Cohort (Health2006)  
Between June 2006 and May 2008, a cross-sectional study was performed in the general population in 
Copenhagen, the Capital of Denmark. A random sample of 7931 subjects aged 18–69 years old was obtained 
from the Danish Central Personal Register, Ministry of Internal Affairs. All were Danish adults with Danish 
citizenship and born in Denmark. A total of 3471 (44%) subjects participated in a general health examination 
and 3329 (95.9%) responded to the question about atopic dermatitis. The participation rate was higher among 
older age-groups than among younger age groups in both genders
30. The Ethical Committee of Copenhagen 
County approved the study (KA-20060011). A written informed consent form was obtained from all 
participants prior to the beginning of the study.  
 
All participants were mailed a standard invitation letter and a questionnaire about health, lifestyle, and 
socioeconomic factors. AD was defined by the U.K. Working Party’s diagnostic criteria for atopic dermatitis as a 
history of an itchy skin condition plus a minimum of two of four minor criteria
31. 
Genotyping of SNPs was performed by the PCR KASPar genotyping system (KBiosciences, Hoddesdon, UK). 
None of the SNPs deviated from HW equilibrium (p>0.05 for all SNPs). Lowest call rate for SNPs was 0.98.  
Data analyses were performed using the Statistical Products and Service Solutions package (SPSS Inc., Chicago, 
IL, U.S.A.) for Windows (release 15.0).  
 
KORA 
The Cooperative Health Research in the Region of Augsburg (KORA) study is a series of independent 
population-based epidemiological surveys and follow-up studies of participants living in the region of 
Augsburg, Southern Germany
32. All participants are of German nationality identified through the registration 
office and informed consent has been given by all participants. The study has been approved by the local 
ethics committee. Participants were examined in 1994/95 (KORA S3) or 1999/2001 (KORA S4) and in the 
follow-up examinations in 2004/05 (KORA F3) and 2006/08 (KORA F4). All KORA subjects had completed a 
standardized questionnaire which next to demographic data included the basis allergy questions of the 
European Community Respiratory Health Survey (ECRHS) on respiratory health
22. AD was diagnosed based on a 
reported physician’s diagnosis in the past. For the genome-wide association study we genotyped 1,644 
randomly selected participants of KORA F3 using Affymetrix 500K and 1,814 randomly selected participants of 
KORA F4 using Affymetrix 6.0
33
.
 
Genome-wide association analysis of AD was carried out using logistic 
regression in SNPTEST V2 (http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html), including sex as 
a covariate.  
 
For replication purpose 1100 AD cases of self-reported German ethnicity were obtained from the GENEVA 
(Genetic evaluation of atopic dermatitis) study from the Department of Dermatology and Allergy, Technical 
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University Munich
34. AD was diagnosed on the basis of a skin examination by experienced dermatologists 
according to standard criteria in the presence of a chronic or chronically relapsing pruritic dermatitis with the 
typical morphology and distribution
35. KORA controls were selected of the remaining KORA F4 sample which 
was not included in the GWAS analysis. De novo replication analysis was carried with R 2.12.2 (http://www.R-
project.org) using logistic regression adjusted for sex. Genetic information entered the model as allele counts.  
 
LISA/GINI 
The influence of Life-style factors on the development of the Immune System and Allergies in East and West 
Germany PLUS the influence of traffic emissions and genetics (LISAplus) Study is a population based birth 
cohort study. A total of 3097 healthy, fullterm neonates were recruited between 1997 and 1999 in Munich, 
Leipzig, Wesel and Bad Honnef. The participants were not pre-selected based on family history of allergic 
diseases
36. 
A total of 5991 mothers and their newborns were recruited into the German Infant study on the influence of 
Nutrition Intervention PLUS environmental and genetic influences on allergy development (GINIplus) between 
September 1995 and June 1998 in Munich and Wesel. Infants with at least one allergic parent and/or sibling 
were allocated to the interventional study arm investigating the effect of different hydrolysed formulas for 
allergy prevention in the first year of life
37. All children without a family history of allergic diseases and children 
whose parents did not give consent for the intervention were allocated to the non-interventional arm. 
Detailed descriptions of the LISAplus and GINIplus studies have been published elsewhere 
36
 and 
37
, 
respectively).  
Information on ever having physician-diagnosed AD was collected using self-administered questionnaires 
completed by the parents. The questionnaires were completed at 6, 12, 18 and 24 months and 4, 5, 6 years of 
age in the LISAplus study and 1, 2, 3, 4 and 6 years in the GINIplus study asking for each year of age since the 
previous follow-up. DNA was collected at the age 6 and 10 years. For both studies, approval by the local Ethics 
Committees and written consent from participant’s families were obtained.  
In the discovery analysis, 379 children from the LISAplus study from Munich were included (number of boys: 
227 (57%)). DNA was analysed using the Affymetrix Human SNP Array 5.0 for each individual. Genome-wide 
data was called using BRLMM-P algorithm and imputed in IMPUTE
38. 
Genome-wide association analysis of AD was carried out in SNPTEST V1 
(http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html) regressing expected allelic dosage on 
case-control status, including sex as a covariate.  
 
For replication, 665 children from Munich from both studies were included (499 (75%) children from the 
GINIplus study and 166 (25%) children from the LISAplus study)). 583 individuals (499 from the GINIplus study 
and 84 from the LISA study) were analysed using the Affymetrix Human SNP Array 5.0 and 82 individuals from 
the LISAplus study were analysed using Affymetrix Human SNP Array 6.0. Genotypes were called using 
BRLMM-P algorithm (5.0), respectively BIRDSEED V2 algorithm (6.0), imputed in IMPUTE2
39
 and genome-wide 
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association analysis of AD was carried out in SNPTEST V2 
(http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html) regressing expected allelic dosage on 
case-control status, including sex as a covariate.  
 
Manchester Asthma and Allergy Study (MAAS) 
The Manchester Asthma and Allergy Study is an unselected, population-based prospective study which follows 
the development of atopic disorders in a cohort of children described in detail elsewhere
40-44. The setting is the 
maternity catchment area of Wythenshawe and Stepping Hill Hospitals, comprising of 50 square miles of South 
Manchester and Cheshire, UK, a stable mixed urban-rural population. Study was approved by the Local 
Research Ethics Committee. Informed consent was obtained from all parents.  
 
Screening & Recruitment  
All pregnant women were screened for eligibility at antenatal visits (8th-10th week of pregnancy). The study 
was explained to the parents, and informed consent for initial questionnaires and skin prick testing was 
obtained. Both parents completed a questionnaire about their and their partner’s history of asthma and 
allergic diseases and smoking habits.  
If the pregnant woman’s partner was not present at the antenatal clinic visit, an invitation was sent for him to 
attend an open-access evening clinic for skin prick testing and questionnaire. Once both parents had 
completed questionnaires and skin prick testing, a full explanation of the proposed future follow-up for the 
child was given. Of the 1499 couples who met the inclusion criteria (<10 weeks of pregnancy, maternal age >18 
years, questionnaire and skin test data available for both parents), 288 declined to take part in the study. A 
total of 1185 participants had at least some evaluable data.  
 
Follow-up 
The children have been followed prospectively, and attended review clinics at ages 1, 3, 5 and 8 years (±4 
weeks).  
 
Definitions of outcomes 
AD: Information on the age of onset of parentally-reported AD was collected using an interviewer-
administered validated ISAAC questionnaire to collect information on parentally reported symptoms, 
physician-diagnosed illnesses and treatments received.  
In this analysis eczema was defined as a positive answer to the question “Has your child ever suffered from 
eczema?”. The association study was carried out in the 761 MAAS individuals for which both genotype and 
phenotype data was available.  
 
Genotyping 
DNA samples were genotyping on an illumina 610 quad chip. The illumina genotypes were called using the 
Illumina GenCall application following the manufacturer’s instructions. Quality control criteria for samples 
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included: 97% call rate, exclusion of samples with an outlier autosomal heterozygosity (scree-plot visualisation) 
gender validation and sequenome genotype concordance. Quality control criteria for SNPs included a 95% call 
rate, HWE > 5.9x10
-7
, minor allele frequency > 0.005. Genotypes were imputated with IMPUTE version 2.1.2 
with 1000 genomes and hapmap phase 3 reference genotypes. Association analysis was carried out using 
SNPTEST version 2.1 using frequentist with the score method.  
 
The Norwegian Mother and Child Cohort Study (MoBa) 
The Norwegian Mother and Child Cohort Study (MoBa) is a prospective population-based pregnancy cohort 
study conducted by the Norwegian Institute of Public Health
45,46. Participants were recruited from all over 
Norway from 1999-2008, and 38.5% of invited women consented to participate. The cohort now includes 
108,000 children, 90,700 mothers and 71,500 fathers. Blood samples were obtained from both parents during 
pregnancy and from mothers and children (umbilical cord) at birth. Follow-up is conducted by questionnaires 
at regular intervals and by linkage to national health registries.  
 
The current study is based on version 4 of the quality-assured data files and included participants that were 
recruited between 1999-2005. Informed consent was obtained from each MoBa participant upon recruitment. 
The study was approved by The Regional Committee for Medical Research Ethics in South-Eastern Norway and 
the Norwegian Data Inspectorate.  
 
The cases were indentified from questionnaires at the child’s age 6, 18 and 36 months defined by the following 
questions: Does your child have or has he/she had any of the following health problems? Atopic eczema was 
listed as one of several items here. If yes was entered on the first question, a second were asked: has the 
mother and child health care centre or someone else referred your child for further specialist investigation Our 
cases were restricted to unique cases across age 6, 18 and 36 months with yes on both questions. 
Consequently the controls were unique controls across age 6, 18 and 36 months with no on both questions.  
 
The genotype platform used were Illumina 660W and imputed SNPs were only included if the met the 
recommended threshold for imputation quality (PLINK INFO >0.8). Logistic regression analyses for AD was 
performed using an additive model in PLINK, including sex as a covariate. The children included in this study 
are originally genotyped for a case control study (n=1200 children) of spontaneous preterm delivery.  
 
The Northern Finland Birth Cohort 1966 (NFBC66) 
The Northern Finland Birth Cohort 1966 is a prospective follow-up study of children from the two 
northernmost provinces of Finland
47. Women with expected delivery dates in 1966 were recruited through 
maternity health centres
48. Cohort members living in northern Finland or in the capital area were invited to a 
clinical examination as well as questionnaire at age 31 years. DNA was extracted from blood samples given at 
the clinical examination
49. For the purpose of this meta-analysis, we included data from the following 
questions:  
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1. Have you had eczema (infantile, atopic or allergic)?  
2. If yes, have you ever been treated by a doctor 
 
Individuals who answered yes to both questions were defined as cases (1208). Individuals that answered no to 
the first question were defined as controls (2294). Genotyping was completed at the Broad Institute Biological 
Sample Repository in participants with available DNA using Illumina HumanCNV370DUO Analysis BeadChip 
array for 339,629 SNPs. We excluded 3,345 SNPs from analysis because HWE was not met at a level p <0.0001, 
55 because of low call rate (<95%) and 7,681 because the MAF was <1%, leaving 329,091 SNPs for the 
association analysis. Imputation was conducted using the algorithm implemented in IMPUTE and association 
analysis using quicktest
50. Informed consent for the use of the data including DNA was obtained from all 
subjects. The study was approved by the ethics committees in Oulu (Finland) and Oxford (UK) universities in 
accordance with the Declaration of Helsinki.  
 
Northern Finland Birth Cohort 1986 (NFBC86) 
The Northern Finland Birth Cohort 1986 comprises 9432 live-born children with an expected date of birth 
between July 1, 1985, and June 30, 1986 from the two northernmost provinces of Finland, Oulu and Lapland. 
The cohort covers over 99% of all the deliveries in the target area during that time (N=9,362 mothers with 
N=9,432 liveborn children)
51. At the age of 16, the cohort members were sent a postal questionnaire including 
questions on eczema, and 80% returned it. At the same time, they were invited to a clinical examination with 
74% taking part in it. DNA was extracted from blood samples given at the clinical examination for 6,266 
subjects. For the purpose of this meta-analysis, we included data from 1717 individuals that answered the 
following questions:  
1. Have you ever had eczema which has been called infantile eczema, atopic eczema or allergic eczema?  
2. Diagnosed or treated by a doctor? 
Individuals who answered yes to both questions were defined as cases (316). Individuals that answered no to 
the first question were defined as controls (1401). Genotyping was performed by KBiosciences (Hoddesdon) 
using their own system of fluorescence-based competitive allele-specific PCR (KASPar) with genotype success 
rate >97%. Association analysis was conducted using quicktest
50. Informed consent for the use of the data 
including DNA was obtained from all subjects at the age of 16 years. The study was approved by ethics 
committees in Oulu (Finland) university in accordance with the Declaration of Helsinki.  
 
Netherlands Twin Register (NTR) 
The Netherlands Twin Register (NTR) is a large population based study that registers approximately 40% of all 
multiple births in the Netherlands since 1986
52. At age 5 of the children, a survey is sent out in which the 
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parents of the twins are asked to indicate for each child separately whether a doctor has ever diagnosed 
eczema. A similar question concerns doctor diagnosed baby eczema
53. 
Blood and/or buccal samples for DNA extraction were collected for a subsample of the NTR in several projects. 
Genotyping was performed on the Affymetrix Human SNP Array 6.0 in the Avera Institute, Sioux Falls, South 
Dakota (USA). Genotypes were called using the BIRDSEED V2 algorithm and imputed in BEAGLE in the MD 
Anderson Cancer Center, Houston, Texas (USA). After QC, one individual of each family was selected. If both 
twins were cases or controls, one individual was picked at random, otherwise the case was selected. A total of 
123 cases and 306 controls were included in the study. Logistic regression analyses were performed using an 
additive model in PLINK, including sex as a covariate. The study was approved by the Medical Ethical 
Committee of the VU Medical Centre, Amsterdam, the Netherlands (IRB00002991).  
 
PIAMA  
PIAMA is a birth cohort study consisting of two parts: a placebo controlled intervention study in which the 
effect of mite impermeable mattress covers was studied and a natural history study in which no intervention 
took place. Details of the study design have been published previously
54. Recruitment took place in 1996-1997. 
A screening questionnaire was distributed to pregnant women visiting one of 52 prenatal clinics at three 
regions in the Netherlands. A total of 10,232 pregnant women completed a validated screening questionnaire. 
Mothers reporting a history of asthma, current hay fever or allergy to pets or house dust mite were defined as 
allergic. Based on this screening, 7862 women were invited to participate, of whom 4,146 women (1327 
allergic and 2819 nonallergic) gave written informed consent. The response rates to the annual questionnaires 
ranged from 3030 (92%) at age 1 to 2732 (83%) at age 8 years. DNA was collected from 2162 children at age 4 
and/or 8 years. Genome-wide genotyping was performed within the framework of the Gabriel Consortium
7. 
For this, DNA samples from 213 children with parental reported doctor diagnosed asthma ever at age 8 years 
and from 213 controls without doctor diagnosed asthma or wheeze ever at age 8 years were provided. From 
these children, 186 cases of eczema and 167 controls were selected for the current study. Cases of eczema 
were defined as parental reported doctor diagnosed eczema ever at age 2 years or doctor diagnosed eczema 
in the last 12 months at ages 3, 4, 5, 6 ,7 or 8 years. Controls were defined as children whose parents denied 
the presence of doctor diagnosed eczema in the last 12 months at all ages. Genotyping was performed with an 
Illumina Human610 quad array. SNPs were excluded that fullfilled one or more of the following criteria: p-
value for test of Hardy-Weinberg equilibrium  1E -7, genotyping call rate <95% or MAF < 1%. SNPs were 
imputed with IMPUTE version 2 software using HAPMAP CEU release #22 b36. Genome-wide association 
analyses were performed using SNPTEST version 1.1.5. The Medical Ethical Committees of the participating 
institutes approved the study.  
 
QIMR discovery cohort 
We recently performed a GWAS of asthma in 2,832 unrelated individuals of European ancestry ascertained 
from the Australian population as described in detail elsewhere
55. Of these, 2,148 individuals (34% males, 
mean age 32 years, range 10 to 92) reported information on their AD status in health questionnaires, including 
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482 individuals who reported having had AD at any point in their lifetime (32% diagnosed by a doctor) and 
1,666 AD-free controls. Genotyping was performed with Illumina 610K or 370K arrays and stringent quality 
control filters applied as described in Supplementary Table 2. Imputation of HapMap 2 SNPs (CEU release 21) 
was performed with MACH and SNPs tested for association with disease status using logistic regression in 
PLINK, with sex included as a covariate. Participants provided informed consent to participate in this study, 
which was approved by the QIMR ethics committee.  
 
Western Australian Pregnancy (Raine) cohort  
Recruitment of the Western Australian Pregnancy (Raine) cohort has previously been described in detail
56-58. 
In brief, between 1989 and 1991 2,900 pregnant women were recruited prior to 18-weeks gestation into a 
randomised controlled trial to evaluate the effects of repeated ultrasound in pregnancy. Recruitment 
predominantly took place at King Edward Memorial Hospital (Perth, Western Australia). Women were 
randomised to repeat ultrasound measurements at 18, 24, 28, 34 and 38 weeks gestation or to a regular 
ultrasound assessment at 18-weeks. Children have been comprehensively phenotyped from birth to 21 years 
of age (average ages of one, two, three, six, eight, ten, 14, 17 and currently 21) by trained members the Raine 
research team. Data collection included questionnaires completed by the child’s primary carer and by the 
adolescent from age 14, physical assessments by trained assessors at all follow up years, DNA collection from 
the year 14 follow-up. Information on ever having AD diagnosed by a paediatrician or GP was collected using a 
questionnaire at 6 and 8 years of age. The study was conducted with appropriate institutional ethics approval, 
and written informed consent was obtained from all mothers and the children from age 18-years. The cohort 
has been shown to be representative of the population presenting to the antenatal tertiary referral centre in 
Western Australia
56. Genotyping was performed using the Illumina 660w quad array and imputation of 
HapMap 2 (CEU release 22) SNPs was performed using MACH. Association testing was performed using 
MACH2DAT.  
 
SAPALDIA 
SAPALDIA data are derived from among 6,055 SAPALDIA cohort subjects that participated in both, the baseline 
(1991) and follow-up (2002) examinations and agreed to providing blood for genetic analysis.  
SAPALDIA is a population-based cohort that originally recruited subjects aged 18 to 60 from population 
registries in eight Swiss communities representing the three largest language groups (German, French, Italian) 
as well as different levels of air pollution, altitude and degrees of urbanization
59,60. At both baseline and 
follow-up examination subjects underwent spirometry as well as a detailed interview on respiratory health and 
allergies, smoking history, lifestyle factors and anthropometry. At follow-up, 8,047 of 9,651 baseline subjects 
re-participated in at least one part of the study and a formal biobank was established. AD was defined as 
positive answer to the question “Have you ever had atopic dermatitis or any other kind of skin allergy?“ at 
either examination. The basis for this study formed control subjects and a random sample of all asthmatics 
(sampled proportionally to the overall asthma prevalence in the study) that were part of a nested asthma case-
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control sample subjected for genomewide genotyping in the context of the GABRIEL genome-wide association 
study on asthma
7. Genotyping and imputation was carried out within the GABRIEL consortium, details in 
BAMSE methods (page S5).  
Association analysis was performed in ProbABEL. All study participants gave written informed consent, and the 
study was approved by the national and respective cantonal ethics committees.  
  
The Department of Twin Research and Genetic Epidemiology at King’s College London  
(TwinsUK) 
The TwinsUK adult twin registry based at St Thomas’ Hospital in London is a volunteer cohort of over 12,000 
identical and non-identical twins
61
 recruited since 1993. The cohort is predominantly female (92%). Twins 
largely volunteered unaware of the study in which they would subsequently be included, gave fully informed 
consent under a protocol reviewed by the St Thomas’ Hospital Local Research Ethics Committee.  
Subjects were genotyped using Illumina's Human Hap 300k Duo and Human Hap610 Quad. Genotyping was 
performed in part at the Wellcome Trust Sanger Institute (Hinxton, UK) and in part at the Center for Inherited 
Disease Research, NIH, Baltimore, MD, United States. Genotypes were quality controlled and were excluded 
from the analysis for low genotype rate defined as less than 95% for alleles with a minor allele frequency 
(MAF) of 0.05 and above or less than 99% for loci with a MAF of 0.05 or below or for Hardy-Weinberg 
disequilibrium (p<0.0001). Individual samples were included in the analysis if they were of non-admixed 
Caucasian descent, did not show lack or excess heterozygocity, had high (defined as in excess of 99% success 
rate) individual genotypes available.  
Genotypes were imputed using IMPUTE 2.0 using Linkage Disequilibrium patterns observed in the HapMap 2 
CEU population as a template. A total of 1,236 unrelated subjects for which both genetic and phenotypic 
information was available was analyzed using PLINK.  
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Supplementary Table 1. Study characteristics - discovery & replication 
Cohort Type N Percent male 
Mean age @ 
interview 
Atopic dermatitis question 
Physician 
diagnosis 
required 
Case response case # Control response control # 
Discovery cohorts 
ALSPAC Birth cohort 2811 50% 81m, 91m, 103m, 10y, 
13y, 14y 
1. Has your child in the past 12 months had 
eczema? 
 1. Yes, and saw a Dr    
    10y, 14y 2. Has a doctor ever actually said that your child 
has eczema? 
 2. Yes  2. No (@ 14 y)  
      yes Yes to 1 or 2 at any timepoint 909  1902 
B58C-WTCCC Birth cohort 1285 50% 7y 1. Parent interview: History of atopic dermatitis in 
first year? 
 1. Yes    
    7y 2. Parent interview: History of atopic dermatitis 
after first year? 
 2. Yes    
    7y 3. Medical examination      
      no Yes to 1 or 2 103 No to 1 and 2 and 3 1182 
B58C-T1DGC Birth cohort 2186 48% 7y 1. Parent interview: History of atopic dermatitis in 
first year? 
 1. Yes    
    7y 2. Parent interview: History of atopic dermatitis 
after first year? 
 2. Yes    
    7y 3. Medical examination      
      no Yes to 1 or 2 188 No to 1 and 2 and 3 1998 
CHOP Population 
based cohort 
1523 51% 9y ICD9 diagnosis in electronic medical record yes  519  1004 
COPSAC Birth cohort 332 49% 0-6y Diagnosis prospectively by dermatologist at the 
research unit based on Hanifin-Rajka criteria 
yes Diagnosed atopic dermatitis 171 No atopic dermatitis 
diagnosis and followed up 
to 6 yr 
161 
DNBC Birth cohort 1641 52% 18m 1. Has your child had itchy rash?  1. Yes    
    18m 2. Has a doctor told you that your child had atopic 
dermatitis? 
 2. Yes    
    18m 3. Was the rash recurrent?  3. Yes    
    18m 4. In which 0.5 month periods did your child have 
the rash? 
 4. Rash for at least 4 consecutive 
0.5-month periods 
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    18m 5. Where was the rash located?  5. Localization in elbow creases, 
behind the knees, face, 
wrists/hands or generalized/4 or 
more localizations 
   
    7y 6. Has your child ever had atopic dermatitis?  6. Yes    
    7y 7. Has your child ever had an itchy rash which was 
coming and going for at least 6 months? 
 7. Yes    
     9. Hospital Discharge Record of ICD10 code L20      
      no [Yes to 1 or 2 and Yes to 3 or 4 
and 5] or [Yes to 6 and 7] or 9 
225 No AD or AD symptoms 
recorded in interview, 
questionnaire, or register 
data 
1416 
Generation R Birth cohort 1115 53% 1y, 2y, 3y, 4y 1. Has your child had atopic dermatitis in the last 12 
months for which he/she attended a general 
practitioner/hospital? 
     
    5y 2. Has your child ever had atopic dermatitis?      
      no Yes to 1 (at any timepoint) or 2 676 No to 1 and 2 439 
GOYA Mothers 
from birth 
cohort 
3359 0% 29y 1. Have you ever had any skin disease? yes Yes to 1 and 2 and ‘atopic 
dermatitis‘ to 3 
180 No to 1 3179 
     2. Was the skin disease diagnosed by a doctor?      
     3. What kind of skin disease?      
KORA F3 Cohort study 1375 49% 61y 1. Did a physician ever diagnose you with atopic 
eczema? 
yes Yes  42 No  1333 
KORA F4 Cohort study 1791 49% 61y 1. Did you ever have atopic dermatitis/eczema?      
     2. If yes, was it diagnosed by a physician?      
      yes Yes to 1 and 2 101 No to 1 or 2 1690 
LISA Birth cohort 379 57% 6m, 12m, 18m, 24m 1. Did a physician diagnose your child having atopic 
dermatitis in the past 6 months? 
 1. Yes    
    4y, 5y, 6y 2. Did a physician diagnose your child having atopic 
dermatitis in the past 12 months? 
 2. Yes    
      yes Yes to 1 or 2 at any timepoint 93 No to all of the time 
points 
286 
NFBC66 Birth cohort 3502 47% 31y 1. Have you had eczema (infantile, atopic or 
allergic)? 
 1. Yes    
     2. if yes, have you ever been treated by a doctor  2. Yes    
      yes Yes to 1 and 2 1208 No to 1 2294 
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PIAMA Birth cohort 353 53% 3m,1y,2y,3y,4y,5y,6y,
7y,8y 
1. Has your child ever had atopic dermatitis?  1. Yes    
    2y,3y,4y,6y,7y,8y 2. Did a doctor ever diagnose atopic dermatitis in 
your child? 
 2. Yes    
    2y,3y,4y,6y,7y,8y 3. Did your child have atopic dermatitis during the 
past 12 months? 
 3. Yes    
      yes Yes to 1 and 2 and 3 186 No to 1 and 2 and 3 at 
ages 2-8 
167 
RAINE Birth cohort 1135 53% 5y 1. Do you think your child has ever had atopic 
dermatitis? Has anyone ever told you your child has 
atopic dermatitis?[yes and who(paediatrician, GP, 
child health nurse, naturopath, friend, relative) 
 1. Yes    
    8y 2. Has your child had atopic dermatitis in the last 12 
month? 
     
      yes Yes to 1 and were diagnosed by 
a paediatrician/GP 
245 No to 1 and 2 (subject 
excluded in case of 
missing).subjects who 
answered 'Yes' to 1 and 
were diagnosed to 
someone other than a 
paediatrician/GP were 
coded as missing 
890 
QIMR Population 
based cohort 
2148 
(adolescent=765, 
asthma=55, 
adult=1328) 
34% Mean=32, SD=15, 
range=10-92 
1. Adolescent/Asthma study: Have you (your child) 
ever had eczema confirmed by a doctor? 
 1. Yes  1. No  
     2. Adult study: How often have you had any 
eczema? [“Only as a child”, “Quite often”, 
“Sometimes”, “Often”, "Never"] 
 2. Yes to “Only as a child”, 
“Quite often”, “Sometimes” or 
“Often” 
 2. Yes to “Never“  
      no Yes to 1 or 2 482 No to 1 or 2 1666 
Twins UK cohort study 1236 8% 46 years 1. Have you ever had eczema? no Yes 278 No 958 
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Replication cohorts          
AAGC  3881 49% Mean=35, SD=17, 
range=3-89 
     
 
 Population 
base cohort 
QIMR   1. QIMR study: Have you (your child) ever had 
eczema confirmed by a doctor?  
yes 1. Yes 241 1. No 2891 
 Birth cohort CAPS   2. CAPS study: Has your child ever had eczema 
confirmed by a doctor?  
yes 2. Yes 28 2. No 25 
 Population 
based cohort 
LIWA      0  474 
 Birth cohort MESCA      0  64 
 Birth cohort TAHS      0  158 
      yes Yes to 1 or 2 at any timepoint 269  3612 
ALSPAC Birth cohort 2903 50% 81m, 91m, 103m, 10y, 
13y, 14y 
1. Has your child in the past 12 months had 
eczema? 
 1. Yes, and saw a Dr    
    10y, 14y 2. Has a doctor ever actually said that your child 
has eczema? 
 2. Yes  2. No (@ 14 y)  
      yes Yes to 1 or 2 at any timepoint 895  2008 
BAMSE Birth cohort 346 Cases: 62% 1y, 2y, 4y, 8y 1. Has a doctor diagnosed your child as having 
atopic dermatitis after the age of x year 
 1. Yes    
   Controls:48%  1y 2. Has a doctor ever diagnosed your child as having 
atopic dermatitis up to 1 year of age 
 2. Yes    
      yes Yes to 1 and/or 2 100 No to both Q at all times 246 
B58C-REPL Birth cohort 2090 51.3% 7y 1. Parent interview: History of atopic dermatitis in 
first year? 
 1. Yes    
    7y 2. Parent interview: History of atopic dermatitis 
after first year? 
 2. Yes    
    7y 3. Medical examination      
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      no Yes to 1 or 2 170 No to 1 and 2 and 3 1920 
ECRHS Population 
based cohort 
study. 
Information 
provided is 
based on 
follow-up 
1650 49.03% 42.8 (7.1) 1. Have you ever had an itchy rash that was coming 
and going for more than six months? 
 1. Yes    
     2. Have you had this itchy rash in the last 12 
months? 
 2. Yes    
      no Yes to 1 and 2 176 No to 1 or 2 1474 
Generation R Birth cohort 620 48% 1y, 2y, 3y, 4y 1. Has your child had eczema in the last 12 months 
for which he/she attended a general 
practitioner/hospital? 
     
    5y 2. Has your child ever had eczema?      
      no Yes to 1 (at any timepoint) or 2 182 No to 1 and 2 438 
Health2006 Population 
based cohort 
3329 44.7% 49.4 years The U.K. Working Party's diagnostic criteria for 
atopic dermatitis as a history of an itchy skin 
condition plus a minimum of two of four minor 
criteria were used. The major criteria was an itchy 
skin condition and the minor criteria 
were: 1) a history of involvement of the skin 
creases, 2) a personal history of asthma or hay 
fever, 
3) a history of general dry skin in the last year, 4) 
onset under the age of 2 years. 
no AD cases according to U.K. 
Working Party's diagnostic 
criteria for atopic dermatitis 
337 non-AD U.K. Working 
Party's diagnostic criteria 
for atopic dermatitis 
2992 
KORA F4 Population 
based 
controls 
1100 49% 25.4 1. Did a physician ever diagnose you with atopic 
dermatitis/eczema? 
     
     2. Dermatologic examination, UK Working Party 
Criteria 
     
GENEVA Tertiary care 
cases 
1100 42% 49.3 1. Did a physician ever diagnose you with atopic 
dermatitis/eczema? 
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     2. Dermatologic examination, UK Working Party 
Criteria 
 Yes to 1 and actual 
dermatologist's diagnosis 
1100 No to 1 and no actual 
dermatologist's diagnosis 
1100 
      yes Yes to 1 1100 No to 2 1100 
LISA/GINI Birth cohort 665 (GINI: 
499, LISA: 
166) 
51% LISA: 6m, 12m, 18m, 
24m 
1. Did a physician diagnose your child having atopic 
dermatitis in the past 6 months? 
 1. Yes    
    LISA: 3y-6y, GINI: 1y-
6y 
2. Did a physician diagnose your child having atopic 
dermatitis in the past 12 months? 
 2. Yes    
      yes Yes to 1 or 2 at any timepoint 231 No to all of the time 
points 
434 
MAAS Unselected 
birth cohort 
761 55% 1y, 3y, 5y, 8y 1. Has your child ever suffered from atopic 
dermatitis 
no ‘Yes’ at any timepoint 435 No 326 
MoBa Pregnancy 
cohort 
937 51% 6m, 18m, 36m 1. Does your child have or has he/she had any of 
the following health problems? (Enter a cross in a 
box for each item.) Atopic eczema (childhood 
eczema) - listed as an item 
 1. yes    
     2. If yes, has the mother and child health centre or 
someone else referred your child for further 
specialist investigation? 
 2. yes    
      yes Yes to 1 and 2 at any timepoint 70 No to all of the time 
points 
867 
NFBC86 Birth cohort 4465 50% 15-16y 1. Have you ever had eczema which has been called 
infantile eczema, atopic eczema or allergic eczema? 
     
     2. Diagnosed or treated by a doctor? yes yes to 1+2 798 no to 1 3667 
NTR Population 
based cohort 
study 
429 50.8% 5y 1. Did a physician since birth ever diagnosed your 
children with eczema? (Oldest/youngest answered 
seperately ) 
     
     2. Did a physician since birth ever diagnosed your 
children with baby eczema? (Oldest/youngest 
answered seperately ) 
     
      yes Yes to 1 or 2 123 1. No to 1 and 2 306 
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SAPALDIA 
 
Population 
based cohort  
study.  
976 50% 2 examinations: 
baseline in 1991, 
follow-up in 2002.  
Age (sd) in 2002: 
53.2 (11.1) 
Have you ever had atopic dermatitis or any other 
kind of skin allergy? 
no Yes. At either of the 2 
examinations (1991 & 2002) 
533 No' at both examinations  
'No' at follow-up, if 
missing at baseline 
('No' at baseline & 
missing at follow-up set 
to missing) 
443 
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Supplementary Table 2. Study genetic & analysis methods  (a) discovery and (b) replication cohorts 
(a) Genotyping  
BEFORE IMPUTATION QUALITY CONTROL  
PER SUBJECT  
BEFORE IMPUTATION QUALITY CONTROL 
PER SNP  IMPUTATION  DATA ANALYSIS 
Cohort 
Genotyping 
Platform 
Genotype-
Calling 
Algorithm  
call rate 
threshold 
heterozygosity 
thresholds 
ethnicity 
exclusions 
other exclusion 
criteria  
SNP 
call 
rate 
HWE p-
value 
threshold 
MAF 
threshold 
other 
exclusion 
criteria  
Imputation 
Software 
(Version) 
HapMap 
CEU 
Release 
NCBI 
Build  
Association 
Software 
GWAS 
Lambda 
ALSPAC Illumina 317K or 
610k 
  0.97 0.34 & 0.36 MDS - 
eigenstrat 
adjusted 
sex discrpeancies, 
related individuals 
 0.97 5E-07 0.005 no  MACH 1.0 22 36  MACH2DAT 1.0068 
B58C-
WTCCC 
Affymetrix 500 Chiamo  0.97 0.23 & 0.30 yes external 
discordance, 
relatives,gender 
discrepancies 
 0.95 1E-04 0.01 no  IMPUTE 21 35  quicktest 1.0088 
B58C-
T1DGC 
Illumina Infinium 
550 
Illuminus  0.98 no yes external 
discordance, 
relatives,gender 
discrepancies 
 no no no multi-allelic 
SNPs, SNPs 
with 
mismatch in 
alleles 
between 
dbSNP and 
Illumina 
 MACH 21 35  probAbel 1.0125 
CHOP Illumina HH 
550v1/v3 HH610  
Illumina 
BeadStudio 
software 
 0.98 no yes, non-
cauc 
excluded 
no  0.95 1E-04 0.01 no  Impute 22 36  snptest 1.05 
COPSAC Illumina 550K BeadStudio v 
3.3.4 
 0.98 no yes no  0.95 1E-04 0.01 no  IMPUTE v2 22 36  SNPTEST 1.0272 
DNBC Illumina Human 
660w-quad 
BeadStudio 
Genotyping 
Module, version 
3.3.7 
 0.95 no yes no  0.98 0.001 0.01 SNPs where 
strand issues 
could not be 
resolved, e.g., 
A/T and C/G 
SNPs 
 MACH 22 36  MACH2DAT 1.0051 
Generation 
R 
Illumina 610K Quad BeadStudio 
Genotyping 
Module, version 
3.2.32 
 0.975 3 SD of the 
mean 
Yes yes (IBD - check: 
no family 
relations)  
 0.98 1E-06 0.01 no   MACH 
v1.0.16 
22 36  Plink,MACH2DAT 1.0165 
GOYA Illumina 610k   0.95 0.3 & 0.35 MDS sex discrepancies, 
related individuals 
 0.95 1E-07 0.01 NA  MACH 22 36  MACH2DAT 0.9949 
KORA F3 Affymetrix 500K BRLMM  0.93 no german 
passport 
gender 
discrepancies 
 no no no no  IMPUTE  35  snptest 0.9648 
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KORA F4 Affymetrix 
Genome‐Wide 
Human SNP Array 
6.0 
Birdseed2  0.93 no german 
passport 
gender 
discrepancies 
 no no no no  IMPUTE  36  snptest 0.9997 
LISA Affymetrix 
Genome‐Wide 
Human SNP Array 
5.0 
BRLMM-P  0.95 no no no  0.95 0.01 0.01 no  IMPUTE 
v1.06 
22 36  SNPTEST 1.0223 
NFBC66 Illumina 
HumanCNV370DUO 
Analysis BeadChip 
Beadstudio  0.95 no no no phenotype 
data, IBD, 
withdrew consent, 
gender 
discrepancies, 
contaminated or 
duplicate samples 
 0.95 1E-04 0.01 no  IMPUTE 
v1.0 
21 35  quicktest 1.0097 
PIAMA Illumina Human610 
quad array 
GenomeStudio 
Software 
 0.95 no no inconsistent sex  0.95 1E-07 0.01 no  IMPUTE v2 22 36  snptest 1.053 
QIMR Illumina 610K or 
CNV370 
Illumina 
BeadStudio 
software 
 0.95 no yes no  0.95 1E-06 0.01 yes 
(BeadStudio 
GenCall score 
<0.7; SNPs 
exclusive to 
610K or 
CNV370) 
 MACH 21 35  Plink 0.9968 
RAINE Illumina 660K Illumina’s Bead 
Studio 
Genotyping 
Module 
software v.3.1  
 0.95 no Yes yes - IBD check 
and exclude family 
relations, 
congenital 
abnormalities 
 0.95 5.7E-07 0.01 no  MACH 22 36  MACH2DAT 0.9931 
Twins UK Illumina 317K (3/5) 
& 610K (2/5) 
Illuminus  0.95 Yes Yes, only 
caucasian  
no  0.95 1E-04 0.01 no  IMPUTE 22 36  Plink 1.0846 
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(b) 
In silico replication                  
 Genotyping  
BEFORE IMPUTATION QUALITY CONTROL  
PER SUBJECT   
BEFORE IMPUTATION QUALITY CONTROL  
PER SNP   IMPUTATION   
DATA 
ANALYSIS 
Cohort 
Genotyping 
Platform 
Genotype-
Calling 
Algorithm  
call rate 
threshold 
heterozygosity 
thresholds 
ethnicity 
exclusions 
other 
exclusion 
criteria  
SNP 
call 
rate 
HWE p-
value 
threshold 
MAF 
threshold 
other exclusion 
criteria  
Imputation 
Software 
(Version) 
HapMap CEU 
Release 
NCBI 
Build  
Association 
Software 
AAGC Illumina 610K or 
CNV370 
Illumina 
BeadStudio 
software 
 0.95 no yes no  0.95 1E-06 0.01 yes (BeadStudio 
GenCall score 
<0.7; SNPs 
exclusive to 
610K or 
CNV370) 
 Impute2 1000 Genomes 
Project (CEU Mar 
2010) + HapMap3 
(All 11 
populations, Feb 
2009) 
36  Plink 
ALSPAC Illumina 
HumanHap550 
quad 
  0.97 0.32 - 0.345 or 
0.31 - 0.33  
caucasians 
only 
sex 
discrepancies, 
cryptic 
relatedness, 
replicates 
<80% IBD 
 0.95 5E-07 0.01 No  Mach 
1.0.16 
22 36  Mach2Dat 
BAMSE* illumina 610k GenCall  no no caucasians 
only 
sex 
discrepancies, 
related 
individuals 
 no no no No  Mach 22 36  ProbAbel 
B58C-REPL Illumina 550k/610k GenCall  0.98 none yes none  0.95 1E-04 0.01 inconsistency of 
allele frequency 
across multple 
deposits 
 Mach 21 35  ProbAbel 
ECRHS* illumina 610 quad Gencall  no no caucasians 
only 
sex 
discrepancies, 
cryptic 
relatedness 
 no no no no  MACH 22 36  ProbABEL 
Generation R Illumina 610K quad BeadStudio 
Genotyping 
Module, 
version 3.2.32 
 0.975 3 SD of the 
mean 
Yes yes (IBD - 
check: no 
family 
relations) 
 0.98 1E-06 0.01 no  MACH 
v1.0.16 
22 36  Plink, 
MACH2DAT 
 
LISA/GINI Affymetrix 5.0 
Affymetrix 6.0 
BRLMM-P 
(5.0), 
BIRDSEED V2 
(6.0) 
 0.95 Mean +/- 4 SD caucasians 
only 
sex 
discrepancies 
 0.95 1E-5 0.01 no  Impute2 22 36  SnpTest 
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MAAS illumina 610 quad Illumina 
GenCall 
application 
  0.97 outliers caucasians 
only 
sex 
discrepancies, 
were non-
concordant on 
sequenome 
genotyping 
  0.95 5.9E-07 0.01 No   Impute2 3 + 1000 genomes 36   SnpTest 
MoBa illumina 610 quad Gen Call  0.97   sex 
discrepancies 
 0.95 1E-03 0.01   Plink 22 36  Plink 
NTR Affymetrix 6.0 Birdseed V2  no no no Clear sample 
switches 
based on 
fingerprint 
data (64 SNPs) 
 0.95 1E-04 0.01 MI>35  Beagle 22 36  Plink 
SAPALDIA* illumina 610 quad Gencall  no no caucasians 
only 
sex 
discrepancies, 
cryptic 
relatedness 
 no no no no  Mach 22 36  ProbABEL 
                   
de novo genotyping replication                 
     QUALITY CONTROL PER SUBJECT   QUALITY CONTROL PER SNP        
Cohort 
Genotyping 
Method 
Genotype-
Calling 
Algorithm   
call rate 
threshold   ethnicity exclusions 
other exclusion 
criteria   
lowest SNP  
call rate 
SNPs with HWE  
p-values <0.05               
Association 
Software 
Health2006 The PCR KASPar 
genotyping system 
(KBiosciences, 
Hoddesdon, UK).  
Kraken 
(Kbioscience) 
 0.98  caucasians Danish 
citizenship, born 
in Denmark 
 0.98 0        SPSS 
KORA F4 / 
GENEVA 
Sequenom MALDI-
TOF MS 4.0 
Sequenom 
Typer 4.0 
  0.97  caucasian sex discrepancies   0.97 0          R 
NFBC86 The PCR KASPar 
genotyping system 
(KBiosciences, 
Hoddesdon, UK). 
Klustercaller 
(Kbioscience) 
 0.97     0.97 0        Quicktest 
.  
*GABRIEL cohorts had QC applied only after the imputation step, see BAMSE methods for details.
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Supplementary Table 3. Discovery and replication results of the top 11 SNPs for atopic dermatitis. 1 SNP per region was followed up in the replication stage. Results are for 
the fixed effect inverse-variance meta-analysis, with genomic control applied to the individual studies in the discovery meta-analysis. The heterogeneity p-value (het p), testing for overall 
heterogeneity between all discovery and replication studies was generated using Cochran's Q-test for heterogeneity. All OR (odds ratios) are given with the minor allele representing the 
effect allele (Eff). CI denotes the confidence interval 
*rs9050 (and other associated SNP rs11205006 in the same region) were excluded from the replication phase after they were found to not be independent from the association with the 
FLG mutations in the same region. 
†rs2164983 was not included in the HapMap release 21 and so was missing for some discovery cohorts. 
The SNP rs1327914 was replaced by the SNP rs927709 (r
2
=1.00) in the B58C-WTCCC, B58C-T1DGC, KORA-F3, NFBC66 and the B58C replication cohort  
        Alleles   Discovery   Replication   
 
Combined 
chr SNP 
Position 
(bp) Gene Eff Alt   
Effect 
Allele 
Freq N OR (95% CI) pvalue   N OR (95% CI) pvalue   N OR(95%CI) pvalue het p 
11 rs479844 65308533 OVOL1 A G  0.44 26,151  0.89 (0.85, 0.93) 7.8E-07  25,098  0.87 (0.83,0.92) 2.4E-08  51,249 0.88 (0.85,0.91) 1.1E-13 0.23 
19 rs2164983 8650381 ACTL9 A C  0.15 17,403† 1.22 (1.13, 1.32) 1.8E-07  22,996  1.11 (1.04,1.19) 0.002  40,399 1.16 (1.10,1.22) 7.1E-09 0.004 
1 rs9050* 150345938 TCHH A C  0.06 25,788 1.33 (1.20, 1.47) 1.9E-08   - -  -   - - -  0.95 
5 rs2897442 132076926 KIF3A C T  0.29 26,164  1.12 (1.07, 1.18) 7.8E-06  25,064 1.09 (1.04,1.15) 0.001  51,228 1.11 (1.07,1.15) 3.8E-08 0.52 
8 rs7000782 81470705 ZBTB10 A T   0.43 26,077 1.14 (1.09, 1.20) 1.6E-08   20,873  1.03 (0.98,1.08) 0.296   46,950 1.09 (1.05,1.13) 1.1E-06 0.24 
22 rs4821544 35588449 NCF4 C T  0.29 24,770  1.13 (1.07, 1.19) 3.5E-06  25,103  1.05 (0.99,1.10) 0.077  49,873  1.09 (1.05,1.13) 5.5E-06 0.53 
6 rs3853601 31607582 BAT1 G C  0.12 25,528  1.17 (1.09, 1.26) 7.6E-06  21,964  1.09 (1.01,1.17) 0.031  47,492 1.13 (1.08,1.19) 1.9E-06 0.04 
10 rs10994675 51233999 MSMB A G  0.42 24,787  1.12 (1.07, 1.17) 3.1E-06  22,903  1.00 (0.95,1.05) 0.929  47,690 1.06 (1.03,1.10) 0.001 0.39 
13 rs1327914 95891570 HS6ST3 C T  0.17 26,168 1.16 (1.10, 1.24) 8.9E-07  25,088  0.98 (0.92,1.04) 0.434  51,256 1.07 (1.02,1.12) 0.003 0.005 
10 rs4520482 67139368 CTNNA3 A G   0.43 26,031  0.90 (0.86, 0.94) 8.7E-06   25,109  1.02 (0.97,1.07) 0.457   51,140 0.96 (0.92,0.99) 0.008 0.32 
9 rs10983837 119738636 TLR4 A C  0.03 26,101  1.35 (1.18, 1.54) 6.8E-06  24,168  0.92 (0.80,1.05) 0.229  50,269 1.12 (1.02,1.24) 0.015 0.002 
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Supplementary Table 4. AD association results from the discovery meta-analysis for the 15 loci associated with asthma or total serum IgE levels in a 
recent GWAS. Moffat MF, Gut IG, Demenais F, et al. A large-scale consortium-based genomewide association study of asthma. N Engl J Med 2010;125:328-35.  
 
 
     
Moffat et al. (2010) asthma association 
results   
AD association results from current 
meta-analysis 
SNP Gene Position 
effect 
allele 
other 
allele OR (95% CI) pvalue   OR (95% CI) pvalue 
rs3771166 IL18R1 2q12.1 a g 0.87 (0.83-0.91) 3.4E-09  1.00 (0.95-1.05) 0.9791 
rs9273349 HLA-DQB1 6p21.32 g a 1.18 (1.13-1.24) 7.0E-14  0.95 (0.86-1.04) 0.2647 
rs1342326 IL33 9p24.1 c a 1.20 (1.13-1.28) 9.2E-10  0.99 (0.93-1.05) 0.7789 
rs744910 SMAD3 15q22.33 a g 0.89 (0.86-0.92) 3.9E-09  0.98 (0.94-1.03) 0.3987 
rs2305480 GSDMB 17q12 a g 0.85 (0.81-0.90) 9.6E-08  1.00 (0.96-1.05) 0.8723 
rs3894194 GSDM1 17q21.1 a g 1.17 (1.11-1.23) 4.6E-09  1.00 (0.95-1.04) 0.8893 
rs2284033 IL2RB 22q12.3 a g 0.89 (0.86-0.93) 1.1E-08  1.03 (0.98-1.07) 0.2845 
rs1295686 IL13 5q31.1 c t 0.85 (0.79-0.90) 1.4E-07  0.91 (0.86-0.96) 0.0008 
rs2073643 SLC22A5 5q31.1 c t 0.89 (0.84-0.93) 2.2E-07  0.96 (0.92-1.00) 0.0771 
rs11071559 RORA 15q22.2 t c 0.88 (0.81-0.95) 1.1E-07   1.01 (0.95-1.08) 0.7475 
          
     
Moffat et al. (2010) total serum IgE 
association results   
AD association results from current 
meta-analysis 
SNP Gene Position 
effect 
allele 
other 
allele beta pvalue   OR (95% CI) pvalue 
rs2252226 FCER1A 1q23.2 t c NA 6.6E-05  0.96 (0.92-1.01) 0.0817 
rs20541 IL13 5q31.1 a g NA 1.0E-06  1.10 (1.04-1.16) 0.0007 
rs9271300 HLA-DRB1 6p21.32 c g NA 8.3E-15  0.99 (0.90-1.09) 0.9013 
rs167769 STAT6 12q13.3 t c NA 8.5E-07  1.05 (1.00-1.10) 0.0379 
rs1859308 IL4-R/IL21R 16p12.1 a g NA 8.2E-06   0.97 (0.91-1.04) 0.4477 
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Supplementary Table 5. Meta-analysis results for interactions between the three identified loci. Results are based on the discovery cohorts. Betas are 
the ln(odds) of AD per 1 unit change in the interaction variable (SNP1*SNP2, SNPs coded as 0,1,2 with the minor allele as the increasing allele).  
 
Interaction beta 95% CI p-value 
rs2897442*rs479844 -0.020 -0.090 to 0.050 0.578 
rs2897442*rs2164983 0.038 -0.081 to 0.157 0.535 
rs2164983*rs479844 0.019 -0.086 to 0.124 0.722 
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Supplementary Table 6. Immunochip association results on region 5q31.1. Conditional association analysis for markers of the cytokine cluster on 5q31.1 
including IL13 polymorphisms previously shown to be associated with asthma and psoriasis risk, as well as the GWAS KIF3A polymorphism showing the strongest 
association in the meta-analysis and the lead SNP of the corresponding putative LD-block from the finemapping approach. 
 
  Marker 1 
  rs1800925 (IL13) rs20541 (IL13) rs848 (IL13) rs66913936 (IL4) rs2897442 (KIF3A) 
Marker 2 rs1800925 (IL13) 1.32 (1.20-1.46) 
P=1.74 x 10-8 
1.26 (1.11-1.41) 
P=0.0002 
1.27 (1.12-1.42) 
P=0.0001 
1.23 (1.11-1.35) 
P=5.36 x 10-5 
1.19 (1.08-1.31) 
P=0.0005 
rs20541 (IL13) 1.17 (1.04-1.32) 
P=0.0085 
1.37 (1.24-1.52) 
P=4.07 x 10-10 
1.42 (0.72-2.81) 
P=0.3090 
1.18 (1.06-1.31) 
P=0.0018 
1.14 (1.03-1.26) 
P=0.0096 
rs848 (IL13) 1.17 (1.04-1.31) 
P=0.0107 
0.97 (0.49-1.92) 
P=0.9249 
1.38 (1.25-1.52) 
P=1.93 x 10-10 
1.18 (1.06-1.31) 
P=0.0022 
1.14 (1.03-1.26) 
P=0.0113 
rs66913936 (IL4) 1.24 (1.12-1.37) 
P=3.53 x 10-5 
1.27 (1.13-1.42) 
P=2.86 x 10 
1.28 (1.14-1.42) 
P=1.74 x 10-5 
1.31 (1.19-1.43) 
P=2.58 x 10-8 
0.91 (0.71-1.17) 
P=0.4742 
rs2897442 (KIF3A) 1.26 (1.14-1.39) 
P=1.01 x 10-5 
1.29 (1.16-1.44) 
P=3.42 x 10-6 
1.30 (1.17-1.45) 
P=2.00 x 10-6 
1.43 (1.10-1.84) 
P=0.0069 
1.26 (1.15-1.38) 
P=8.84 x 10-7 
Conditional analysis of Marker 1 conditioned on Marker 2 using the logistic regression framework. The diagonal elements shows results of the unconditional analysis. 
Displayed are odds ratios with corresponding 95% confidence intervals in brackets and P-values 
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Supplementary Table 7. Immunochip linkage disequilibrium (LD) in region 5q31.1. Pair-wise LD measures between markers of the cytokine cluster on 5q31.1 
including IL13 polymorphisms previously shown to be associated with asthma and psoriasis risk, as well as the GWAS KIF3A polymorphism showing the strongest 
association in the meta-analysis and the lead SNP of the corresponding putative LD-block from the finemapping approach. 
    Marker 1   
Marker 2  rs1800925 (IL13) rs20541 (IL13) rs848 (IL13) rs66913936 (IL4) rs2897442 (KIF3A) 
 rs1800925 (IL13) 1 0.301 0.298 0.090 0.078 
 rs20541 (IL13) 0.564 1 0.979 0.192 0.164 
 rs848 (IL13) 0.558 0.995 1 0.194 0.166 
 rs66913936 (IL4) 0.328 0.493 0.492 1 0.858 
 rs2897442 (KIF3A) 0.323 0.483 0.483 0.982 1 
The upper triangular matrix shows r2 values, whereas the lower triangular matrix displays D’ values. The color coding refers to the strength of LD. 
Values R2 D’ 
<0.2    
0.2-0.4   
0.4-0.6   
0.6-0.8    
>0.8    
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Supplementary Figure 1. QQ plot for the discovery genome-wide association meta-
analysis, after excluding all SNPs MAF<1% and Rsqr<0.3 or proper_info<0.4.  =1.017.EDC=epidermal 
differentiation complex region (which contains FLG) defined as Chr 1:150.2-151.9Mb. 
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Supplementary Figure 2. Regional association plots for the top 11 regions. Ordered by 
significance in the discovery analysis.  
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Supplementary Figure 3. Meta-analysis of 8 studies with no adjustment for FLG mutations 
(a) and with adjustment for FLG R501X and 2282del4 mutations (b). rs9050 (purple diamond) 
OR=1.28, p-value=0.008 in (a) and OR=0.98, p-value=0.88 in (b). A second SNP in the region (rs11205006 at 
~150.7Mb) OR=1.21, p-value=8x10
-5
 in (a) and OR=1.09, p-value=0.15 in (b). Plotted using LocusZoom 
(csg.sph.umich.edu/locuszoom/). Data from ALSPAC, BAMSE, COPSAC, KORA F3, KORA F4, LISA, MAAS and 
PIAMA studies contributed to these analyses.  
a.  
 
 
 
 
 
 
 
 
 
 
 
b.  
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Supplementary Figure 4. Previously known 11q13 (rs7927894) association in our study. (a) 
The regional association plot for the discovery meta-analysis (top SNP, rs11236810 p=0.0002), (b) The forest 
plot for the association in each of the discovery cohorts for rs7927894 with T as the risk allele (het p=0.127). 
GENR= Generation R.  
a.  
b. 
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Supplementary Figure 5. Forest plots of the association of the 7 SNPs which did not meet 
genome-wide significance with atopic dermatitis for the discovery and replication studies. 
All ORs are reported with the minor allele (shown in brackets) as the effect allele. *MoBa imputation quality 
score was ‘info’ from PLINK. GENR= Generation R. ‘gen’ in the imputation (Gen/Imp) column refers to 
SNPs that were on the genome-wide genotyping chip for the discovery samples and were either on 
the genome-wide genotyping chip or were individually genotyped for the replications samples. Only 
Health2006, KORA/GENEVA and NFBC86` underwent individual SNP genotyping. 
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Supplementary Figure 6. MuTHER pilot eQTL skin data for probes within 1Mb of the SNP (a) rs479844, (b) 
rs2164983 and (c) rs2897442 for 160 female twins. Data is split into two sets (with one of each twin pair in each). 
Results are shown for the candidate genes near to the SNP of interest (OVOL1/, ACTL9/ADAMTS10, KIF3A/IL4/IL13) and for any 
gene with p<0.01 (within 1Mb of the SNP) in either twin set. r=regression coefficient, p= unadjusted p-value, padj=adjusted p-
value, 10,000 permutations. 
a. rs479884 
i. OVOL1 – closest gene. Probe=ILMN_1692936 
 
 
ii.  DKFZp761E198 - close gene. Probe=ILMN_1717594 
 
 
iii KLC2 – p<0.01 in Twin1. Not confirmed in Twin2. Probe=ILMN_1653470 
 
 
iv. LTBP3 – p<0.01 in Twin1. Not confirmed in Twin2. Probe=ILMN_1777121 
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v. SLC25A45 – p<0.01 in Twin2. Not confirmed in Twin1. Probe=ILMN_1810727 
 
 
 
 
b. rs2967675 – best available proxy for rs2164983 (r
2
=0.94) 
i. ACTL9 – closest gene. Probe=ILMN_1656193 
 
 
 
c. rs2299009 – best available proxy for rs2897442 (r
2
=1.0) 
i. KIF3A – close gene. Probe=ILMN_1653385 
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iii.IL4 -close gene. Probe=ILMN_1669174 
 
iv. IL13 – close gene. Probe=ILMN_2052511 
 
 
iv. HSPA4 – p<0.01 in Twin1. Not confirmed in Twin2. Probe=ILMN_175513 
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Supplementary Figure 7. Regional Association Plots for 5q31.1 in the discovery cohorts (a) no conditional 
SNPs and (b) conditional on rs2897442. N=26,164. 
a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. 
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Supplementary Figure 8. Regional association plot of markers within the cytokine cluster on 5q31.1. Results from the Immunochip (custom genotyping SNP- chip designed for 
immunogenetic studies) including IL13 polymorphisms previously shown to be associated with asthma and psoriasis risk, as well as the GWAS KIF3A polymorphism showing the strongest 
association in the meta-analysis and the lead SNP of the corresponding putative LD-block from the finemapping approach. 
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Supplementary Figure 9. Stratified forest plots for SNPs associated with AD (rs479844, 
rs2164983, rs2897442) or with evidence of heterogeneity (rs2164983, rs1327914, 
rs10983837). Stratified by (a) reported physician AD diagnosis versus reported history of AD, (b) diagnosis 
before the age of 15 (child) versus up to and including adults. GENR = Generation R.  
a. reported physician AD diagnosis versus reported history of AD. Difference between subgroup p-
values: rs479844 p=0.653; rs2164983 p=0.134; rs2897442 p=0.023; rs1327914 p=0.191; rs10983837 
p=0.568.  
 
*CHOP used sub-optimal ICD9 diagnosis in medical record to identify cases. Reported physician’s AD diagnosis 
subgroup result with CHOP excluded: OR=0.89 (95%CI 0.85 - 0.93). 
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*CHOP used sub-optimal ICD9 diagnosis in medical record to identify cases. Reported physician’s AD diagnosis 
subgroup result with CHOP excluded: OR=1.18 (95%CI 1.10 - 1.26). 
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*CHOP used sub-optimal ICD9 diagnosis in medical record to identify cases. Reported physician’s AD diagnosis 
subgroup result with CHOP excluded: OR=1.15 (95%CI 1.09 - 1.20). 
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*CHOP used sub-optimal ICD9 diagnosis in medical record to identify cases. Reported physician’s AD diagnosis 
subgroup result with CHOP excluded: OR=1.07 (95%CI 1.01 - 1.14). 
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*CHOP used sub-optimal ICD9 diagnosis in medical record to identify cases. Reported physician’s AD diagnosis 
subgroup result with CHOP excluded: OR=1.06 (95%CI 0.94 - 1.19). 
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b. diagnosis before the age of 15 (child) versus up to and including adults. Difference between subgroup p-
values: rs479844 p=0.224; rs2164983 p=0.037; rs2897442 p=0.465; rs1327914 p=0.028; rs10983837 p=0.773.  
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Abstract
Objective: To describe regional differences between eastern and western
Germany with regard to food, nutrient and supplement intake in 9–12-year-old
children, and analyse its association with parental education and equivalent
income.
Design: Data were obtained from the 10-year follow-up of the two prospective
birth cohort studies – GINIplus and LISAplus. Data on food consumption and
supplement intake were collected using an FFQ, which had been designed for
the specific study population. Information on parental educational level and
equivalent income was derived from questionnaires. Logistic regression model-
ling was used to analyse the effect of parental education, equivalent income and
region on food intake, after adjusting for potential confounders.
Setting: Germany.
Subjects: A total of 3435 children aged 9–12 years.
Results: Substantial regional differences in food intake were observed between
eastern and western Germany. Intakes of bread, butter, eggs, pasta, vegetables/salad
and fruit showed a significant direct relationship with the level of parental education
after adjusting for potential confounders, whereas intakes of margarine, meat
products, pizza, desserts and soft drinks were inversely associated with parental
education. Equivalent income had a weaker influence on the child’s food intake.
Conclusions: Nutritional education programmes for school-age children should
therefore account for regional differences and parental education.
Keywords
Diet
Children
Germany
Regional differences
Socio-economic determinants
In Germany, in the early 1990s, shortly after reunification,
substantial differences in diet between the eastern and
western parts were reported in adults(1). Although food
consumption patterns have since largely converged, dif-
ferences still existed in 1998(2) and hence they probably
do even today.
Furthermore, socio-economic inequalities in food
choice and dietary intakes have been reported constantly
in the past(3–6). These studies supported the hypothesis
that people from higher socio-economic classes have higher
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intakes of healthy foods, such as whole grains, fish, low-fat
dairy products, fresh fruit and vegetables, and lower intakes
of unfavourable foods, such as meat and added fat, and
were thus more likely meet dietary recommendations than
people from lower socio-economic classes. Although these
associations have been studied mainly in adults, as reviewed
recently(7), it is less clear how parental socio-economic
position influences food intake in school-age children. In
this context, it would be worth knowing whether and how
dietary supplement use in children depends on parental
education and household income, as this has become
common in German children and adolescents over the past
years(8). According to the German Health Interview and
Examination Survey for Children and Adolescents (KiGGS),
15% of 12–13-year-old boys and 23% of 12–13-year-old
girls were taking dietary supplements in 2006(9). Educational
inequalities were found; however, as most dietary supple-
ments are quite expensive, household income is likely to
further limit supplement intake in children.
Detailed knowledge of dietary differences associated
with socio-economic inequalities or region of living has
important implications, both for the analysis of epide-
miological studies and for improving interventions to
promote healthy eating. Therefore, the aim of the present
study was to describe potential differences between
eastern and western Germany and the effect of parental
education and equivalent income on food, nutrient and
supplement intake in our study population of 9–12-year-
old children living in Germany.
We hypothesise that the intake of favourable foods in
children, such as fruit and vegetables, as well as the
intake of clearly unfavourable foods such as sweets and
cakes, shows a social gradient, which is probably mainly
determined by the level of parental education and
equivalent income. We further hypothesise that, in addi-
tion to socio-economic differences, regional differences
between eastern and western Germany exist for particular
foods and food groups.
Methods
Study population
Data from two ongoing German birth cohort studies were
combined for the present analysis.
The GINIplus (German Infant Nutritional Intervention)
study is a prospective birth cohort study that comprises the
GINI intervention study (I) and the GINI non-intervention
study (NI) and was initiated to investigate the influence of
nutritional intervention during infancy, as well as that of air
pollution and genetics on allergy development. Details on
study design, recruitment and exclusion criteria have been
described elsewhere(10,11). In brief, between September
1995 and June 1998, a total of 5991 healthy full-term
newborns were recruited from obstetric clinics in two
regions of Germany (urban Munich and rural Wesel).
Group I (n 2252) included infants with a family history of
allergy. In this prospective, double-blind intervention
trial, newborns were randomized at birth to one of three
hydrolysed formulae or to a conventional cow’s milk
formula. The formulae were provided only if the recom-
mended exclusive breast-feeding for the first 4 months
was not feasible or wanted. Infants with no family history
of allergy (n 2507) or with a positive family history but
from parents who refused to participate in the interven-
tion trial (n 1232) were allocated to the NI group. This
group was sent only the yearly questionnaires and did not
receive any of the additional intervention procedures.
All children (I and NI groups) were followed up with
identical questionnaires at 1, 2, 3, 4, 6 and 10 years of age to
collect information on health outcomes and covariates,
such as children’s nutrition and other lifestyle factors. A
total of 3317 children (55?4%) of the original study popu-
lation participated in the 10-year follow-up. Loss to follow-
up was associated with a lower level of parental education,
a negative history of parental atopy, the absence of atopic
diseases in the child during the first 2 years of life and
residency in Wesel; the presence of older siblings was not
associated with discontinuation of the study.
The LISAplus study is a population-based birth cohort
investigating ‘influences of lifestyle-related factors on
the immune system and the development of allergies in
childhood’. Details on study design are described else-
where(12,13). In brief, between November 1997 and January
1999, a total of 3097 newborns were initially recruited
from four German cities: Munich, Leipzig, Wesel and Bad
Honnef. Questionnaires on family history of atopy, par-
ental education and other lifestyle factors were completed
by parents shortly after delivery. Data on the child’s health
were collected by repeated parental-completed ques-
tionnaires at regular time intervals during the first 10 years
(0?5, 1, 1?5, 2, 4, 6 and 10 years of age). Since the 6-year
follow-up, the influences of traffic emission and genetics
on allergy development have become the focus of the
study. A total of 1761 children (56?9%) of the original study
population participated in the 10-year follow-up. Loss to
follow-up was strongly associated with a lower level of
parental education and residency in Wesel or Leipzig,
whereas the absence of older siblings, a negative history of
parental atopy and absence of atopic diseases in the child
during the first 2 years of life showed a weak association
with discontinuation of the study.
In the 10-year follow-up of both studies, an FFQ was
sent to all parents of children who completed the main
questionnaire in advance and who indicated a willingness
to participate in the dietary assessment. Since the FFQ
was provided subsequent to the main questionnaire and
only one written reminder was sent, the participation rate
in the FFQ was overall 67?9 %, based on participation in
the 10-year main questionnaire. Subjects were excluded
because of excessive missing information in the FFQ (n 6)
or because of implausible energy intake (n 6). Thus, the
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present analysis is based on 3435 subjects from GINIplus
(n 2190) and LISAplus (n 1245).
For both studies, approval from the local ethics com-
mittees (Bavarian General Medical Council, University of
Leipzig, Medical Council of North-Rhine-Westphalia) and
written consent from participant’s families were obtained.
FFQ
The FFQ administered to parents was designed to measure
children’s usual food and nutrient intake over the past year,
and more specifically to estimate energy, fatty acid and
antioxidant intake at 10 years of age. The development
including the selection process of the food item list and
validation of the FFQ has been described previously(14).
The FFQ comprised a list of eighty-two food items
accompanied by several questions about the preferred fat
and energy content of products, preparation methods,
diets and food preferences, buying habits and dietary
supplement use. To estimate how often food was con-
sumed by their child on average over the previous year,
parents were asked to choose one of nine frequency
categories, ranging from ‘never’ to ‘four times a day or
more’. In addition, common portion sizes were assigned
for each food item to enable an estimation of quantities.
For food items that are difficult to describe in common
household measures, coloured photographs from the
EPIC (European Prospective Investigation into Cancer
and Nutrition) study showing three different portion sizes
were included(15). The consumption frequencies and
portion size estimates were converted into average con-
sumption in g/d and this information was linked to the
German Food Code and Nutrient Database (BLS) version
II?3?1(16). Where food portions were not illustrated by
pictures, portion size data were obtained from a German
list of portion sizes, and weighting of single foods of
one FFQ item was carried out according to information
obtained from the DONALD (Dortmund Nutritional and
Anthropometric Longitudinally Designed) Study(17) in
order to represent the common consumption frequencies
among the children’s age group. This has been described
in more detail by Stiegler et al.(14). Missing categorical and
continuous variables were replaced by median and mean
frequencies of consumption, respectively, obtained from
the remaining study population.
For food items rich in fat, such as butter, margarine,
sausages and dairy products, additional questions on the
fat content that subjects usually choose were asked and
answers were applied to the relevant items on the list.
Likewise, the energy content of beverages such as soft
drinks and fruit drinks was considered.
Summation questions as introduced by Block et al.(18)
about the average consumption frequencies (per day or
per week) of the food groups bread, fruit, vegetables and
beverages were included at the end of the FFQ as general
consumption frequencies have been assumed to be more
valid than the sum of single frequencies(19). They permit
the adjustment of food consumption to reduce the over-
estimation resulting from the use of a long food item list
while retaining the reported distribution of these foods. If
the sum of the single food items was different from the
overall estimate, individual correction factors were calcu-
lated by dividing the food group intake obtained by the
summation question by the sum of intakes from the single
food items belonging to this food group. Daily food intake
was then multiplied by individual correction factors.
Questions on regular dietary vitamin and mineral sup-
plement use were included at the end of the FFQ. The list
of possible answers included ‘multivitamins’, ‘vitamin C’,
‘vitamin E’, ‘vitamin B’, ‘b-carotene’, ‘Ca’, ‘Mg’, ‘fluorine’ and
‘others’, allowing to specify other supplements regularly
used by the participant. For the purpose of nutrient calcu-
lation, this information was linked to the supplement data-
base of the DONALD Study, which contains detailed data on
all supplement products ever recorded in the study’s 3d
weighted dietary records(17). However, as the contribution
of vitamin intake by supplements was not significant and as
we had only rough information about the dosage and fre-
quency of supplement use, we abstained from including
vitamin intake from supplements for our analyses. Fatty acid
intake by supplementation such as fish oil could anyway
not be considered because this was not recorded in the
DONALD supplement database.
Socio-economic status: parental education
and household income
Parental education was determined on the basis of ques-
tionnaire-derived information about school education
according to the German educational system, and was
defined by the highest grade completed by either the
mother or the father. Thus, children were assigned to the
group of low (less than tenth grade), medium (tenth grade)
or high (more than tenth grade) parental education.
Net household income per month was reported in the 10-
year questionnaire using a 9-point scale ranging from
,h500 to .h3500. The calculation of equivalent income
according to the OECD (Organisation for Economic Coop-
eration and Development) guidelines(20) was carried out by
dividing the net household income by an equivalence fac-
tor, which gives a weight of 1?0 to the first adult, 0?5 to all
other adults and children .14 years, and 0?3 to all children
up to 14 years. As income was measured categorically, we
took the mid-point of each income class to calculate the
income level. For the lowest income level (,h500) we
calculated two-thirds (h333) of this limit, and for the highest
income level (.h3500) four-thirds (h4667), as described
before(21). Finally, the new variable was collapsed into three
groups of low, medium and high household income. To
enable comparing parental education with household
income, a similar class size for both variables was needed.
Therefore, the classification was based on quintiles so that
the percentage of subjects in each group of household
income equals the percentage of children in the respective
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group of parental education. Owing to the different income
structure in the four study areas, classes were calculated
separately for each study centre.
Statistical analysis
Nutrient and food intake data are presented by median
and the 25th and 75th percentiles, stratified by region and
gender. Food intake data are presented in g/d (Table 2)
and as mean contribution to total energy intake (Table 4).
For all nutrients, intake data are given in U/MJ and for
macronutrients the percentage contribution to total daily
energy intake (%E) is also shown (Table 3). Statistically
significant differences between study centres and gender
in food and nutrient intake were tested by the non-
parametric Kruskal–Wallis test.
Logistic regression modelling was used to analyse the
effect of parental education, equivalent income and region
on food intake adjusting for potential confounders. Food
intake data were dichotomised and the upper 25% of intake
for each gender- and centre-specific subgroup was used
as outcome variable. Adjusted OR and the corresponding
95% CI were computed. First, we examined the association
between parental education and food intake adjusted for
the covariates age and parental atopy. We then calculated a
model that included equivalent income, age and parental
atopy. Owing to the correlation between parental educa-
tion and household income (r50?28; P,0?0001), mutual
adjustment for these two influencing variables was not
allowed. Furthermore, a model for the effect of living in
Leipzig compared with Munich on food intake was ana-
lysed. For this purpose, gender-specific cut-off points for
defining high food intake were used.
Supplement use is described as a percentage of the
study population for boys and girls. In addition, logistic
regression models were calculated to estimate the prob-
ability of regular supplement intake dependent on parental
education and equivalent income, adjusted for gender,
study centre and age. All computations were carried out
using the statistical software R, version 2?9?1 (R Foundation
for Statistical Computing, Vienna, Austria)(22).
Results
The study population consisted of 3435 children (1683 girls
and 1752 boys) aged 9–12 years (median: 10?7). Altogether,
50?3% and 7?8% of all children lived in the urban areas of
Munich (western Germany) and Leipzig (eastern Germany),
respectively, whereas 37?4% and 4?5% lived in the more
rural areas of Wesel and Bad Honnef (both in western
Germany). Table 1 shows the basic characteristics of the
study population stratified for the four study centres.
Children in Munich and Bad Honnef had a higher parental
education than children in Leipzig and Wesel. Similarly,
the highest equivalent income was reported in Munich,
followed by Bad Honnef, Leipzig and Wesel. The mean
body weight and height were 38?0 (SD 7?5) kg and 147?8
(SD 7?4) cm, respectively. The median (50th percentile)
BMI in the whole study population was 16?8kg/m2, 90%
of all children showed a BMI ,20?7kg/m2 and 97%
,23?2kg/m2. Minor differences in the distribution of these
anthropometric measures among the study centres could
be explained by age differences. An FFQ was mostly com-
pleted in autumn (63?9%) compared with winter (15?5%),
spring (13?3%) and summer (7?3%).
The food group intakes in g/d are presented in Table 2
according to study centre and gender. Children in Munich
consumed less bread, margarine, dairy products and
potatoes and more breakfast cereals (only boys), vege-
table oil and fruit/vegetable juices than did children in the
other study centres. The intakes of cheese, fruit, cake/
pastry and tea were highest in children from Leipzig,
whereas they had the lowest intakes of rice, pizza and
vegetables/salad compared with children from the other
study centres. The highest intake for meat and the lowest
intake for butter were observed in Wesel.
The median nutrient intakes per unit energy are pre-
sented in Table 3 according to study centre and gender.
For boys, total energy intake was lowest in Munich, and
for girls in Bad Honnef, whereas Wesel showed the
highest energy intake for boys and Leipzig for girls. The
macronutrient profiles, including energy derived from
protein, carbohydrates and fat, were similar between the
four study centres. Relying on P values, statistically sig-
nificant differences between the four study centres were
observed for all nutrients, except vitamin C.
The two main sources of total daily energy intake were
dairy products and bread, followed by meat products,
breakfast cereals, pasta and fruit/vegetable juices (Table
4). The food groups with the smallest contribution to total
energy intake (,1 %) were ice cream and fruit gums, eggs
and nuts and seeds. The food group ranking in terms
of %E contribution was similar although not identical
between boys and girls. Regional differences between the
study centres were small and derived from the differences
in daily food intake described in Table 2.
Parental education, household income, region and
food intake
The impact of parental education, equivalent income and
regional effects on children’s food intake was investigated
by logistic regression models (Table 5), where the upper
25% of food intake for each gender- and centre-specific
subgroup was the dependent variable. Food groups that
showed a significant direct relationship with the level of
parental education after adjusting for age and parental atopy
were butter, eggs, vegetables/salad, fruit and vegetable oil.
In turn, the intake of meat products, desserts, snacks and
soft drinks was inversely associated with parental education.
In contrast, equivalent income showed a weaker
influence on the child’s food intake. Children with a
comparatively high equivalent income had lower intakes
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of meat products and soft drinks and a higher pasta and
fruit intake than those in the lowest income category. A
model including age, parental atopy, parental education
and equivalent income did not indicate that mutual
adjustment would have any effect on the magnitude of
OR (data not shown).
Table 5 also shows the effect estimates for the associa-
tion between region (Leipzig, eastern Germany) compared
with Munich (western Germany) and gender-specific
high food intake controlling for parental education, age
and parental atopy. Compared with Munich, children
from Leipzig had statistically significant higher intakes
of margarine, dairy products, eggs, potatoes, fruit, cake/
pastry, soft drinks and tea and lower intakes of breakfast
cereals, pasta, rice, pizza and vegetable oil.
Supplement use
In total, the percentage of regular supplement users
was 6?9 among boys and 6?6 among girls. About 9?2 % of
both sexes reported adding supplements irregularly to
their diet (Table 6). Multivitamins were the most common
supplements, used by 57?0 % (boys) and 50?5 % (girls) of
all regular supplement users. Among the single vitamin or
mineral products, vitamins C and E, Ca and Mg were the
most important ones. Fluorine was used by 9?0 % of the
boys and 17?1 % of the girls who were taking supple-
ments regularly. A high proportion of children (28?9 % of
all boys and 27?0 % of all girls) indicated taking dietary
supplements other than the ones presented here. Due
to the large variety of different supplements, they have
been summarised into one heterogeneous group labelled
‘other supplements’. The majority of supplement users
(5?8 % and 4?8 %) reported the use of only one type of
supplement; ,2 % took two or more.
Regular supplement use was more common among
children in Munich (7?9 %) and Bad Honnef (8?4 %) than
in Leipzig (4?5 %) and Wesel (5?5 %; data not shown).
The proportion of supplement types varied between
study centres, but because of the small numbers sig-
nificance testing is limited. In Leipzig (66?7 %) and Bad
Honnef (69?2 %), the use of multivitamins was more often
reported than in Munich (54?0 %) and Wesel (48?6 %; data
not shown).
Supplement users were compared with non-users with
respect to parental education and equivalent income in
a multiple logistic regression model (Table 7). Neither
parental education nor equivalent income showed a sta-
tistically significant relationship with regular supplement
use in children, although more regular supplement users
were found among children with medium (7?4 %) or high
(6?8 %) parental education compared with children with
low parental education (4?7 %).
Discussion
The results of the present study suggest an association of
parental education and region with food intake in 9–12-
year-old children, whereas association with the level of
equivalent income was weak. No statistically significant
associations were observed between parental education
or equivalent income and supplement intake in children.
The descriptive food and nutrient intake data of the
present study were partly in very good agreement with
data from the nationally representative eating study
(EsKiMo)(23) as part of the KiGGS study. The absolute
intakes (in g/d) for 10–11-year-old boys in the EsKiMo
study and for 9–12-year-old boys in the present study
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Table 1 Basic characteristics of the study population: German children aged 9–12 years, GINIplus and LISAplus studies
Total (n 3435) Munich (n 1730) Leipzig (n 267) Wesel (n 1284) Bad Honnef (n 154)
Mean SD Mean SD Mean SD Mean SD Mean SD
Boys (%) 51?0 51?0 51?7 51?2 48?1
Age (years)
Median 10?72 10?7 10?3 11?0 10?6
P5 10?13 10?2 9?9 10?3 10?0
P95 11?77 11?7 10?9 11?8 11?1
Level of parental education (%)
Low 5?9 3?5 1?1 10?5 3?3
Medium 26?7 16?9 39?7 37?6 22?2
High 67?4 79?6 59?2 52?0 74?5
Equivalent income
Median 1513 1729 1317 1250 1498
P25 1071 1310 972 913 1071
P75 1945 2222 1765 1528 1945
Body height (cm) 147?8 7?4 147?1 7?2 144?5 7 149?5 7?5 146?4 6?2
Body weight (kg) 38 7?5 37?2 7 35?6 6?4 39?6 8?2 37?6 7?4
BMI (kg/m2)
P3 13?8 13?8 14?1 13?8 13?7
P50 (median) 16?8 16?7 16?6 17?1 16?9
P90 20?7 20?1 19?5 21?3 20?9
P97 23?2 22?5 21?8 23?9 22?4
P5, 5th percentile; P95, 95th percentile; P25, 25th percentile; P75, 75th percentile; P3, 3rd percentile; P50, 50th percentile; P90, 90th percentile; P97, 97th percentile.
Socio-economic determinants of children’s diet 5
were very similar for the food groups bread (105 g and
115 g), cheese (17 g and 15 g), eggs (9 g and 8 g), potatoes
(53 g and 51 g), pasta (37 g and 38 g) and fruit (112 g and
110 g). In contrast, the reported intakes of meat (52 g and
25 g), breakfast cereals (25 g and 9 g), dairy products
(341 g and 244 g) and fruit/vegetable juice (368 g and
193 g) derived from our FFQ were much higher than the
corresponding EsKiMo intake data and may have even
overestimated the true intakes. However, absolute intake
data are in general hardly comparable because of differ-
ent food group definitions and aggregation levels. In any
case, the main sources of total daily energy intake in our
study population were comparable to those reported by
the EsKiMo study. Dairy products (15?5 % and 11 %),
bread (13?8 % and 14 %), fruit/vegetable juices (5?7 % and
7 %) and cake/pastry (5?0 % and 7 %) were ranked among
the first eight food groups in both studies, where the first
value given in brackets corresponds to all boys of the
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Table 2 Median intake of food groups per day in the study population by gender and region
Total (n 3435) Munich (n 1730) Leipzig (n 267) Wesel (n 1284) Bad Honnef (n 154)
Food group (g/d) Gender Mean P25 P75 Mean P25 P75 Mean P25 P75 Mean P25 P75 Mean P25 P75 P value*
Bread Boys 115 82 158 104 77 146 124 93 180 134 92 216 124 92 205 ,0?0001
Girls 103 76 141 98 72 137 127 96 170 118 76 176 125 82 162 ,0?0001
Butter Boys 2 0 8 4 1 10 2 1 6 0 0 3 3 0 9 ,0?0001
Girls 2 0 6 4 1 10 4 1 10 0 0 2 2 0 5 ,0?0001
Margarine Boys 1 0 5 0 0 2 3 0 9 4 1 10 1 0 4 ,0?0001
Girls 1 0 5 0 0 1 3 0 10 3 1 9 3 1 6 ,0?0001
Cheese Boys 15 6 35 17 7 36 21 8 38 13 4 33 12 4 23 ,0?0001
Girls 16 6 33 17 7 34 23 12 40 13 5 29 22 8 40 ,0?0001
Meat Boys 52 33 81 45 30 70 46 33 70 64 43 91 47 32 79 ,0?0001
Girls 43 28 64 35 24 55 44 28 61 54 35 79 45 32 65 ,0?0001
Meat products Boys 49 29 75 47 29 73 49 30 73 51 30 82 46 27 74 0?0492
Girls 38 22 59 38 20 57 44 26 60 38 22 63 33 25 52 0?0841
Breakfast cereals Boys 25 8 54 36 11 54 27 9 50 18 7 49 19 9 51 ,0?0001
Girls 19 7 40 21 8 50 20 8 36 18 6 37 22 7 43 0?0074
Dairy products Boys 341 210 580 294 190 464 358 219 571 449 243 740 335 175 577 ,0?0001
Girls 263 153 427 246 134 369 302 176 471 307 166 521 272 147 397 ,0?0001
Eggs Boys 8 5 16 8 5 16 8 8 16 8 5 16 8 5 19 0?0150
Girls 8 5 9 8 5 8 8 5 14 8 5 10 8 5 8 0?5300
Potatoes Boys 51 29 83 38 23 65 64 41 87 73 46 110 65 43 83 ,0?0001
Girls 46 28 73 32 21 63 52 41 77 63 43 98 63 37 83 ,0?0001
Pasta Boys 38 18 61 38 24 61 38 18 38 38 15 38 38 18 55 ,0?0001
Girls 38 18 61 38 24 61 38 15 38 38 15 38 38 18 61 ,0?0001
Rice Boys 13 7 19 13 7 22 8 7 13 13 7 18 10 6 13 0?0123
Girls 13 7 13 13 7 18 8 4 13 13 7 13 13 7 13 0?0060
Pizza Boys 28 13 33 28 16 47 13 11 28 28 13 33 28 11 33 ,0?0001
Girls 28 11 28 28 13 33 11 6 28 28 11 28 28 11 28 ,0?0001
Fish Boys 17 10 28 17 10 28 19 11 28 17 10 28 18 10 31 0?2765
Girls 14 7 24 16 7 25 17 10 26 12 7 22 12 7 23 0?0214
Vegetables
and salad
Boys 104 65 157 111 69 167 54 24 91 100 62 145 119 79 171 ,0?0001
Girls 115 72 171 123 78 177 54 34 102 106 70 160 109 63 161 ,0?0001
Fruit Boys 110 66 159 110 65 156 131 77 232 108 66 154 110 69 161 ,0?0001
Girls 114 79 162 115 83 162 137 93 234 111 67 157 113 67 156 ,0?0001
Cake and pastry Boys 24 15 38 23 15 37 30 19 49 24 15 38 22 13 34 0?0005
Girls 23 15 37 23 14 35 28 19 53 23 15 38 23 15 32 0?0010
Desserts Boys 10 3 18 10 3 17 10 8 18 10 4 18 8 3 18 ,0?0001
Girls 8 3 14 8 3 14 8 4 14 8 3 16 8 4 14 0?0296
Chocolate Boys 11 6 23 10 5 23 12 7 19 12 7 23 10 4 23 0?0653
Girls 10 5 19 9 4 18 9 5 19 10 5 19 10 6 18 0?0871
Ice cream and
fruit gums
Boys 7 4 12 7 4 12 7 3 16 7 4 12 8 4 15 0?5502
Girls 6 4 11 6 3 11 8 4 14 6 4 11 7 4 12 0?1968
Snacks Boys 4 1 7 2 1 4 4 2 6 4 2 7 2 1 7 ,0?0001
Girls 2 1 6 2 1 4 2 1 4 4 2 7 2 1 4 ,0?0001
Nuts and seeds Boys 1 0 3 1 0 3 1 0 2 1 0 2 1 0 3 0?4357
Girls 1 0 2 1 0 2 1 0 2 1 0 2 1 0 4 0?0670
Vegetable oil Boys 2 1 5 3 2 6 1 1 2 2 1 4 2 1 4 ,0?0001
Girls 2 1 4 3 2 5 1 1 3 2 1 3 2 1 5 ,0?0001
Fruit/vegetable
juice
Boys 368 132 714 429 145 744 313 133 665 328 124 683 248 85 624 0?0184
Girls 331 115 630 367 120 656 363 128 640 283 99 584 313 114 623 0?0478
Soft drinks Boys 34 13 120 31 12 94 36 10 132 42 15 162 30 10 83 0?0008
Girls 22 8 65 18 7 48 27 8 78 28 10 94 24 7 98 ,0?0001
Tea Boys 15 0 79 25 5 104 76 22 276 4 0 25 13 2 53 ,0?0001
Girls 24 4 99 34 7 123 90 24 249 11 0 51 21 0 104 ,0?0001
P25, 25th percentile; P75, 75th percentile.
*Kruskal–Wallis test.
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Table 3 Median nutrient intakes per unit energy in the study population by gender and region
Total (n 3435) Munich (n 1730) Leipzig (n 267) Wesel (n 1284) Bad Honnef (n 154)
Nutrient Gender Mean P25 P75 Mean P25 P75 Mean P25 P75 Mean P25 P75 Mean P25 P75 P value*
Energy (kJ) Boys 8971 7349 11 016 8658 7077 10 499 8855 7388 10 991 9472 7707 11 681 8947 7226 10 908 0?0000
Girls 7708 6295 9352 7604 6250 8991 8261 6519 9948 7854 6334 9698 7432 6261 9557 0?0033
Energy (kcal) Boys 2143 1756 2631 2069 1691 2508 2116 1765 2626 2262 1841 2791 2139 1727 2606 ,0?0001
Girls 1840 1503 2234 1816 1493 2147 1973 1557 2373 1874 1512 2316 1775 1496 2281 0?0034
Protein (%E) Boys 14 11 18 14 12 18 14 12 17 15 11 19 14 12 18 ,0?0001
Girls 14 11 18 14 11 17 14 11 17 15 12 19 15 12 20 ,0?0001
Carbohydrates (%E) Boys 54 44 67 55 44 67 56 45 68 54 43 67 57 42 65 ,0?0001
Girls 55 44 68 54 44 66 54 42 68 54 44 68 58 46 72 0?0093
Total fat (%E) Boys 29 22 37 29 23 37 28 22 36 29 23 38 29 21 37 ,0?0001
Girls 29 22 36 29 22 36 29 23 36 28 23 36 29 24 40 0?0406
SFA (mg/MJ) Boys 3237 2433 4268 3212 2445 4170 3265 2494 4114 3264 2457 4359 3123 2228 4499 0?0000
Girls 3163 2425 4080 3138 2388 4098 3324 2536 4015 3146 2401 3955 3237 2493 4316 0?0202
MUFA (mg/MJ) Boys 2707 2068 3519 2754 2094 3587 2617 2190 3239 2707 2049 3582 2767 2024 3323 0?0013
Girls 2645 2025 3391 2634 2016 3409 2663 2087 3232 2600 2021 3374 2679 2149 3374 0?1191
PUFA (mg/MJ) Boys 1130 866 1458 1126 863 1455 1073 861 1268 1150 889 1440 1065 865 1387 ,0?0001
Girls 1140 882 1439 1106 848 1391 1048 813 1327 1183 904 1492 1172 985 1516 ,0?0001
Linoleic acid (n-6; mg/MJ) Boys 955 729 1233 959 726 1235 908 707 1085 974 744 1249 905 705 1165 ,0?0001
Girls 960 741 1230 939 714 1185 872 679 1097 1005 766 1287 981 834 1267 ,0?0001
Arachidonic acid (n-6; mg/MJ) Boys 21 15 28 20 14 27 19 14 24 22 16 31 21 16 31 ,0?0001
Girls 20 15 28 19 13 26 19 13 24 22 17 32 22 17 30 ,0?0001
EPA (n-3; mg/MJ) Boys 3767 2038 6845 3713 2014 6895 4454 2674 8068 3603 2054 6431 3817 1909 7358 0?0284
Girls 3498 1898 6904 3695 1946 7487 4124 2210 8338 3301 1782 5802 3052 1913 6730 0?0151
DPA (n-3; mg/MJ) Boys 1262 720 2010 1195 676 1939 1491 827 2127 1259 741 2076 1303 766 1853 0?0022
Girls 1212 691 2068 1199 660 2058 1373 797 2352 1218 703 1993 1068 727 2236 0?1037
Vitamin A (mg/MJ) Boys 114 75 172 117 77 176 117 77 178 108 72 166 122 88 171 0?6453
Girls 121 86 183 128 89 188 117 82 195 112 82 169 126 89 203 0?0098
Vitamin E (mg/MJ) Boys 999 781 1311 1042 802 1374 942 724 1205 959 763 1259 961 835 1207 0?0166
Girls 1077 835 1382 1092 850 1408 1007 751 1211 1053 820 1352 1183 904 1488 0?3731
Vitamin C (mg/MJ) Boys 10 7 14 10 7 14 10 6 14 10 7 13 10 7 14 0?2121
Girls 11 8 15 11 8 15 10 8 15 11 8 16 12 8 16 0?9318
P25, 25th percentile; P75, 75th percentile.
*Kruskal–Wallis test.
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present study population and the second value to 6–11-
year-old boys of the EsKiMo study. This general good
agreement was also reflected on the nutrient level, as
intakes of the macronutrients fat, protein and carbohy-
drates as well as vitamins E and C corresponded to the
values reported by the EsKiMo study. Only total energy
intake in boys (8971 kJ (2143kcal) and 7586kJ (1813kcal))
seemed to be overestimated in the present study.
For children, the KiGGS study suggests no persisting
dietary differences in intakes between children from
eastern and western Germany(24), which is in contrast to
our findings. We compared food group intakes between
metropolitan areas such as Leipzig in the east and Munich
in the west of Germany and observed some significant
differences for the food groups margarine, dairy products,
eggs, potatoes, fruit, cake/pastry, soft drinks, tea, breakfast
cereals, pasta, rice, pizza and vegetable oil. The study
centres Wesel and Bad Honnef have been excluded
from the analysis although they are located in the west
of Germany. Owing to the heterogeneity of the three
western study centres, rural/urban and north/west differ-
ences would be implied in the east/west comparison.
Certainly, the different socio-economic structures of the
two study centres might have contributed to the observed
regional effects as, for example, parents in Munich (79?6%)
more likely had a high educational level than in Leipzig
(59?2%; see Table 1). Thus, the correlation between
parental education and region (r5 0?17; P, 0?0001) might
have led to residual confounding even after controlling for
parental education. As this could also affect the association
between parental education and food intake, we calcu-
lated gender- and centre-specific cut-off points for defining
high food intake for analysing the association with parental
education to minimise the described effect.
Comparing present findings with other studies is difficult
because various measures for socio-economic position
have been used, including education, income or occupa-
tion, which have been shown not to serve as adequate
proxies for one another(25). According to the findings of
the present study, the intakes of butter, eggs, vegetables/
salad, fruit, vegetable oil, meat products, desserts, snacks
and soft drinks in children varied by level of parental
education. Our findings are thus in line with probably the
most consistent evidence of dietary inequalities in adults,
showing a lower consumption of fruit and vegetables
among socio-economically disadvantaged groups(4). This
has also been reported by a study carried out in German
schoolchildren, a part of WHO’s cross-sectional survey
HBSC (Health Behaviour in School-Aged Children)(26),
showing that the impact of the social situation was parti-
cularly strong for healthy foods, such as raw vegetables,
fruit and wholegrain wheat bread. A Finnish study in
children aged 9–15 years also reported that children of
families with higher socio-economic status used more fruit
than did children of families with lower socio-economic
status, where family’s socio-economic status was defined
according to the father’s educational level, his occupation
and family income(27). Contrary to our findings, they
reported that high socio-economic status was associated
with a higher margarine intake, whereas children of low
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Table 4 Mean contribution of food groups to total energy intake in boys and girls
Boys (n 1752) Girls (n 1683)
Food group
Mean contribution to
total energy intake (%) Food group
Mean contribution to
total energy intake (%)
Dairy products 15?5 Bread 14?3
Bread 13?8 Dairy products 13?6
Meat products 8?7 Meat products 7?7
Breakfast cereals 6?6 Pasta 7?2
Pasta 6?4 Fruit/vegetable juices 6?1
Fruit/vegetable juices 5?7 Breakfast cereals 5?8
Meat 5?5 Cake and pastry 5?5
Cake and pastry 5?0 Meat 5?3
Chocolate 3?9 Fruit 4?5
Fruit 3?5 Chocolate 3?9
Cheese 3?0 Cheese 3?3
Soft drinks 3?0 Butter 2?9
Butter 2?9 Rice 2?8
Potatoes 2?5 Potatoes 2?6
Rice 2?4 Soft drinks 2?3
Vegetable oil 1?7 Vegetable oil 1?8
Pizza 1?6 Vegetables, salad 1?7
Fish 1?4 Pizza 1?5
Vegetables and salad 1?3 Fish 1?4
Margarine 1?2 Margarine 1?3
Desserts 1?2 Desserts 1?1
Snacks 1?2 Snacks 1?1
Ice cream and fruit gums 0?8 Ice cream and fruit gums 0?8
Eggs 0?7 Eggs 0?7
Nuts and seeds 0?7 Nuts and seeds 0?7
8 S Sausenthaler et al.
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Table 5 Results of logistic regression models of parental education, equivalent income and region on children’s food intake (defined as the upper 25 % of each gender- and center-specific
subgroups)
Parental education Equivalent income Region
Medium v. low (n 888) High v. low (n 2236) Medium v. low (n 699) High v. low (n 2401) Leipzig v. Munich (n 267)
Food group (g/d) aOR* 95 % CI aOR* 95 % CI aOR* 95 % CI aOR* 95 % CI aOR- 95 % CI
Bread 0?89 0?61, 1?29 1?16 0?82, 1?65 0?68 0?48, 0?95 0?90 0?66, 1?22 1?05 0?75, 1?48
Butter 1?11 0?73, 1?67 1?88 1?28, 2?78 1?06 0?74, 1?54 1?37 0?98, 1?92 0?99 0?70, 1?40
Margarine 1?09 0?77, 1?54 0?79 0?57, 1?09 0?95 0?68, 1?32 0?79 0?58, 1?07 3?89 2?85, 5?32
Cheese 0?95 0?66, 1?37 1?12 0?80, 1?58 0?76 0?54, 1?05 0?79 0?58, 1?06 1?19 0?85, 1?65
Meat 1?10 0?78, 1?57 0?81 0?58, 1?14 1?04 0?74, 1?46 0?95 0?70, 1?30 1?15 0?82, 1?60
Meat products 0?78 0?55, 1?10 0?64 0?46, 0?88 0?82 0?59, 1?14 0?68 0?50, 0?92 1?03 0?74, 1?44
Breakfast cereals 1?34 0?91, 1?96 1?43 0?99, 2?07 0?84 0?60, 1?17 0?87 0?64, 1?18 0?64 0?45, 0?92
Dairy products 1?06 0?74, 1?50 0?85 0?61, 1?18 0?82 0?59, 1?14 0?78 0?58, 1?05 1?81 1?31, 2?48
Eggs 1?39 0?94, 2?04 1?45 1?01, 2?09 1?17 0?83, 1?65 1?02 0?74, 1?39 1?39 1?00, 1?92
Potatoes 0?92 0?65, 1?31 0?89 0?64, 1?25 0?87 0?63, 1?21 0?74 0?55, 1?00 2?23 1?63, 3?05
Pasta 1?09 0?79, 1?50 1?25 0?92, 1?69 1?07 0?78, 1?46 1?36 1?02, 1?81 0?42 0?29, 0?59
Rice 1?11 0?80, 1?56 1?09 0?80, 1?50 1?23 0?88, 1?72 1?25 0?92, 1?70 0?60 0?43, 0?83
Pizza 0?85 0?61, 1?17 0?77 0?57, 1?05 1?05 0?76, 1?45 0?99 0?74, 1?33 0?27 0?18, 0?41
Fish 0?83 0?58, 1?18 0?85 0?61, 1?19 1?00 0?71, 1?40 0?93 0?68, 1?27 1?08 0?77, 1?50
Vegetables and salad 1?43 0?95, 2?14 1?70 1?16, 2?51 1?07 0?75, 1?52 1?08 0?78, 1?49 0?73 0?51, 1?05
Fruit 1?99 1?27, 3?10 2?44 1?60, 3?74 1?16 0?80, 1?68 1?44 1?03, 2?02 2?32 1?69, 3?18
Cake and pastry 1?16 0?80, 1?68 1?10 0?77, 1?56 0?85 0?61, 1?19 0?78 0?58, 1?06 1?94 1?42, 2?66
Desserts 0?66 0?48, 0?91 0?53 0?39, 0?73 0?88 0?64, 1?22 0?89 0?66, 1?19 1?15 0?84, 1?58
Chocolate 0?88 0?63, 1?24 0?73 0?53, 1?01 1?00 0?71, 1?41 0?95 0?70, 1?29 0?86 0?61, 1?21
Ice cream and fruit gums 1?01 0?71, 1?43 0?83 0?60, 1?17 1?17 0?84, 1?64 0?86 0?63, 1?17 1?18 0?85, 1?63
Snacks 1?07 0?78, 1?48 0?73 0?54, 0?99 0?95 0?70, 1?29 0?77 0?58, 1?03 1?19 0?88, 1?62
Nuts and seeds 1?14 0?79, 1?64 1?14 0?81, 1?61 1?04 0?74, 1?45 0?88 0?65, 1?19 0?78 0?55, 1?11
Vegetable oil 1?28 0?86, 1?92 1?68 1?15, 2?45 1?24 0?86, 1?80 1?37 0?98, 1?92 0?20 0?12, 0?34
Fruit/vegetable juice 1?06 0?74, 1?52 1?00 0?71, 1?40 1?25 0?87, 1?78 1?16 0?84, 1?61 0?84 0?60, 1?19
Soft drinks 0?67 0?49, 0?93 0?44 0?32, 0?59 0?81 0?59, 1?12 0?63 0?47, 0?84 1?44 1?04, 2?00
Tea 1?03 0?71, 1?49 1?14 0?80, 1?61 0?78 0?55, 1?09 0?82 0?60, 1?10 2?55 1?86, 3?49
aOR, adjusted OR.
Low parental education, low family income and the study centre in Munich formed the reference category.
*OR adjusted for age and parental atopy; centre- and gender-specific cut-off points were used to define high intake (upper 25 %).
-OR adjusted for parental education, age and parental atopy; gender-specific cut-off points were used to define high intake (upper 25 %)
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socio-economic status had a higher intake of butter.
However, although the parental education level was
lower in Leipzig compared with Munich, fruit intake was
higher in this eastern German city. This result strongly
points to the additional impact of further influencing
factors on food intake.
Another study showed that among several potential
predictors of fruit and vegetable consumption analysed in
pre-school children, maternal education emerged to be
positively associated with children’s vegetable consump-
tion whereas no effect of fruit intake was reported(28).
Although the dependence of healthy food intake, such as
fruit and vegetables, on social class has been studied well,
the situation is less clear for some of the foods for which
significant associations have been described in the pre-
sent study. Within the ALSPAC (Avon Longitudinal Study
of Parents and Children) study(29), a positive association
between maternal education and intake of meat products
and soft drinks was shown in 18-month-old children.
Compared with school age, food choice at this age is
completely under the control of parents, which is why
parental socio-economic position might have a different
effect than later in childhood.
Several possible limitations of the study should be
considered. First, it should be noticed that the present
findings are based on a cross-sectional analysis within the
two cohort studies – LISAplus and GINIplus. Even though
study sampling was primarily population-based, the study
population is, as almost every cohort study, subject to
selection bias, and thus the findings are not representative
for Germany. Owing to non-random loss to follow-up,
both cohorts on which the present analysis is based under-
represent children from lower social classes. The true
social inequalities might therefore even be stronger than
reported here. Furthermore, the intakes of a large number
of nutrients and foods were examined, many of which are
correlated with one another. As a result there is the pos-
sibility of type I errors occurring. However, the significant
associations that we have found are either similar to pre-
vious findings or are in line with our previous hypothesis,
which leads us to believe that they are unlikely to be
the result of type I error. Certainly, it has to be considered
that the FFQ was actually not designed to measure, for
example, carbohydrate and protein intakes. However,
since total energy intake as well as the percentage con-
tribution to total daily energy intake of carbohydrates and
protein shows plausible values, we think that this justifies
the analysis of the respective macronutrients. However, it
has to be considered that the food item list included only
those foods that significantly contribute to the intake of
total energy, fatty acids and selected antioxidants.
Unfortunately, we do not have any information on
whether fortified foods were consumed. However,
according to a recent publication(30), the contribution of
fortified foods to total nutrient intake is rather low in
Germany, in particular for vitamins E and A. The authors
further conclude that the base diet is the major con-
tributor to intakes of all nutrients in Europe. When we
included nutrients from supplement intake in our ana-
lyses, the numbers did not change substantially, as the
rather low frequency of regular supplement use in our
study population (,7 %) let assume. However, the rather
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Boys Girls
n % n %
Number of supplements (n 1752) (n 1683)
0 1631 93?1 1572 93?4
1 101 5?8 80 4?8
$2 20 1?1 31 1?8
Frequency
Regular supplement use 121 6?9 111 6?6
Irregular supplement use 161 9?2 155 9?2
Specification (only regular
supplement user)*
(n 121) (n 111)
Multivitamins 69 57?0 56 50?5
Vitamin C 26 21?5 28 25?2
Vitamin E 16 13?2 13 11?7
Vitamin B 3 2?5 7 6?3
b-Carotene 1 0?8 4 3?6
Ca 12 9?9 19 17?1
Mg 18 14?9 16 14?4
Fluorine 11 9?0 19 17?1
Zn 12 9?9 13 11?7
Iodine 5 4?1 9 8?1
Fe 4 3?3 8 7?2
Others 35 28?9 30 27?0
*Multiple answers possible.
Table 7 Results of logistic regression models of parental education and equivalent income on children’s supplement use
Parental education Equivalent income
Low (n 193) Medium (n 888) High (n 2236) Low (n 335) Medium (n 699) High (n 2401)
n % n % n % n % n % n %
User v. non-user 9 4?7 66 7?4 153 6?8 25 7?5 47 6?7 160 6?7
aOR* 95 % CI aOR* 95 % CI aOR* 95 % CI aOR* 95 % CI
1?00 1?62 0?83, 3?55 1?48 0?78, 3?18 1?00 0?89 0?54, 1?50 0?88 0?58, 1?40
aOR, adjusted OR.
*Adjusted for gender, study centre and age.
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vague estimation of nutrient intake from supplements
and the missing information on fortified foods could
have led to misclassification of nutrient intake. However,
the statistical models for the association between socio-
economic factors and region on food intake are not
affected by this matter.
One of the major strengths of the present study was the
food selection method underlying the dietary assessment
method as described previously(14). In brief, this newly
developed FFQ was designed for the specific purpose of
measuring diet, especially fatty acid and antioxidant intake,
in school-age children. The food selection method was
based on a regression approach using data from 9–11-year
old children from the German DONALD Study. The FFQ has
been validated against one 24h dietary recall and has shown
good practicability in the past. In summary, even if the FFQ
is generally believed to overestimate dietary intakes(31), we
believe that this FFQ is valid to rank individuals according
to their dietary intakes and to detect differences between
levels of socio-economic status. Furthermore, this is one of
the few studies in children collecting specific information on
dietary supplement use.
In conclusion, we have found that food intake in
school-age children differs by the level of parental edu-
cation and area of living, but the differences cannot be
attributed to healthy or unhealthy dietary habits. This
suggests that particular efforts should be made to adjust
nutrition education programmes to the target population
characterised not only in terms of education but also by
considering regional particularities.
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Abstract
Background: Elevated cholesterol levels in children can be a risk factor for cardiovascular diseases in later life. In adults, it
has been shown that blood lipid levels are strongly influenced by polymorphisms in the fatty acid desaturase (FADS) gene
cluster in addition to nutritional and other exogenous and endogenous determinants. Our aim was to investigate whether
lipid levels are determined by the FADS genotype already in children and whether this association interacts with dietary
intake of n-3 fatty acids.
Methods: The analysis was based on data of 2006 children from two German prospective birth cohort studies. Total
cholesterol, HDL, LDL and triglycerides were measured at 10 years of age. Six single nucleotide polymorphisms (SNPs) of the
FADS gene cluster were genotyped. Dietary n-3 fatty acid intake was assessed by food frequency questionnaire. Linear
regression modeling was used to assess the association between lipid levels, n-3 fatty acid intake and FADS genotype.
Results: Individuals carrying the homozygous minor allele had lower levels of total cholesterol [means ratio (MR) ranging
from 0.96 (p = 0.0093) to 0.98 (p = 0.2949), depending on SNPs] and LDL [MR between 0.94 (p = 0.0179) and 0.97 (p = 0.2963)]
compared to homozygous major allele carriers. Carriers of the heterozygous allele showed lower HDL levels [b between
20.04 (p = 0.0074) to 20.01 (p = 0.3318)] and higher triglyceride levels [MR ranging from 1.06 (p = 0.0065) to 1.07
(p = 0.0028)] compared to homozygous major allele carriers. A higher n-3 PUFA intake was associated with higher
concentrations of total cholesterol, LDL, HDL and lower triglyceride levels, but these associations did not interact with the
FADS1 FADS2 genotype.
Conclusion: Total cholesterol, HDL, LDL and triglyceride concentrations may be influenced by the FADS1 FADS2 genotype
already in 10 year old children. Genetically determined blood lipid levels during childhood might differentially predispose
individuals to the development of cardiovascular diseases later in life.
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Introduction
Lipid concentrations in blood are associated with cardiovascular
diseases [1–4]. Elevated cholesterol levels during childhood and
adolescence increases the risk for cardiovascular diseases in
adulthood. Moreover treatments which effectively lower choles-
terol levels early in life have been shown to prevent disease
manifestation in later life [5–7].
Among other factors, dietary polyunsaturated fatty acid (PUFA)
intake can attenuate high blood lipid concentrations [8–10].
In addition to dietary influences, recent genome wide associ-
ation studies have identified several genetic loci that are associated
with blood lipid levels in adults [11–15]. Among the top hits for
the determination of lipid levels are polymorphisms in the fatty
acid desaturase (FADS) gene cluster. Lower total cholesterol [11],
low-density lipoprotein (LDL) [11–13], high-density lipoprotein
(HDL) [13,14] and higher triglyceride levels [14,15] are all
associated with the minor alleles of the tested FADS polymor-
phisms. The genes FADS1 and FADS2, which are both located in
this gene cluster, encode the enzymes delta-5-desaturase and delta-
6-desaturase, which are involved in the conversion of dietary n-3
and n-6 fatty acids to their longer chain metabolites [16].
Polymorphisms in these genes are associated with n-3 and n-6
fatty acid levels in blood and several tissues [17–23]. Carriers of
the minor alleles exhibit increased levels of desaturase substrates
and decreased levels of desaturase products. This trend may be the
result of lower transcription levels or diminished enzyme
conversion rates in individuals carrying the minor alleles [17].
The previously reported strong association of FADS polymor-
phisms with lipid levels in adults makes these genes good
candidates for genetic association studies focused on lipid levels
in children. Given the role of the gene products in the conversion
of dietary fatty acids to biologically important longer chain
polyunsaturated fatty acids, which in turn have been shown to
influence lipid levels, interaction analysis between genetic poly-
morphisms and dietary intake of fatty acids for individual lipid
levels is of interest.
In this study we investigated whether genetic variations of the
FADS gene cluster already pre-determines total cholesterol, HDL,
LDL and triglyceride levels in 10 year old children and whether
genetic variation interacts with dietary intake of n-3 PUFAs to
determine individual blood lipid levels.
Results
Information on lipid concentrations in blood and FADS1 FADS2
genotype was available for 2006 children (1288 (64%) children
from the GINIplus study and 718 (36%) children from the
LISAplus study). Information on n-3 PUFA intake was only
available for 1697 of these children (1100 (65%) children from the
GINIplus study and 597 (35%) children from the LISAplus study).
Basic characteristics of the study population are presented in
Table 1. Total cholesterol, LDL and triglyceride concentrations
were significantly higher in the GINIplus study, whereas HDL
concentrations were higher in the LISAplus study.
The genotype and allele frequencies of the six SNPs which were
included in the analysis are shown in Table 2. There was no
difference in the allele frequency distribution between the
GINIplus and LISAplus studies.
Five of the six SNPs (rs174545, rs174546, rs174556, rs174561
and rs3834458) are in high LD with each other. For these five
SNPs, the pairwise squared correlations r2 ranged from 0.83 to
0.99, and Lewontin’s D’ ranged from 0.98 to 1.
For rs174575, the linkage disequilibrium is lower. The pairwise
correlation r2 for this SNP ranged from 0.49 to 0.66 and
Lewontin’s D’ ranged from 0.77 to 0.96.
Median levels of total cholesterol, HDL, LDL and triglyceride
concentrations, stratified by FADS genotype, are presented in
Table 3. Homozygous minor allele carriers had lower levels of
total cholesterol and LDL compared to homozygous or heterozy-
gous major allele carriers. In contrast, triglyceride concentrations
were higher in minor allele carriers compared to homozygous
major allele carriers. After adjustment for multiple testing
(acorr = 0.025), these associations remained significant for triglyc-
eride levels and LDL (rs174556 and rs174561).
The results of the linear regression models for total cholesterol,
HDL, LDL and triglyceride concentrations, the FADS genotype
and n-3 PUFA intake are presented in Table 4. Adjusted means
ratios for total cholesterol, LDL and triglyceride concentrations
and effect estimates for HDL are shown.
The p-values describing the association between n-3 PUFA
intake and elevated concentrations of total cholesterol [MR = 1.01
for all six SNPs (p-value ranging from 0.0288 to 0.0884)], LDL
[MR from 1.01 (p = 0.1075) to 1.02 (p = 0.0411)], HDL [b= 0.02
for all six SNPs (p-value between 0.0126 and 0.0306)] and reduced
triglyceride levels [MR between 0.97 (p = 0.0219) and 0.98
(p = 0.0841)] were statistically significant. However, after correct-
ing for multiple testing, only five (out of six) SNPs for HDL and
triglyceride levels and rs3834458 remained significant.
Additional analyses showed similar results for the n-3 PUFAs
ALA, EPA, DPA and DHA, which were combined into the total
dietary n-3 PUFA intake (data not shown).
There was no association between dietary n-6 PUFA intake and
lipid levels (data not shown).
Homozygous minor allele carriers had decreased levels of total
cholesterol [MR ranging from 0.96 (p = 0.0093) to 0.98
(p = 0.2949)] and LDL [MR between 0.94 (p = 0.0179) and 0.97
(p = 0.2963)] compared to homozygous major allele carriers. After
correcting for multiple testing (acorr = 0.025), the association
remained significant for rs174556 and rs174561 and total
cholesterol and LDL.
HDL concentrations were reduced in carriers of the heterozy-
gous genotype compared to homozygous major allele carriers [b
between 20.04 (p = 0.0074) to 20.01 (p = 0.3318)]. These
associations remained significant for four SNPs after correction
for multiple testing.
Individuals carrying the heterozygous genotype showed signif-
icantly increased triglyceride levels compared to homozygous
major allele carriers [MR ranging from 1.06 (p = 0.0065) to 1.07
(p = 0.0028)]. These associations remained significant after
correcting for multiple testing. Although homozygous minor allele
carriers also showed increased triglyceride levels, these effects did
not reach statistical significance. Additional analyses restricted to
fasting blood samples did not show substantially different results
and the magnitude of the association between FADS genotype, n-3
PUFA and lipid concentration was similar. However, this result
did not reach statistical significance, likely because of the reduced
sample size (Table S1).
For each model, including the FADS SNP increased the
percentage of explained variance compared to the model without
any SNPs (Table S2). The maximal increase in the explained
variance was 0.71% for the total cholesterol model (1.98% to
2.69%), 1.28% for the LDL model (from 4.21% to 5.49%), 0.96%
for the HDL model (from 7.83% to 8.79%) and 0.48% for the
triglycerides model (from 12.38% to 12.86%). Additional analyses
stratified by study (GINIplus and LISAplus) showed similar results,
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although again, the lack of statistical significance is likely
attributable to the reduced sample size (Figure S1).
There was no significant interaction between n-3 PUFA intake
and FADS1 FADS2 genotype for any of the tested lipid
concentrations (data not shown).
Discussion
The present study investigated the association between n-3
PUFA intake and FADS genotype with total cholesterol, HDL,
LDL and triglyceride concentrations in 10-year-old children from
the GINIplus and LISAplus birth cohort studies.
Although not all associations were statistically significant after
adjustment for multiple testing, in these children, a higher n-3
PUFA intake was associated with higher total cholesterol, HDL
and LDL and lower triglyceride levels. These associations
remained significant after adjustment for multiple testing for
HDL (five out of six tested SNPs) and triglyceride concentrations
(rs3834458).
Minor alleles of FADS1 and FADS2 SNPs were significantly
associated with higher levels of triglycerides and lower levels of
total cholesterol, HDL, and LDL levels. However, not all of these
associations reached statistical significance after correcting for
multiple testing.
Generally, our results on trends in children are in line with
previously published GWA studies that report an association
between the minor allele of the tested FADS variant with lower
total cholesterol [11], LDL [11–13], HDL [13,14] and higher
triglyceride [14,15] concentrations in adults. Although the sample
size of our cohort is relatively large, failure to reach statistical
significance for all SNPs after correcting for multiple testing may
be due to a lack of statistical power and small effect sizes.
Nevertheless, our effect sizes for total cholesterol and triglycerides
are comparable to those reported for adults [11,14]. Bokor et al.
[24] investigated the association between FADS haplotypes and
lipid levels in adolescents, and reported no associations between
any of the haplotypes and total cholesterol, HDL or LDL.
However, the haplotype carrying the minor allele of rs174546 was
significantly associated with higher triglyceride levels and the effect
size reported is similar to that observed in our study.
The lack of statistical significance with respect to triglyceride
levels in homozygous minor allele carriers may be due to the small
size of this group (7% to 12% of the complete sample).
The inclusion of the FADS SNPs to the model lead to an
increase of explained variance ranging from 0.48% for the
triglyceride model to 1.28% for the LDL model, which showed a
similar level as reported by several studies [25].
Table 1. Basic characteristics of the study population.
GINIplus
(n=1288)
LISAplus
(n =718)
Total
(n = 2006) p-value
Median (25%-Qu.,75%-Qu.) or %
Gender [% male] 49.0 55.6 51.3 0.00521
Age [weeks] 531 (526,538) 529 (525,536) 530 (525,537) 0.00722
BMI 17 (16,19) 17 (15,18) 17 (16,19) ,0.00012
Fasting blood samples [%] 16.5 21.9 18.4 0.00321
n-3 PUFA intake [mg/MJ] 0.14 (0.13,0.16) 0.14 (0.13,0.16) 0.14 (0.13,0.16) 0.59502
Total energy intake [MJ] 8237 (6900,9907) 8198 (6654,9906) 8231 (6824,9906) 0.40122
Total cholesterol [mmol/L] 4.81 (4.28,5.39) 4.75 (4.30,5.23) 4.79 (4.28,5.32) 0.04222
HDL [mmol/L] 1.20 (1.02,1.41) 1.33 (1.15,1.50) 1.24 (1.06,1.44) ,0.00012
LDL [mmol/L] 2.14 (1.73,2.58) 2.08 (1.72,2.45) 2.12 (1.72,2.53) 0.02252
Triglyceride [mmol/L] 1.24 (0.94,1.67) 1.11 (0.83,1.58) 1.19 (0.90,1.64) ,0.00012
1p-value derived from Fisher’s exact test.
2p-value derived from Wilcoxon rank sum test.
doi:10.1371/journal.pone.0037780.t001
Table 2. Characteristics of the SNPs in the FADS gene cluster.
SNP Alleles N Number of subjects with
(major/minor) genotype (%) allele (%)
A/a aa Aa AA a A
rs174545 G/C 1829 211 (12%) 793 (43%) 825 (45%) 1215 (33%) 2443 (67%)
rs174546 G/A 1854 211 (11%) 804 (43%) 839 (45%) 1226 (33%) 2482 (67%)
rs174556 G/A 1849 165 (9%) 758 (41%) 926 (50%) 1088 (29%) 2610 (71%)
rs174561 A/G 1867 165 (9%) 766 (41%) 936 (50%) 1096 (29%) 2638 (71%)
rs174575 C/G 1974 139 (7%) 738 (37%) 1097 (56%) 1016 (26%) 2932 (74%)
rs3834458 T/DEL 1971 216 (11%) 855 (43%) 900 (46%) 1287 (33%) 2655 (67%)
doi:10.1371/journal.pone.0037780.t002
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Lipid levels in children are determinants for cardiovascular
diseases in adulthood [5–7]. Analysis of the underlying causes for
disturbances in lipid metabolism during childhood can contribute
to the prevention of cardiovascular diseases later in life. Our study
suggests that the FADS1 FADS2 gene cluster may influence lipid
levels in early life.
The underlying causal biological mechanism between an
individual’s FADS genotype and their lipid concentrations is not
Table 3. Median total cholesterol, HDL, LDL and triglyceride concentrations [mmol/L] in with 25%- and 75%-quantiles stratified by
FADS genotype (A: major allele/ a: minor allele).
Total cholesterol HDL LDL Triglyceride
rs174545
AA 4.81
(4.29,5.34)
1.27
(1.06,1.47)
2.13
(1.74,2.57)
1.14
(0.87,1.57)
Aa 4.77
(4.28,5.30)
1.23
(1.06,1.42)
2.13
(1.74,2.51)
1.23
(0.93,1.67)
aa 4.68
(4.18,5.16)
1.26
(1.09,1.43)
2.01
(1.67,2.47)
1.23
(0.92,1.69)
p-value1 0.1189 0.2246 0.0718 0.0058
rs174546
AA 4.82
(4.29,5.34)
1.27
(1.07,1.47)
2.13
(1.74,2.57)
1.14
(0.88,1.57)
Aa 4.77
(4.28,5.31)
1.23
(1.06,1.42)
2.13
(1.74,2.51)
1.24
(0.94,1.68)
aa 4.66
(4.18,5.15)
1.26
(1.09,1.43)
2.01
(1.67,2.47)
1.22
(0.92,1.68)
p-value1 0.0793 0.1494 0.0701 0.0078
rs174556
AA 4.83
(4.30,5.38)
1.27
(1.07,1.47)
2.14
(1.74,2.58)
1.15
(0.88,1.58)
Aa 4.76
(4.28,5.30)
1.23
(1.06,1.41)
2.12
(1.73,2.49)
1.23
(0.94,1.69)
aa 4.65
(4.18,5.08)
1.25
(1.09,1.43)
1.98
(1.65,2.38)
1.22
(0.90,1.68)
p-value1 0.0263 0.0842 0.0182 0.0071
rs174561
AA 4.83
(4.30,5.38)
1.27
(1.07,1.47)
2.14
(1.74,2.59)
1.15
(0.88,1.58)
Aa 4.76
(4.28,5.29)
1.23
(1.06,1.42)
2.12
(1.73,2.49)
1.23
(0.94,1.69)
aa 4.65
(4.18,5.11)
1.25
(1.09,1.43)
2.00
(1.65,2.38)
1.25
(0.92,1.68)
p-value1 0.0288 0.1042 0.0145 0.0076
rs174575
AA 4.80
(4.28,5.32)
1.26
(1.06,1.46)
2.12
(1.73,2.53)
1.15
(0.88,1.57)
Aa 4.80
(4.31,5.35)
1.23
(1.06,1.43)
2.16
(1.75,2.54)
1.25
(0.93,1.72)
aa 4.63
(4.18,5.08)
1.24
(1.04,1.41)
1.96
(1.68,2.36)
1.24
(0.98,1.70)
p-value1 0.0390 0.3346 0.0325 0.0032
rs3834458
AA 4.81
(4.30,5.35)
1.26
(1.06,1.47)
2.13
(1.73,2.56)
1.15
(0.88,1.58)
Aa 4.79
(4.28,5.33)
1.23
(1.06,1.42)
2.16
(1.75,2.53)
1.24
(0.94,1.68)
aa 4.65
(4.23,5.14)
1.25
(1.06,1.43)
2.01
(1.68,2.40)
1.22
(0.94,1.69)
p-value1 0.0434 0.2505 0.0414 0.0081
1p-value derived from Kruskal-Wallis rank sum test. Significance level after correction for multiple testing: acorr = 0.025. Values reaching significance after adjustment for
multiple testing are highlighted in bold.
doi:10.1371/journal.pone.0037780.t003
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entirely clear. It is likely that the composition of polyunsaturated
fatty acids in human tissues, which has been shown to be highly
associated with the FADS genotype [17], is the direct link between
the observed associations. Tanaka et al. [26] presumed that higher
concentrations of the precursor fatty acids in minor allele carriers
may result in increased membrane fluidity, and thus, in lower
LDL. In addition to altered membrane fluidity, differential
concentrations of long-chain PUFAs (LC-PUFAs) may lead to a
change in the activation of transcription factors such as
peroxisome proliferator activating receptor alpha (PPARA).
Endogenous LC-PUFAs are natural ligands of PPARA [27],
whose activation has been shown to influence the expression of
apo-lipoproteins (e.g. ApoAI, Apo-AII, and ApoCIII) and enzymes
(lipoprotein lipase) that are involved in the metabolism of
lipoprotein particles [28–31].
The effect of FADS genotypes on fatty acid levels, which are also
influenced by nutrition, leads to further interesting questions. One
of which is whether there is a concerted interaction effect between
FADS genotypes and PUFA intake on lipid levels. To date, few
studies have dealt with this issue. Lu et al. [32] reported an
association between FADS genotype and lipid levels, but only in
groups with a high n-3 or n-6 PUFA intake. This result suggests an
interaction between genotype and fatty acid intake, although a
complete interaction analysis was not performed in this study. In
our study, a higher intake of n-3 PUFA was associated with higher
total cholesterol, HDL and LDL levels and lower triglyceride
concentrations, although these effects were not significant after
adjustment for multiple testing. We did not find any association
between lipid levels, FADS genotype and dietary n-6 PUFA intake
(data not shown). In our interaction analysis, we did not find a
modification of the effect of n-3 PUFA intake on lipid
concentrations in blood by the FADS genotype.
Additionally, the number of multiple comparisons has to be
considered. In our manuscript, 24 hypotheses are investigated (6
SNPs and 4 traits). A correction for multiple testing is necessary, if
several independent hypotheses are tested simultaneously. In the
present manuscript, neither the SNPs, nor traits are independent.
A more stringent approach, which would account for the number
of outcome variables, would lead to a corrected alpha level of
0.0063. Taking this alpha level as a basis, the association between
individuals carrying the heterozygous genotype and triglyceride
levels compared to homozygous major allele carriers remains
significant for five out of six SNPs. However, the reported
associations with each of the selected six SNPs with traits were
similar, possibly due to high correlation. A chance finding would
be obvious, if just one of the tested SNPs were highly statistical
significant, where the others were not. This is not the case in our
Table 4. Results of linear regression models for total cholesterol, HDL, LDL and triglyceride concentrations, FADS genotype (A:
major allele/ a: minor allele, reference: homozygous major allele) and n-3 PUFA intake (per IQR increase, IQR (n-3 PUFA) = 0.04 mg/
MJ) adjusted for gender, study centre, age, BMI, fasting status and total dietary energy intake [MJ].
Total cholesterol HDL LDL Triglycerides
MR 95% CI p-value1 Estimate Sd p-value1 MR 95% CI p-value1 MR 95% CI p-value1
rs174545 n= 1532 N= 1531 n= 1531 n = 1531
n-3 PUFA 1.01 (1.00, 1.02) 0.0568 0.02 0.01 0.0193 1.01 (1.00, 1.03) 0.1023 0.98 (0.96, 1.00) 0.0841
Aa (ref AA) 1.00 (0.98, 1.02) 0.8311 20.04 0.02 0.0214 1.01 (0.98, 1.04) 0.6525 1.06 (1.02, 1.11) 0.0063
aa (ref AA) 0.98 (0.95, 1.00) 0.0909 20.01 0.02 0.6368 0.97 (0.92, 1.02) 0.1758 1.05 (0.97, 1.12) 0.2148
rs174546 n= 1554 n= 1553 n= 1553 n = 1553
n-3 PUFA 1.01 (1.00, 1.02) 0.0823 0.02 0.01 0.0147 1.01 (1.00, 1.03) 0.1072 0.98 (0.95, 1.00) 0.0413
Aa (ref AA) 1.00 (0.98, 1.02) 0.9721 20.04 0.02 0.0113 1.01 (0.97, 1.04) 0.7541 1.07 (1.02, 1.11) 0.0048
aa (ref AA) 0.97 (0.95, 1.00) 0.0592 20.01 0.02 0.6663 0.97 (0.92, 1.02) 0.1777 1.03 (0.96, 1.11) 0.3621
rs174556 n= 1548 n= 1547 n= 1547 n = 1547
n-3 PUFA 1.01 (1.00, 1.02) 0.0884 0.02 0.01 0.0173 1.01 (1.00, 1.03) 0.1075 0.98 (0.95, 1.00) 0.0363
Aa (ref AA) 1.00 (0.98, 1.01) 0.6460 20.04 0.02 0.0074 0.99 (0.96, 1.03) 0.7434 1.07 (1.02, 1.12) 0.0035
aa (ref AA) 0.96 (0.93, 0.99) 0.0093 0.00 0.03 0.8902 0.94 (0.88, 0.99) 0.0179 1.02 (0.94, 1.10) 0.6769
rs174561 n= 1564 n= 1563 n= 1563 n = 1563
n-3 PUFA 1.01 (1.00, 1.02) 0.0577 0.02 0.01 0.0306 1.01 (1.00, 1.03) 0.0790 0.98 (0.96, 1.00) 0.0533
Aa (ref AA) 1.00 (0.98, 1.01) 0.7075 20.04 0.02 0.0094 1.00 (0.96, 1.03) 0.8039 1.07 (1.02, 1.11) 0.0041
aa (ref AA) 0.96 (0.93, 0.99) 0.0107 0.00 0.03 0.9700 0.94 (0.89, 0.99) 0.0207 1.02 (0.95, 1.11) 0.5278
rs174575 n= 1662 n= 1661 n= 1661 n = 1661
n-3 PUFA 1.01 (1.00, 1.02) 0.0290 0.02 0.01 0.0140 1.02 (1.00, 1.03) 0.0411 0.97 (0.95, 1.00) 0.0258
Aa (ref AA) 1.01 (1.00, 1.03) 0.1070 20.01 0.01 0.3318 1.03 (0.99, 1.06) 0.1020 1.07 (1.02, 1.11) 0.0028
aa (ref AA) 0.98 (0.95, 1.02) 0.2949 20.01 0.03 0.6907 0.97 (0.91, 1.03) 0.2963 1.07 (0.99, 1.16) 0.0922
rs3834458 n= 1659 n= 1658 n= 1658 n = 1658
n-3 PUFA 1.01 (1.00, 1.02) 0.0288 0.02 0.01 0.0126 1.02 (1.00, 1.03) 0.0422 0.97 (0.95, 1.00) 0.0219
Aa (ref AA) 1.00 (0.98, 1.02) 0.9479 20.03 0.01 0.0324 1.01 (0.98, 1.04) 0.6232 1.06 (1.02, 1.11) 0.0065
aa (ref AA) 0.97 (0.95, 1.00) 0.0704 20.01 0.02 0.6009 0.97 (0.92, 1.01) 0.1674 1.04 (0.98, 1.12) 0.2130
1Significance level after correction for multiple testing: acorr = 0.025. Values reaching significance after adjustment for multiple testing are highlighted in bold.
doi:10.1371/journal.pone.0037780.t004
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analyses. Therefore, we do not consider these results as chance
finding.
Nevertheless, our results suggest that there is an effect of n-3
PUFA intake as well as an effect of FADS genotype on lipid levels,
although these effects do not interact with each other. It is known,
that the conversion rate from dietary PUFA intake to longer chain
metabolites is depending on the FADS genotype [17]. Therefore, it
might be possible that dietary n-3 PUFA intake as well as the
FADS genotype have a linear influence on the endogenous PUFA
levels. This would be in line with the results presented by Molto´-
Puigmartı´ et al. [22]. They reported lower DHA proportions in
plasma phospholipids in women carrying the homozygous minor
allele, but the DHA proportions increased with higher intake of
fatty fish to a similar extent for all genotypes.
To our knowledge, this is the first study which has examined the
complex associations between genetics, diet, and lipid levels in
10 year old children.
In addition to its strength, our study also faces some limitations
which must be considered. Although lipid levels were measured
from blood samples, the dietary fatty acid intake was assessed by a
FFQ. The FFQ used in the present study measured dietary intake
over the past 12 months and was validated for the dietary n-3
PUFA intake. Alternatively, it might be interesting to examine the
association of FADS genes, lipid concentrations and measured fatty
acid blood levels. A further limitation of our study is the low
proportion of fasting blood samples (18.4%). The presented results
were adjusted for fasting status. Additionally, the magnitude of the
association between FADS genotype, n-3 PUFA and lipid
concentration was similar when the sample was restricted to those
with information on fasting blood, although statistical significance
was lacking due to a reduced sample size (Results for triglyceride
levels are presented in Table S1).
In order to increase the power, the two independent studies
GINIplus and LISAplus were analyzed together. Additional
analyses stratified for the GINIplus and LISAplus studies showed
consistent results (Figure S1), except for LDL, although signifi-
cance was missed due to the reduced sample size. This
investigation addressed a complex hypothesis and is based on a
specific data situation: Dietary fatty acid intake was assessed using
a FFQ, which was especially developed and validated for dietary
fatty acid intake in this specific study population [33], blood lipid
levels of total cholesterol, HDL, LDL and triglycerides were
measured and genotyping of six variants of the FADS1 FADS2 gene
cluster was performed. Nevertheless, the results in the two
independent studies GINIplus and LISAplus, which are based
on the same methodology, are similar and our results are
comparable to those reported for adults.
Our study suggests that the FADS1 FADS2 gene cluster may
affect lipid levels already in childhood. Although the explained
variance is low, and can therefore not be used for prevention or
prediction purposes, these results underline the hypothesis that
there is a causal association between dietary n-3 PUFA intake and
lipid levels in children and may help to identify the causal
biological mechanism.
However, further studies are needed to investigate the long-term
effects of the impact of dietary intervention on the development of
cardiovascular diseases, while considering the influence of the
FADS gene cluster.
Materials and Methods
Study population
Data from two ongoing German birth cohort studies were
included in this investigation: the German LISAplus (Life-style
Related Factors on the Immune System and the Development of
Allergies in Childhood PLUS the influence of traffic emissions and
genetics) and GINIplus (German Infant Nutritional Intervention
PLUS environmental and genetic influences on allergy develop-
ment) studies. LISAplus is a population based birth cohort study in
which a total of 3097 neonates were recruited between 1997 and
1999 from the German cities of Munich, Leipzig, Wesel and Bad
Honnef. The participants were not pre-selected based on family
history of allergic diseases [34]. A total of 5991 mothers and their
newborns were recruited from Munich and Wesel into the
GINIplus study between September 1995 and June 1998. Infants
with at least one allergic parent and/or sibling were allocated to
the interventional study arm which investigated the effect of
different hydrolysed formulas consumed during the first year of life
on the development of allergies [35]. All children without a family
history of allergic diseases and children whose parents did not give
consent for the randomized clinical trial were allocated to the non-
interventional arm. Given that the entire current GINIplus study is
composed of both the interventional and non-interventional arm,
this cohort is also population-based. Detailed descriptions of the
LISAplus and GINIplus studies have been published elsewhere
[34–36]).
In both studies only individuals with Caucasian German descent
were included.
For this analysis, only data from the 10 year follow-up is used.
During this follow-up, blood samples were collected and in a
subset of almost 20% of the children fasting blood samples could
be collected.
For both studies, approval by the local Ethics Committees
(Bavarian Board of Physicians, University of Leipzig, Board of
Physicians of North-Rhine-Westphalia) and written consent from
participant’s families were obtained.
Dietary n-3 PUFA intake
A food frequency questionnaire (FFQ) was developed to
measure a child’s usual food and nutrient intake during one year,
and more specifically, to estimate energy, fatty acid and
antioxidant intake at 10 years of age. The FFQ comprised a list
of 82 food items accompanied by several questions about the
preferred fat and energy content of products, preparation
methods, diet and food preferences, buying habits and dietary
supplement use. The consumption frequencies and portion size
estimates were converted to average consumption in grams per
day and linked to the German Nutrient Data Base, version II.3.1
[37]. The design of the FFQ, including the selection of the food
item list, validation, and the calculation of food and nutrient intake
is described in more detail by Stiegler et al. [33].
The intake of n-3 PUFA was calculated by summing a child’s
daily intake of a-linolenic acid (ALA, 18: 3n-3), eicosapentaenoic
acid (EPA, 20: 5n-3), docosapentaenoic acid (DPA, 22: 5n-3) and
docosahexaenoic acid (DHA, 22: 6n-3).
Genotyping
Six single nucleotide polymorphisms (SNPs) in the FADS1
FADS2 gene cluster (rs174545, rs174546, rs174556, rs174561,
rs174575 and rs3834458) were genotyped. Five of these variants
(rs174545, rs174546, rs174556, rs174561 and rs3834458) are in
strong linkage disequilibrium (LD) with each other (r2.0.7,
D’.0.9) [17], and were selected based on previous publications in
adult populations [17,38]. Additionally, we included the rs174575
SNP in order to obtain a better coverage of the FADS gene cluster.
This SNP was selected based on a previous publication in children
[39]. By applying the tagger server program (http://www.
broadinstitute.org/mpg/tagger/) in combination with HapMap
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(http://hapmap.ncbi.nlm.nih.gov/), we were able to tag 27
additional SNPs between base pair positions 61234329 and
61372379 in the FADS1 FADS2 gene cluster using three of our
original SNPs (rs174545, rs174546 and rs174556). The efficiency
was 10.7 fold, however of these new 27 SNPs, rs174561 and
rs3834458 could not be used in the analysis as these are not
included in the HapMap database. Genotyping of SNPs was
conducted using the iPLEX (Sequenom, San Diego, CA, USA)
method by means of matrix assisted laser desorption ionization-
time of flight mass spectrometry (MALDI-TOF MS, Mass Array;
Sequenom) in one laboratory, according to the manufacturer’s
instructions. Standard genotyping quality control included 10%
duplicate and negative samples. The genotyping discordance rate
was below 0.3%.
Measurement of lipids
The measurement of serum lipids and lipoproteins was
performed using homogenous enzymatic colorimetric methods
according to the manufactures instructions (Roche Diagnostics
GmbH Mannheim). All parameters and controls were analysed on
a Modular Analytics System from Roche Diagnostics GmbH
Mannheim.
External controls were used in accordance with the guidelines of
the German Society of Clinical Chemistry and Laboratory
Medicine.
Statistical analysis
Because of the skewed distribution, total cholesterol, LDL and
triglyceride concentrations were naturally log-transformed. After-
wards, linear regression modelling was used to assess the
association between log-transformed total cholesterol, HDL, log-
transformed LDL and log-transformed triglyceride concentrations,
n-3 PUFA intake and FADS genotype. Therefore, for HDL, the
regression coefficient b (Estimate) with standard deviation (Sd) is
shown.
For total cholesterol, LDL and triglyceride, the results are
presented as means ratio (MR) with 95% confidence interval (95%
CI). The MR can be easily calculated for lognormal distributed
variables and is derived by applying the exponential function on
the regression coefficient b (i.e. MR = exp (b)). It describes the
ratio of the mean of the outcome variable in one group compared
to the mean of the outcome variable in the reference group. The
MR can be interpreted as percentage change in the mean of the
outcome variable in one group compared to the reference group
adjusted for confounder variables.
The dietary n-3 PUFA intake was included in the regression
analyses as nutrient density (n-3 PUFA intake divided by total
energy intake). Additionally, the results were adjusted for total
energy intake [40]. In order to compare the effect size of high
(75% quantile) and low (25% quantile) dietary n-3 PUFA intake,
the influence of n-3 PUFA intake is given per interquartile range
increase (IQR (n-3 PUFA) = 0.04 mg/MJ).
All regression models were adjusted for gender, study centre
(Munich, Wesel, Leipzig and Bad Honnef), age, BMI at 10 years
of age and fasting status.
Moreover, in additional analyses, an interaction between n-3
PUFA and FADS genotype (reference: homozygous major allele),
was included in the linear regression models in order to test
whether the effect of dietary n-3 PUFA intake is modified by FADS
variants.
Statistical significance was defined by a two-sided alpha level of
5%. We corrected for multiple testing according to Nyholt [41]. In
brief, this method takes the correlation pattern between the SNPs
into account and reduces the number of variables in a set to the
effective number of variables and provides thereby an estimate of
the number of independent tests.
The alpha level is divided by the number of effective loci (which
was computed as two, based on the number of effective loci of the
six SNPs in the FADS gene cluster), which yields a corrected two-
sided alpha level of 0.025 (5%/2 = 2.5%).
Differences between the GINIplus and LISAplus studies were
tested using Fisher’s exact test or Wilcoxon rank sum test. The
association between lipid concentrations and FADS genotype was
tested using Kruskal-Wallis rank sum test, a nonparametric
method to test whether the median of the lipid concentrations is
different between the FADS genotypes.
Statistical analysis was performed using the statistical software
R, version 2.13.1 (http://www.R-project.org) [42].
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the GINIplus and LISAplus studies. Presented are means
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reference: homozygous major allele) and n-3 PUFA intake (per
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adjusted for gender, study centre, age, BMI and total dietary
energy intake [MJ]. a) Total cholesterol b) HDL c) LDL d)
Triglycerides
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MJ) adjusted for gender, study centre, age, BMI and
total dietary energy intake [MJ].
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Table S1 
 
 
MR 95% CI p-value 
rs174545 n=293 
  n-3 PUFA 0.97 (0.94, 1.01) 0.1573 
Aa 1.02 (0.93, 1.11) 0.7443 
aa 1.09 (0.93, 1.27) 0.2813 
rs174546 n=296 
  n-3 PUFA 0.97 (0.93, 1.01) 0.1486 
Aa 1.02 (0.94, 1.12) 0.6004 
aa 1.05 (0.91, 1.23) 0.4927 
rs174556 n=296 
  n-3 PUFA 0.97 (0.93, 1.01) 0.1429 
Aa 1.02 (0.93, 1.12) 0.6167 
aa 1.04 (0.88, 1.23) 0.6426 
rs174561 n=298 
  n-3 PUFA 0.97 (0.93, 1.01) 0.1310 
Aa 1.02 (0.93, 1.12) 0.6457 
aa 1.04 (0.88, 1.23) 0.6504 
rs174575 n=316 
  n-3 PUFA 0.97 (0.94, 1.01) 0.1342 
Aa 0.99 (0.91, 1.08) 0.8606 
aa 1.02 (0.86, 1.21) 0.7950 
rs3834458 n=315 
  n-3 PUFA 0.97 (0.94, 1.01) 0.1331 
Aa 1.03 (0.94, 1.12) 0.5267 
aa 1.06 (0.92, 1.23) 0.4059 
 
 
1 
 
 
 
Table S2 
  
Total 
cholesterol LDL HDL Triglycerides 
Without SNP 1.98% 4.21% 7.83% 12.38% 
rs174545 2.38% 5.26% 8.16% 12.40% 
rs174546 2.44% 5.30% 8.45% 12.72% 
rs174556 2.53% 5.43% 8.56% 12.86% 
rs174561 2.69% 5.49% 8.38% 12.47% 
rs174575 2.66% 5.19% 8.59% 12.54% 
rs3834458 2.60% 5.09% 8.79% 12.44% 
Max. difference 0.71% 1.28% 0.96% 0.48% 
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